0001493152-24-019729.txt : 20240515 0001493152-24-019729.hdr.sgml : 20240515 20240515143809 ACCESSION NUMBER: 0001493152-24-019729 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 56 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240515 DATE AS OF CHANGE: 20240515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NovelStem International Corp. CENTRAL INDEX KEY: 0000912544 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-RETAIL STORES, NEC [5990] ORGANIZATION NAME: 07 Trade & Services IRS NUMBER: 650385686 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-14332 FILM NUMBER: 24949478 BUSINESS ADDRESS: STREET 1: 2255 GLADES RD STREET 2: STE 237 W CITY: BOCA RATON STATE: FL ZIP: 33431 BUSINESS PHONE: 5619988000 MAIL ADDRESS: STREET 1: 2255 GLADES RD STREET 2: STE 237 W CITY: BOCA RATON STATE: FL ZIP: 33431 FORMER COMPANY: FORMER CONFORMED NAME: NovelStem International Corp DATE OF NAME CHANGE: 20220802 FORMER COMPANY: FORMER CONFORMED NAME: HOLLYWOOD MEDIA CORP DATE OF NAME CHANGE: 20001215 FORMER COMPANY: FORMER CONFORMED NAME: HOLLYWOOD COM INC DATE OF NAME CHANGE: 20000511 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2024

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________________ to _________________

Commission file number: 001-14332

NOVELSTEM INTERNATIONAL CORP.

(Exact name of registrant as specified in its charter)

Florida

65-0385686

(State or other jurisdiction

of incorporation or organization)

(I.R.S. Employer

Identification No.)

2255 Glades Road, Suite 221A, Boca Raton, FL		33431
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code

(410) 598-9024

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filed, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer  ☒	Smaller reporting company  ☒
	Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Class		Outstanding at May 15, 2024
Common Stock, $0.01 par value per share		46,881,475

NOVELSTEM INTERNATIONAL CORP.

Quarterly Report on Form 10-Q

for the Quarterly Period Ended March 31, 2024

TABLE OF CONTENTS

		PAGE

Part I Financial Information

Item 1. Unaudited Condensed Financial Statements:

Condensed Balance Sheets as of March 31, 2024 and December 31, 2023		3

Condensed Statements of Operations for the three months ended March 31, 2024 and 2023		4

Condensed Statements of Changes in Shareholders’ Deficit for the three months ended March 31, 2024 and 2023		5

Condensed Statements of Cash Flows for the three months ended March 31, 2024 and 2023		6

Notes to Condensed Financial Statements		7

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		15

Item 3. Quantitative and Qualitative Disclosures About Market Risk		18

Item 4. Controls and Procedures		18

Part II Other Information

Item 1. Legal Proceedings		18

Item 1A. Risk Factors		19

Item 6. Exhibits		19

Signatures		20

PART I

ITEM 1.

UNAUDITED CONDENSED FINANCIAL STATEMENTS

NOVELSTEM INTERNATIONAL CORP.

CONDENSED BALANCE SHEETS

	March 31,			December 31,
	As of
	March 31,			December 31,
	2024			2023
	(Unaudited)

ASSETS
Current assets:
Cash	$	5,181		$	53,063
Accounts receivable, administrative fees		3,000			-
Prepaid expenses		27,855			33,540
Total current assets		36,036			86,603
Investment in Netco Partners		132,358			133,709
Note receivable, NewStem Ltd		500,000			250,000
Investment in NewStem Ltd		1,732,375			1,784,234
Total assets	$	2,400,769		$	2,254,546

LIABILITIES AND SHAREHOLDERS’ DEFICIT
Current liabilities:
Accounts payable	$	149,672		$	54,257
Notes payable		250,000			250,000
Current portion of long-term notes payable, including accrued interest		2,850,916			-
Accrued expenses		45,974			42,223
Total current liabilities		3,296,562			346,480
Long-term liabilities:
Long-term notes payable, including accrued interest, net		810,527			3,324,599
Derivative liability, guarantee		535,000			535,000
Total long-term liabilities		1,345,527			3,859,599
Total liabilities		4,642,089			4,206,079
Commitments and contingencies (see Note 7)		-			-
Shareholders’ deficit:
Common stock, $.01 par value, 100,000,000 shares authorized, 50,316,672 shares issued, and 46,881,475 shares outstanding as of March 31, 2024 and December 31, 2023		468,815			468,815
Additional paid-in capital		290,920,710			290,907,217
Accumulated deficit		(293,431,091	)		(293,127,811	)
Treasury stock, at cost, 3,435,197 shares as of March 31, 2024 and December 31, 2023		(199,754	)		(199,754	)
Total shareholders’ deficit		(2,241,320	)		(1,951,533	)
Total liabilities and shareholders’ deficit	$	2,400,769		$	2,254,546

The accompanying notes are an integral part of these condensed financial statements.

NOVELSTEM INTERNATIONAL CORP.

CONDENSED STATEMENTS OF OPERATIONS

(UNAUDITED)

	2024			2023
	Three Months Ended
	March 31,
	2024			2023

Administrative fee income	$	3,000		$	-
Operating expenses:
General and administrative expenses		183,306			164,792
Total operating expenses		183,306			164,792
Loss from operations		(180,306	)		(164,792	)
Other expenses:
Gain on derivative instrument		(25,000	)		-
Interest expense		94,764			7,313
Total other expenses		69,764			7,313
Loss before income taxes		(250,070	)		(172,105	)
Provision for income tax		-			-
Loss before equity in net income of equity method investees		(250,070	)		(172,105	)
Equity in net loss of equity method investees		(53,210	)		(96,716	)
Net loss	$	(303,280	)	$	(268,821	)
Basic and diluted net loss per share:
Net loss per share - basic and diluted	$	(0.01	)	$	(0.01	)
Weighted average number of shares outstanding - basic and diluted		46,881,475			46,881,475

The accompanying notes are an integral part of these unaudited condensed financial statements.

NOVELSTEM INTERNATIONAL CORP.

CONDENSED STATEMENTS OF SHAREHOLDERS’ EQUITY

(UNAUDITED)

For the Three Months Ended March 31, 2024:

	Number of		Common		Additional Paid-In		Accumulated			Number of Treasury		Treasury			Total Shareholders’
	Shares		Stock		Capital		Deficit			Shares		Stock			Equity

Balance, January 1, 2024		46,881,475	$	468,815	$	290,907,217	$	(293,127,811	)		3,435,197	$	(199,754	)	$	(1,951,533	)
Net loss		-		-		-		(303,280	)		-		-			(303,280	)
Stock option compensation		-		-		13,493		-			-		-			13,493
Balance, March 31, 2024		46,881,475	$	468,815	$	290,920,710	$	(293,431,091	)		3,435,197	$	(199,754	)	$	(2,241,320	)

For the Three Months Ended March 31, 2023:

					Additional					Number of					Total
	Number of		Common		Paid-In		Accumulated			Treasury		Treasury			Shareholders’
	Shares		Stock		Capital		Deficit			Shares		Stock			Equity

Balance, January 1, 2023		46,881,475	$	468,815	$	290,604,327	$	(288,940,510	)		3,435,197	$	(199,754	)	$	1,932,878
Balance, value		46,881,475	$	468,815	$	290,604,327	$	(288,940,510	)		3,435,197	$	(199,754	)	$	1,932,878
Net loss		-		-		-		(268,821	)		-		-			(268,821	)
Stock option compensation		-		-		15,077		-			-		-			15,077
Balance, March 31, 2023		46,881,475	$	468,815	$	290,619,404	$	(289,209,331	)		3,435,197	$	(199,754	)	$	1,679,134
Balance, value		46,881,475	$	468,815	$	290,619,404	$	(289,209,331	)		3,435,197	$	(199,754	)	$	1,679,134

The accompanying notes are an integral part of these condensed financial statements.

NOVELSTEM INTERNATIONAL CORP.

CONDENSED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	2024			2023
	Three Months Ended
	March 31,
	2024			2023

Cash flows from operating activities:
Net loss	$	(303,280	)	$	(268,821	)
Equity in net loss of equity method investees		53,210			96,716
Distribution from NetCo Partners		-			7,875
Accretion of discount on note payable		44,398			-
Gain on derivative instrument		(25,000	)		-
Accrued interest added to long-term notes payable		42,446			7,079
Stock-based compensation		13,493			15,077
Change in operating assets and liabilities:
Accounts receivable, administrative fees		(3,000	)		12,000
Prepaid expenses		5,685			994
Accounts payable		95,415			107,296
Accrued expenses		3,751			(6,000	)
Net cash used in operating activities		(72,882	)		(27,784	)

Cash flows from investing activities:
Loans made		(250,000	)		-
Net cash used in investing activities		(250,000	)		-

Cash flows from financing activities:
Proceeds from long term notes payable		275,000			62,000
Net cash provided by financing activities		275,000			62,000

Net change in cash		(47,882	)		34,216
Cash at the beginning of the period		53,063			6,346
Cash at the end of the period	$	5,181		$	40,562

Supplemental cash flow information:
Cash paid during the period for:
Interest	$	441		$	234

The accompanying notes are an integral part of these condensed financial statements.

NOVELSTEM INTERNATIONAL CORP.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

NOTE 1—NATURE OF OPERATIONS

Description of Business

NovelStem International Corp. (“NovelStem” or the “Company”) is a holding company whose principal assets are an approximate 31% equity interest in NewStem Ltd, an Israeli biotech company (“NewStem”), and a 50% equity interest in NetCo Partners (“NetCo”). NovelStem was formerly known as Hollywood Media Corp. The Company was incorporated in the State of Florida on January 22, 1993 and changed its name to NovelStem International Corp. in September 2018 as a result of its business focus shift from a media business to biotech.

NewStem focuses on the development and commercialization of diagnostic technology that can predict patients’ anti-cancer drug resistance, allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. NewStem is collaborating with life sciences companies for the development of drugs and reagents. NetCo is a legacy media business interest which owns “Net Force”, a book publishing franchise.

Going Concern, Liquidity and Management’s Plans

Since inception, the Company has accumulated a deficit of approximately $293,000,000. The accumulated deficit of the Company subsequent to its business focus shift and name change in September 2018 is approximately $6,750,000 which is comprised primarily of allocated losses from equity method investments and general and administrative costs incurred by the Company.

The Company will need to obtain additional funds to continue its operations. Management’s plans with regard to these matters include additional financing and fundraising until its equity investment in NewStem is profitable. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient cash from financing on terms acceptable to the Company, or that NewStem will be able to continue as a going concern and become profitable (see Note 3).

The Company has in place a finance agreement with two individuals who are shareholders and directors to borrow $650,000 and an additional finance agreement with a shareholder to borrow $300,000 for working capital needs (see Note 4). Additionally, the Company entered into additional finance agreements with unrelated parties in December 2023 and April 2024 to borrow an additional $350,000 for working capital needs and to fund NewStem (see Note 4). As of the date of these financial statements, these borrowings have been fully utilized and the Company will need to obtain additional funds to continue operations for the next 12 months.

In view of the matters described above, the Company’s ability to meet financing requirements is dependent upon the ability to complete additional fundraising or obtain additional financing, and/or monetize its investment in NetCo, along with NewStem continuing as a going concern. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

NOTE 2—SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period.

The accompanying unaudited condensed financial statements and related disclosures have been prepared with the presumption that users of the unaudited condensed financial statements have read or have access to the audited financial statements for the preceding fiscal year. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Form 10-K, which was filed with the United States Securities and Exchange Commission (“SEC”) on April 1, 2024, from which the Company derived the balance sheet data at December 31, 2023.

Certain information and footnote disclosures normally included in condensed financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations for interim reporting. The Company believes that the disclosures contained herein are adequate to make the information presented not misleading. These condensed financial statements should be read in conjunction with the Company’s Form 10K filed with the Securities and Exchange Commission on April 1, 2024 for the years ended December 31, 2023 and 2022.

Equity Investments

Investee companies that are not consolidated, but over which the Company exercises significant influence, are accounted for under the equity method of accounting. Whether or not the Company exercises significant influence with respect to an investee depends on an evaluation of several factors, including, among others, representation on the investee company’s board of directors and ownership level, which is generally a 20% to 50% interest in the voting securities of the investee company. Under the equity method of accounting, an investee company’s accounts are not reflected within the Company’s balance sheets or statements of operations; however, the Company’s share of the earnings or losses of the investee company is reflected in the caption “Equity in net income (loss) of investee company” in the statements of operations. The Company’s carrying value in an equity method investee company is reflected in the caption “Investment in investee company’ in the Company’s balance sheets.

The Company reviews equity investments for impairment on an annual basis, or earlier if events or changes in circumstances indicate that the carrying amounts might not be recoverable.

The Company holds a minority investment in an entity, NewStem, which is accounted for pursuant to the equity method of accounting. Additionally, the Company is a 50% partner in NetCo (which is accounted for pursuant to the equity method of accounting). See Note 3.

Derivative Financial Instruments

The Company has in place a financial instrument, in the form of a note payable, with an identified embedded derivative in the form of a guarantee. The identified embedded derivative has been bifurcated and accounted for separately. Such derivative financial instruments are measured at fair value at each financial statement reporting date. If the fair value of a financial liability (the derivative) exceeds the proceeds received for the issuance of a hybrid instrument in an arms length transaction with no rights or privileges that require separate accounting recognition as an asset identified, then the embedded derivative is recorded at fair value with the excess of fair value over proceeds recognized as a loss in earnings. During the three months ended March 31, 2024, the Company recognized a gain on derivative financial instruments of $25,000. Proceeds from the note payable are shown as cash from financing instruments and the gain on derivative instrument is included as an adjustment to reconcile loss to net cash used in operating activities in the statements of cash flows for the three months ended March 31, 2024.

Basic and Diluted Net Loss Per Share

Basic net loss per share is computed by dividing the net loss by the weighted average number of shares outstanding during the period, excluding treasury stock. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares outstanding plus the dilutive potential of common shares which would result from the exercise of stock options and warrants. The dilutive effects of stock options and warrants are excluded from the computation of diluted net income (loss) per share if the effect of doing so would be antidilutive.

The following data represents the amounts used in computing earnings per share and the effect on loss and the weighted average number of shares of dilutive potential common stock (unaudited):


	Three Months Ended March 31,
	2024			2023
Net loss attributable to common shareholders	$	(303,280	)	$	(268,821	)

Weighted average shares outstanding:
-Basic		46,881,475			46,881,475
Add: Warrants		-			-
Add: Stock options		-			-
-Diluted		46,881,475			46,881,475

Basic and diluted net loss per share	$	(0.01	)	$	(0.01	)

Options and warrants excluded from the computation of earnings per share:

SCHEDULE OF WARRANTS AND STOCK OPTIONS

	2024		2023
	Three Months Ended March 31,
	2024		2023
Warrants		3,000,000		3,000,000
Stock options		5,760,000		5,760,000
Anti-dilutive securities		5,760,000		5,760,000

NOTE 3—EQUITY METHOD INVESTMENTS

Investment in NewStem

In 2018, the Company entered into a Share Purchase Agreement with NewStem and other related parties to provide aggregate funding of up to $4,000,000 to NewStem. This funding was to be provided through the sale of up to 50,000 common shares of NewStem to the Company representing 33% of New Stem’s outstanding shares. In 2018, the Company purchased 25,000 shares of NewStem for $2,000,000 acquiring an ownership interest of 20%. The Company made additional investments in 2019 and 2020 purchasing 12,500 shares each year for a $1,000,000 investment each year. NewStem sold and issued shares to third party investors in 2021, 2022 and 2023 resulting in the Company recognizing a gain on dilution of equity method investment. These transactions resulted in the Company having an ownership interest of 30.51% as of March 31, 2024 and December 31, 2023.

The Company accounts for its investment in NewStem under the equity method. As of March 31, 2024 and December 31, 2023, the carrying value of the investment in NewStem exceeded its portion of the underlying net assets of NewStem by approximately $1,655,000 and $1,800,000, respectively. The excess relates to identified intangible assets including license agreements, specialized work force (goodwill) and two separate projects of in process research and development (“IPR&D”) related to stem cell-based diagnostics and therapeutics for cancer chemotherapies.

The Company assesses its investment in NewStem for impairment on an annual basis or more frequently if indicators of impairment exist.

During the three months ended March 31, 2024, the Company recorded a reimbursement due to NewStem of approximately $36,000 (included in accounts payable in the accompanying balance sheet) for audit related costs. During the three months ended March 31, 2023, the Company reimbursed NewStem for audit related costs of approximately $37,000.

As disclosed in Note 8, the Company is in negotiations to acquire the remainder of NewStem in exchange for shares of Company stock. In anticipation of this transaction, the Company advanced $250,000 to NewStem in December 2023 and an additional $250,000 in March 2024. The related note agreement bears no interest and is payable on December 30, 2024. The agreement provides for discharge of the note upon the closing of the anticipated acquisition transaction. This note receivable has been presented as a noncurrent asset along with the investment in NewStem in the accompanying balance sheets. The second advance on the note was not received and recorded by NewStem until April 2024 and therefore is not reflected in the schedule of financial position of NewStem presented below.

NewStem is in the development stage and has incurred losses since its inception and has generated only minimal revenues under a licensing agreement. NewStem will need to obtain additional funds to continue its operations. NewStem management’s plans with regard to these matters include continued development, marketing and licensing of its products, as well as seeking additional financing arrangements. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient cash from sales, licensing or financing on terms acceptable to the Company. NewStem obtained additional funding of approximately $1,450,000 in April 2022 through the sale of shares of ordinary stock. NewStem’s management has adopted a cost reduction plan in order to adjust future operation expenses to its cash balance. In October 2023, the NewStem board of directors unanimously resolved to dismiss most employees which occurred in December 2023.

The aforementioned events indicate significant difficulties to continue as a concern. Additionally, Israel declared a state of war in October 2023 which resulted in a decrease in Israel’s economic and business activity. The security situation in Israel led to a disruption in the chain of supply and production, a decrease in the volume of national transportation, and a shortage in manpower as well as a decrease in the value of financial assets. As a result of the movement and work restrictions, NewStem began operating on a limited scale. Additionally, the situation has brought further difficulties in management’s efforts to seek additional financing.

The following table represents the Company’s investment in NewStem:

SCHEDULE OF INVESTMENTS

	2024			2023
	Three Months Ended March 31, 2024			Year Ended December 31, 2023
	(Unaudited)
Investment in NewStem, beginning	$	1,784,234		$	2,090,286
Allocation of net loss from NewStem, Ltd.		(51,859	)		(342,191	)
Gain on dilution of equity method investment		-			36,139
Distribution from NetCo
Investment in NewStem, ending	$	1,732,375		$	1,784,234

The results of operations of the Company’s investment in NewStem is summarized below (unaudited):

	2024			2023
	Three Months Ended March 31,
	2024			2023
Condensed income statement information:
Net revenues	$	-		$	95,000
Gross margin	$	-		$	84,000
Net loss	$	(170,000	)	$	(342,000	)
Company’s allocation of net loss from NewStem, Ltd.	$	(51,859	)	$	(104,591	)

The financial position of the Company’s investment in NewStem is summarized below:

	2024		2023
	As of
	March 31,		December 31,
	2024		2023
	(Unaudited)
Condensed balance sheet information:
Current assets	$	246,000	$	353,000
Non-current assets	$	6,000	$	9,000
Current liabilities	$	86,000	$	284,000
Non-current liabilities	$	250,000	$	-

Investment in NetCo

NovelStem owns a 50% interest in NetCo, a joint venture that owns the Net Force publishing franchise. The Company accounts for its investment in NetCo under the equity method and recognizes nominal royalties and administrative fees from this arrangement. The Company assesses its investment in NetCo for impairment on an annual basis or more frequently if indicators of impairment exist.

The following table represents the Company’s investment in NetCo:

SCHEDULE OF INVESTMENTS

	Three Months Ended March 31, 2024			Year Ended December 31, 2023
		(Unaudited)
Investment in NetCo, beginning	$	133,709		$	137,011
Allocation of net income (loss) from NetCo		(1,351	)		3,573
Distribution from NetCo		-			(6,875	)
Investment in NetCo, ending	$	132,358		$	133,709

The results of operations of the Company’s investment in NetCo is summarized below (unaudited):

	2024			2023
	Three Months Ended March 31,
	2024			2023
Condensed income statement information:
Net sales	$	373		$	15,750
Gross margin	$	373		$	15,750
Net income	$	(2,702	)	$	15,750
Company’s allocation of net income from NetCo	$	(1,351	)	$	7,875

The financial position of the Company’s investment in NetCo is summarized below:

	2024		2023
	As of
	March 31,		December 31,
	2024		2023
	(Unaudited)
Condensed balance sheet information:
Current assets	$	2,042	$	1,820
Non-current assets	$	272,799	$	272,799
Current liabilities	$	3,249	$	325
Non-current liabilities	$	-	$	-

NOTE 4—NOTES PAYABLE

In December 2023, the Company entered into two short term notes payable with unrelated parties, Hewlett Fund and AIGH Investment Partners, LLC. The notes are for $125,000 each, for a total of $250,000 in borrowings utilized for the funding of NewStem. The notes bear interest at 12% per annum and mature December 21, 2024, at which time all principal and accrued interest are due and payable. The note agreements include a provision whereby, in the event of a capital raise transaction by the Company, the note holders would be entitled to participate in the transaction in an amount equal to 133% of the amounts owed on the note agreements at the closing of the transaction. Interest expense related to these notes was $7,479 for the three months ended March 31, 2024.

Long-term notes payable are summarized as follows:

SCHEDULE OF LONG TERM NOTES PAYABLE

	As of
	March 31,			December 31,
	2024			2023
	(Unaudited)
Notes payable related parties:
Notes payable director and Executive Chairman	$	650,000		$	400,000
Accrued interest added to note balance		54,314			43,588
Total notes payable director and Executive Chairman		704,314			443,588
Note payable shareholder, principal amount		300,000			275,000
Less unamortized discount		(193,787	)		(213,185	)
Total note payable shareholder		106,213			61,815
Note payable, litigation funding agreement:
Note payable Omni Bridgeway (Fund 4) Invt. 3 L.P.		2,819,196			2,819,196
Accrued interest added to agreement balance		31,720			-
Total note payable, litigation funding agreement		2,850,916			2,819,196
Total notes payable		3,661,443			3,324,599
Less current portion		(2,850,916	)		-
Long-term notes payable	$	810,527		$	3,324,599

In May 2022, the Company entered into note agreements with two individuals who are related parties to borrow up to $600,000 for working capital needs. The agreements were amended in March 2024 to increase the total borrowing to $650,000 and extend the maturity date. The agreements provide for interest at a rate of 8% per annum through November 11, 2022, at which time the interest rate increased to 10% per annum for subsequent advances. The agreements mature September 1, 2025. The Company received advances of $650,000 and $400,000, respectively, pursuant to these agreements through March 31, 2024 and December 31, 2023.

On May 5, 2023, the Company entered into a long term note payable with a shareholder for $300,000 in financing to be funded $150,000 at inception and $150,000 in October 2023. This note bears interest at zero percent (0%) and matures on May 5, 2025. The note includes a guarantee which has been identified as an embedded derivative with a fair value of a liability of $535,000 at March 31, 2024 and December 31, 2023 which is reported separately on the balance sheet. The fair value of the note exceeds the proceeds, and the note has been discounted at inception so that the net liability is the fair value of the derivative. Accretion of the note discount of $44,398 has been reflected as part of interest expense in the statement of operations for three months ended March 31, 2024.

Note Payable, Litigation Funding Agreement

On February 11, 2022, the Company entered into a nonrecourse litigation funding agreement (the “Agreement”) with Omni Bridgeway (Fund 4) Invt. 3 L.P. (“Omni”) related to an arbitration proceeding disclosed in Note 7. The Agreement provides for Omni to fund all costs related to the arbitration up to $1,000,000 in exchange for an assignment of a certain portion of rights to and interest in claims related to this arbitration. The agreement provides for specific calculations of the portion of any claims collected to be received by Omni with the remainder collectible by the Company. Additionally, the agreement provides for repayment of funded costs pursuant to the same multiple calculations in the event of a favorable outcome that does not include the collection of claims.

During July 2023, the arbitration was settled with a partially favorable outcome for the Company. As a result of the ruling disclosed in Note 7, the liability became probable and reasonably estimable, and the Company has recorded the full liability due to Omni as of December 31, 2023. This liability consists of expenses funded by Omni of $933,065, including $310,000 advanced for working capital, and related fees or investment return to Omni calculated as contractual multiples of funding totaling $1,886,131 as of December 31, 2023 for a total liability of $2,819,196. This agreement bears interest at 5% per annum beginning January 2024 and is payable on January 10, 2025.

NOTE 5—EQUITY

(a) General

At March 31, 2024 and December 31, 2023, the Company had issued and outstanding 46,881,475 shares of its common stock, par value $0.01 per share. Holders of outstanding common stock are entitled to receive dividends when, as and if declared by the Board and to share ratably in the assets of the Company legally available for distribution in the event of a liquidation, dissolution or winding up of the Company.

(b) Summary Employee Option Information

The Company’s stock option plan provides for the grant to officers, directors, third party contractors and other future key employees of options to purchase shares of common stock. The purchase price may be paid in cash or, if the option is “in-the-money”, it is automatically exercised “net”. In a net exercise of an option, the Company does not require a payment of the exercise price of the option from the optionee but reduces the number of shares of common stock issued upon the exercise of the option by the smallest number of whole shares that has an aggregate fair market value equal to or in excess of the aggregate exercise price for the option shares covered by the option exercised. Each option is exercisable to one share of the Company’s common stock. Most options expire within six years from the date of the grant and generally vest on the first anniversary date of their issuance. Pursuant to the Equity Incentive Plan the Company’s board of directors approved on November 12, 2018, an aggregate of 5,760,000 options have been issued to directors and investor relations professionals as of March 31, 2024. An additional 600,000 options were issued to directors on April 1, 2024.

The Company utilized the Black-Scholes option-pricing model to estimate fair value, utilizing the following assumptions for the options issued during the three months ended March 31, 2023 (all in weighted averages):

Risk-free interest rate		3.5	%
Expected term of options, in years		4.00
Expected annual volatility		191.1	%
Expected dividend yield		0	%
Determined weighted average grant date fair value per option	$	0.19

The expected term of the options represents an estimate of the length of time until the expected date of exercising the options. Options granted have a maximum life of 7 years. With respect to determining expected exercise behavior, the Company has grouped its option grants into certain groups to track exercise behavior and establish historical rates. The Company estimated volatility by considering historical stock volatility over the expected term of the option. The risk-free interest rates are based on the U.S. Treasury yields for a period consistent with the expected term. The dividend yield of 0% is based on the Company’s history and expectation of dividend payout. The Company has not paid and does not anticipate paying dividends in the near future.

A summary of the Company’s option plans for the three months ended March 31, 2024, is presented below (unaudited):

SCHEDULE OF STOCK OPTION ACTIVITIES

	Number		Weighted
	of		Average
	Options		Exercise
	(in shares)		Price
Outstanding, December 31, 2023		5,760,000	$	0.14
Granted		-		-
Outstanding, March 31, 2024		5,760,000	$	0.14
Exercisable, March 31, 2024		5,760,000	$	0.14

Stock-based compensation expense was approximately $13,000 and $15,000 in the three months ended March 31, 2024 and 2023, respectively.

The total compensation cost related to non-vested awards not yet recognized was approximately $67,000 as of March 31, 2023. As of March 31, 2023, 360,000 options were unvested. These options vested during March 2024.

(d) Warrants

The Company has issued warrants at exercise prices equal to or greater than the market value of the Company’s common stock at the date of issuance. A summary of warrant activity follows (unaudited):

SUMMARY OF WARRANTS ACTIVITY

	Number of		Weighted
	shares		Average
	underlying		Exercise
	warrants		Price
Outstanding, December 31, 2023		3,000,000	$	0.12
Granted		-		-
Exercised		-		-
Forfeited or expired		-		-
Outstanding, March 31, 2024		3,000,000	$	0.12

The warrant agreements were amended on May 12, 2023 to extend the expiration date to June 28, 2025. The warrants outstanding at March 31, 2024 have a weighted average remaining contractual life of approximately one year and three months.

NOTE 6—INCOME TAXES

The Company’s income tax provision differs from the expense that would result from applying statutory rates to income (loss) before taxes. A reconciliation of the provision (benefit) for income taxes with amounts determined by applying the statutory U.S. federal income tax rate to income before income taxes is as follows (unaudited):

SCHEDULE OF INCOME BEFORE INCOME TAX

	2024			2023
	Three Months Ended March 31,
	2024			2023
Computed tax at the federal statutory rate of 21%	$	(63,689	)	$	(56,452	)
State income taxes, net of federal income tax benefit		(13,178	)		(11,680	)
Change in federal valuation allowance		85,164			87,972
Foreign rate differential		(8,297	)		(19,840	)
Total provision for income tax	$	-		$	-

NOTE 7—COMMITMENTS AND CONTINGENCIES

The Company was the claimant in an arbitration proceeding against their 50% partner in NetCo. The Company initiated the arbitration proceeding in an effort to maximize the total potential value to be derived from fully utilizing the NetCo intellectual property across publishing, entertainment, digital media, merchandising and other ancillary markets. Arbitration hearings were held at the end of July 2022. Arbitration proceedings for the joint owners of NetCo concluded during 2022 and the arbitrator rendered a decision in July 2023. The arbitrator ruled against the Company on certain key issues of the arbitration and in the Company’s favor on two key issues of the arbitration.

As a result of this ruling, the costs related to the litigation funding agreement disclosed in Note 4 were recognized and a total liability of $2,819,196 was recorded.

NOTE 8—SUBSEQUENT EVENTS

The Company evaluated subsequent events through the date these financial statements were available to be issued and filed with the SEC.

During the fourth quarter of 2023, the Company entered into negotiations with NewStem stockholders for the acquisition of the shares not held by the Company. The negotiations are ongoing for the transaction in which the Company would acquire all outstanding shares in exchange for shares of NovelStem stock. Company management anticipates the transaction to conclude in the second quarter of 2024. In anticipation of the Company acquiring the remaining ownership of NewStem, the Company has loaned $500,000 to NewStem to ensure continuing operations. See Note 3.

An additional 600,000 options were issued to directors on April 1, 2024 pursuant to the Company’s Equity Incentive Plan.

In April 2024, the Company borrowed $100,000 from unrelated parties pursuant to convertible debt agreements. These agreements bear interest at 10% per annum and mature December 30, 2025. The unpaid principal balance of these notes and any accrued interest may be converted into shares of the Company’s common stock at a conversion price of $0.13 per share.

NOVELSTEM INTERNATIONAL CORP.

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Statements in the following discussion and throughout this Form 10-Q that are not historical in nature are “forward-looking statements.” You can identify forward-looking statements by the use of words such as “expect,” “anticipate,” “estimate,” “may,” “will,” “should,” “intend,” “believe,” and similar expressions. Although we believe the expectations reflected in these forward-looking statements are reasonable, such statements are inherently subject to risk and we can give no assurances that our expectations will prove to be correct. Actual results could differ from those described in this Form 10-Q because of numerous factors, many of which are beyond our control. We undertake no obligation to update these forward-looking statements to reflect events or circumstances after the date of this Form 10-Q or to reflect actual outcomes.

Overview

We are a development stage company and reported net losses of approximately $303,000 and $269,000 for the three months ended March 31, 2024 and 2023, respectively. We had current assets of approximately $36,000 and current liabilities of $3,297,000 as of March 31, 2024. As of December 31, 2023, our current assets and current liabilities were approximately $87,000 and $346,000, respectively. The significant increase in current liabilities is primarily due to the litigation funding agreement liability classification changing from noncurrent to current in January 2024.

We have prepared our financial statements for the three months ended March 31, 2024 assuming that we will continue as a going concern. Our continuation as a going concern is dependent upon NewStem’s ability to successfully develop and commercialize its products, improving our profitability and the continuing financial support from our shareholders as well as obtaining additional outside funding. Our sources of capital in the past have included the sale of equity securities, which include common stock sold in private transactions, large alternative minimum tax refunds, and related party debt as well as debt from unrelated parties.

NewStem is a development stage Israeli biotech limited liability company focused on pioneering intellectual property related to haploid human embryonic stem cells for the development of personalized diagnostics and therapeutics for genetic and epigenetic diseases. NewStem has incurred losses related to in process research and development since inception and the Company records our percentage allocation of these net losses as incurred. We have included the condensed financial statements of NewStem as an exhibit to this Form 10-Q.

RESULTS OF OPERATIONS

The following discussion of our financial condition and results of operations should be read in conjunction with our financial statements and the related notes thereto and other financial information appearing elsewhere in this Form 10-Q. In the discussion below, general and administrative expenses are referred to as “G&A expenses”.

	Three Months Ended March 31,
	2024			2023			Change
Administrative fee income	$	3,000		$	-		$	3,000
Operating expenses:
G&A expenses		183,306			164,792			(18,514	)
Total operating expenses		183,306			164,792			(18,514	)
Loss from operations		(180,306	)		(164,792	)		(15,514	)
Other expenses:
Gain on derivative instrument		(25,000	)		-			(25,000	)
Interest expense		94,764			7,313			87,451
Total other expenses		69,764			7,313			62,451
Net loss before equity in net
loss of equity method investees		(250,070	)		(172,105	)		(77,965	)
Equity in net loss of equity method investees		(53,210	)		(96,716	)		43,506
Net loss	$	(303,280	)	$	(268,821	)	$	(34,459	)

We are a holding company whose primary assets are our ownership of equity interests in NewStem and NetCo. We conduct no other business and as a result, we have no revenue or cost of revenue. We do charge annual administrative fees to an affiliated entity.

The Company incurs G&A expenses primarily related to professional fees, insurance and stock based compensation. We incurred G&A expenses of approximately $183,000 and $165,000 for the three months ended March 31, 2024 and 2023, respectively. Specifically, professional fees increased by approximately $22,000 in the three months ended March 31, 2024 as compared to the three months ended March 31, 2023. Primarily due to an increase in audit fees and general counsel legal fees. Other miscellaneous G&A expenses decreased by approximately $2,000.

Stock compensation expense, included in G&A expenses, decreased by approximately $2,000 in the three months ended March 31, 2024 as compared to the three months ended March 31, 2023 due to a smaller number of options awarded in the current period as compared to the prior period.

Interest expense increased by approximately $87,000 in the three months ended March 31, 2024 as compared to the three months ended March 31, 2023 due to the increased debt incurred through March 31, 2024.

The Company has recorded no income tax expense as we have incurred operating losses and all deferred tax assets are fully offset by an income tax valuation allowance.

We reported net losses from equity method investees in all periods presented. The net losses reported for the three months ended March 31, 2024 included a loss from NetCo of $1,351 and a loss from NewStem of $51,859. The net losses reported for the three months ended March 31, 2023 included net income of $7,875 from NetCo which was offset by net loss of $104,591 from NewStem.

Liquidity and Capital Resources

We have not paid dividends on our common stock since our name change and business focus shift in 2018. Our present policy is to apply cash to investments in product development at NewStem, acquisitions or expansion; consequently, we do not expect to pay dividends on common stock in the foreseeable future.

We expect to continue to incur greater expenses in the near future as we expand our business, including funding NewStem, or enter into strategic partnerships. We also expect our G&A expenses to increase as we expand our administrative staff and add infrastructure.

The Company will need to obtain additional funds to continue its operations. Management’s plans with regard to these matters include additional financing and fundraising until our equity investment in NewStem is profitable. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient cash from financing on terms acceptable to the Company, or that NewStem will become profitable.

In May 2022, the Company entered into note agreements with Jan Loeb, our Executive Chairman and Jerry Wolasky, a member of the Board, to borrow up to an aggregate of $600,000 for working capital needs. The note agreements were amended in March 2024 to increase the total borrowing to $650,000 and extend the maturity date. The agreements provide for interest at a rate of 8% per annum, increased to 10% per annum for advances subsequent to November 11, 2022, and mature September 1, 2025. As of the date of this Quarterly Report, the full amount of $650,000 has been funded pursuant to these agreements.

During the year ended December 31, 2023, the Company entered into a note agreement with a shareholder to borrow $300,000 for continued working capital. This note bears interest at zero percent (0%) and matures on May 5, 2025. The note includes a guarantee which has been identified as an embedded derivative with a fair value of a liability of $535,000 at March 31, 2024 and December 31, 2023.

In December 2023, the Company entered into two short term notes payable with unrelated parties for a total of $250,000 in borrowings utilized for the funding of NewStem. The notes bear interest at 12% per annum and mature December 21, 2024, at which time all principal and accrued interest are due and payable. The note agreements include a provision whereby, in the event of a capital raise transaction by the Company, the note holders would be entitled to participate in the transaction in an amount equal to 133% of the amounts owed on the note agreements at the closing of the transaction.

In April 2024, the Company borrowed $100,000 from unrelated parties pursuant to convertible debt agreements. These agreements bear interest at $10% per annum and mature December 30, 2025. The unpaid principal balance of these notes and any accrued interest may be converted into shares of the Company’s common stock at a conversion price of $0.13 per share.

Net Cash Used In Operating Activities.

For the three months ended March 31, 2024, net cash used in operating activities was approximately $73,000, which consisted primarily of a net loss of approximately $303,000, offset by noncash equity in loss of equity method investees of approximately $53,000, accretion of discount on notes payable of approximately $44,000, stock based compensation of approximately $14,000 and interest added to notes payable of approximately $42,000 and reduced by gain on derivative instrument of $25,000. Additionally, cash was used in operations related to an increase in current assets of approximately $3,000 and an increase in accrued liabilities and other payables of approximately $95,000.

For the three months ended March 31, 2023, net cash used in operating activities was approximately $28,000, which consisted primarily of a net loss of approximately $269,000, offset by noncash equity in loss of equity method investees of approximately $97,000 and distributions from equity method investees of approximately $8,000, stock based compensation of approximately $15,000 and interest added to notes payable of approximately $7,000. Additionally, cash was used in operations related to an increase in current assets of approximately $13,000 and an increase in accrued liabilities and other payables of approximately $101,000.

Net Cash Used In Investing Activities.

During the three months ended March 31, 2024, $250,000 was loaned to NewStem in an investing activity. For the three months ended March 31, 2023, no net cash was used in investing activities.

Net Cash Provided By Financing Activities.

For the three months ended March 31, 2024, net cash provided by financing activities was $275,000, consisting of long-term borrowings from two directors and a significant stockholder totaling $275,000.

For the three months ended March 31, 2023, net cash provided by financing activities was $62,000, consisting of long-term borrowings from two directors.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK

This section is not applicable.

ITEM 4.

CONTROLS AND PROCEDURES

Our Principal Executive Officer and Chief Financial Officer conducted an evaluation of our controls and procedures. We have identified material weaknesses in our internal control and procedures and internal control over financial reporting. If not remediated, our failure to establish and maintain effective disclosure controls and procedures and internal control over financial reporting could result in material misstatements in our financial statements and a failure to meet our reporting and financial obligations, each of which could have a material adverse effect on our financial condition and the trading price of our common stock.

Maintaining effective internal control over financial reporting and effective disclosure controls and procedures are necessary for us to produce reliable financial statements. We have re-evaluated our internal control over financial reporting and our disclosure controls and procedures and concluded that they were not effective as of March 31, 2024 and we concluded there was a material weakness in the design of our internal control over financial reporting as it relates to insufficient resources to employ proper segregation of duties over the processing of transactions and financial reporting.

A material weakness is defined as a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act) during the period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II

ITEM 1.

LEGAL PROCEEDINGS

As noted above, NetCo owns all rights to the “Tom Clancy’s Net Force” intellectual property in all media, including film, television, and video games. As part of the joint venture, NetCo has published more than a dozen books and had an ABC miniseries.

After Tom Clancy passed away in 2013, his estate and business partners refused to cooperate in exploiting the intellectual property. After trying to amicably resolve the dispute, the Company initiated arbitration proceedings with the American Arbitration Association. The Company’s arbitration demand asserted claims for breach of the joint venture agreement and breach of fiduciary duty. Both claims arise from C.P. Group’s failure to make reasonable, good faith efforts to exploit the full array of media rights relating to Net Force. The Company’s goal is to maximize the total potential value of the NetCo intellectual property across video games, streaming, digital media, merchandising and other ancillary markets. The Company believes that the value of the intellectual property is significant.

The arbitration evidentiary hearing concluded on October 20, 2022, and the arbitrator ordered the parties to submit post-hearing briefs. Final briefs were filed in January 2023. The Arbitrator ruled in the Company’s favor on two key issues of the arbitration and ruled against the Company in other key issues.

The Arbitrator ruled in NovelStem’s favor on the issue of contract interpretation of the Netco Partners JV Agreement. The Arbitrator also found that the Company’s joint venture partner failed to use “reasonable, good faith efforts” to license and exploit the Net Force concept, in breach of its contractual obligations under the Netco Partners’ Joint Venture Agreement. The Arbitrator confirmed NovelStem’s contractual right to use Tom Clancy’s name as a possessory credit in the Net Force title (Tom Clancy’s Net Force). However, the arbitrator did not award any damages to the Company and did not cede operating control of the joint venture to the Company as requested. As such, the Company continues to struggle to maximize the potential of the NetCo asset.

To fund efforts to maximize the value of NetCo, NovelStem has secured non-recourse litigation funding. As a result of this ruling, the costs related to the litigation funding agreement were recognized. All costs related to the litigation and the related litigation funding agreement were recorded by the Company for a total liability of $2,819,196.

ITEM 1A.

RISK FACTORS

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

	(a)	Not applicable.

	(b)	Not applicable.

	(c)	Not applicable.

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4.

MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5.

OTHER INFORMATION

None.

ITEM 6.

EXHIBITS

#31.1	Certification of Principal Executive Officer and Executive Chairman pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
#31.2	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
#32.1	Certification of Principal Executive Officer and Executive Chairman pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
#32.2	Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
#33.1	Condensed Financial Statements of NewStem Ltd. As of and for the three months ended March 31, 2024

#101.1 The following financial statements from NovelStem International Corp.’s Form 10-Q for the quarter ended March 31, 2024, filed on May 15, 2025, formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Balance Sheets, (ii) Condensed Statements of Operations, (iii) Condensed Statements of Changes in Shareholders’ Equity, (iv) Condensed Statements of Cash Flows and (v) Notes to Condensed Financial Statements, tagged as blocks of text.

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

#	This exhibit is filed or furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

	NOVELSTEM INTERNATIONAL CORP.

Date: May 15, 2024	By:	/s/ Jan Loeb
	Name:	Jan Loeb
	Title:	Executive Chairman

EX-31.1 2 ex31-1.htm

Exhibit 31.1

I, Jan H. Loeb, the Principal Executive Officer and Executive Chairman of NovelStem International Corp. certify that:

	1.	I have reviewed this report on Form 10-Q of NovelStem International Corp.;

	2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

	3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

	4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a- 15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and l have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: May 15, 2024

By:	/s/ JAN H. LOEB
	Jan H Loeb
	Principal Executive Officer and Executive Chairman

EX-31.2 3 ex31-2.htm

Exhibit 31.2

I, Christine T. Jenkins, the Chief Financial Officer of NovelStem International Corp. certify that:

	1.	I have reviewed this report on Form 10-Q of NovelStem International Corp.;

	2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

	3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

	4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a- 15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: May 15, 2024

By:	/s/ CHRISTINE T. JENKINS
	Christine T. Jenkins
	Chief Financial Officer

EX-32.1 4 ex32-1.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of NovelStem International Corp. (the “Company”) for the quarterly period ended March 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jan H. Loeb, Principal Executive Officer and Executive Chairman of the Company, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Jan H. Loeb
Jan H. Loeb
Principal Executive Officer and Executive Chairman
May 15, 2024

EX-32.2 5 ex32-2.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of NovelStem International Corp. (the “Company”) for the quarterly period ended March 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Christine T. Jenkins, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Christine T. Jenkins
Christine T. Jenkins
Chief Financial Officer
May 15, 2024

EX-33.1 6 ex33-1.htm

Exhibit 33.1

NewStem Ltd.

Condensed Interim Financial Statements

As of March 31, 2024

(Unaudited)

NewStem Ltd.

Condensed Interim Financial Statements as of March 31, 2024

(Unaudited)

Contents

	Page

Condensed Interim Balance Sheets	2

Condensed Interim Statements of Operations	3

Condensed Interim Statements of Changes in Shareholders’ Equity (Deficiency)	4

Condensed Interim Statements of Cash Flows	5

Notes to the Condensed Interim Financial Statements	6

NewStem Ltd.

Condensed Interim Balance Sheets as of

(Unaudited)

		March 31,			December 31,
		2024			2023
	Note	US$ thousands			US$ thousands
Assets

Current assets
Cash and cash equivalents			184			324
Other current assets			62			29
Total current assets			246			353

Non-current assets
Property and equipment, net			6			9

Total assets			252			362

Liabilities and shareholders’ equity (deficiency)

Current liabilities
Accounts payable			39			34
Related party	3		250			250

Total Liabilities			289			284

Shareholders’ equity (Deficiency)
Ordinary shares			*			*
Additional paid-in capital			9,174			9,167
Accumulated deficit			(9,211	)		(9,089	)
Total shareholders’ equity (Deficiency)			(37	)		78

Total liabilities and shareholders’ equity			252			362

/s/ Jan Loeb
Jan Loeb
Chairperson of the Board

Date of approval of the financial statements: May15, 2024.

* Represents an amount less than $1 thousand.

The accompanying notes are an integral part of the condensed interim financial statements.

NewStem Ltd.

Condensed Interim Statements of Operations for the

(Unaudited)

	Three-month		Three-month
	period ended		period ended
	March 31,		March 31,
	2024		2023
	US$ thousands		US$ thousands
Revenues		-		95

Cost of revenues		-		11

Gross profit		-		84

Operating expenses:

Research and development expenses		108		388

General and administrative expenses, net		12		30

Operating loss		120		334

Financial expenses, net		2		8

Loss for the period		122		342

The accompanying notes are an integral part of the condensed interim financial statements.

NewStem Ltd.

Condensed Interim Statements of Changes in Shareholders’ Equity (Deficiency)

(Unaudited)

	Ordinary shares				Additional paid-in capital		Accumulated deficit			Total
	Number of shares		US$ thousands		US$ thousands		US$ thousands			US$ thousands
For the three - month period ended March 31, 2024

Balance as of January 1, 2024		163,906		*		9,167		(9,089	)		78

Stock based compensation		-		-		7		-			7
Loss for the period		-		-		-		(122	)		(122	)

Balance as of March 31, 2024		163,906		*		9,174		(9,211	)		(37	)

For the three - month period ended March 31, 2023

Balance as of January 1, 2023		163,494		*		8,686		(7,970	)		716

Stock based compensation		-		-		78		-			78
Loss for the period		-		-		-		(342	)		(342	)

Balance as of March 31, 2023		163,494		*		8,764		(8,312	)		452

* Represents an amount less than $1 thousand.

The accompanying notes are an integral part of the condensed interim financial statements.

NewStem Ltd.

Condensed Interim Statements of Cash Flows for the

(Unaudited)

	Three-month			Three-month
	period ended			period ended
	March 31,			March 31,
	2024			2023
	US$ thousands			US$ thousands
Cash flows from operating activities

Loss for the period		(122	)		(342	)

Adjustments required to reconcile loss to net cash used in operating activities:

Depreciation		3			4
Revaluation of convertible financial instrument		-			3
Stock based compensation		7			78
Increase in other current assets		(33	)		(25	)
Increase in accounts payable		5			25

Net cash used in operating activities		(140	)		(257	)

Net decrease in cash and cash equivalents		(140	)		(257	)

Cash and cash equivalents at the beginning of the period		324			878

Cash and cash equivalents at the end of the period		184			621

The accompanying notes are an integral part of the condensed interim financial statement.

NewStem Ltd.

Notes to the Condensed Interim Financial Statements as of March 31, 2024

Note 1 - General

	A.	NewStem Ltd. (“the Company”) was incorporated in September 2016 under the laws of the State of Israel and commenced its business operations in July 2018.

	B.	The Company is a development stage company utilizing its pioneering intellectual property related to haploid human embryonic stem cells for the development of personalized diagnostics and therapeutics for genetic and epigenetic diseases.

	C.	Going Concern

Since inception, the Company has accumulated losses of US$9,211 thousand. During the three-month period ended March 31, 2024, the Company has incurred losses of US$122 thousand. As of March 31, 2024, the Company’s cash and cash equivalents balance is US$184 thousand, and the net cash used in operating activities during the three-month period ended March 31, 2024, is US$140 thousand.

The Company will need to obtain additional funds to continue its operations over the next 12 months. Management’s plans with regard to these matters include continued development, marketing and licensing of its products, as well as seeking additional financing arrangements. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient cash from sales, licensing or financing on terms acceptable to the Company (See also Note 1D). The Company’s management has adopted a cost reduction plan in order to adjust future operation expenses to its cash balance. On December 31, 2023, most employees were dismissed as per the board of directors resolution on October 23, 2023.

The above-mentioned events incur significant difficulties to continue to operate the Company’s business and there is a substantial doubt about its ability to continue as a going concern during the look-forward period. The financial statements do not include any adjustments to the carrying amounts and classification of assets, liabilities, and reported expenses that may be necessary if the Company were unable to continue as a going concern.

“Iron Swords” war

Following the brutal attacks on Israel, the mobilization of army reserves, and the Government declaring a state of war (“Iron Swords” war) in October 2023, there was a decrease in Israel’s economic and business activity. The security situation has led, inter alia, to a disruption in the chain of supply and production, a decrease in the volume of national transportation, a shortage in manpower as well as a decrease in the value of financial assets.

The situation has brought further difficulties in management’s efforts to seek additional financing arrangements.

Definitions

In these financial statements –

	1.	The Company – NewStem Ltd.
	2.	Related Party – Within its meaning in ASC 850, “Related Party Transactions”.

NewStem Ltd.

Notes to the Condensed Interim Financial Statements as of March 31, 2024

Note 2 - Basis of Presentation

The accompanying condensed interim balance sheet as of March 31, 2024, and the condensed interim statement of operations, changes in shareholders’ equity (deficiency) and cash flows for the three-month period ended March 31, 2024, are unaudited. These unaudited condensed interim financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America.

In the opinion of management, the accompanying unaudited condensed interim financial statements contain all adjustments, necessary for a fair statement of its financial position as of March 31, 2024. It is suggested that these condensed interim financial statements be read in conjunction with the audited financial statements and accompanying notes included in the Company’s report for the year ended December 31, 2023. Results for the interim periods presented are not necessarily indicative of the results to be expected for the full year.

The accounting principles used in the preparation of the interim statements are consistent with those used in the preparation of the financial statements of the Company as of December 31, 2023.

Note 3 - Related Parties

The Company engaged with its shareholders to receive consulting services and lab renting.

In addition, the Company is required to pay a shareholder sublicense fees at a rate of up to 12% of sublicense.

Transactions

	Three-month		Three-month
	period ended		period ended
	March 31,		March 31,
	2024		2023
	US$ thousands		US$ thousands
Cost of revenues		-		11

Research and development expenses		27		83

Balances

	March 31,		December 31,
	2024		2023
	US$ thousands		US$ thousands
Other accounts receivable		50		14

Accounts payable		11		11

Related party (See C below)		250		250

Note 3 - Related Parties (cont’d)

C.	(1)	The Company negotiated with a related party to make an additional investment in the Company. In December 2023, as part of this negotiation, the Company received funds from the related party in the amount of US$250 thousand. At the date of the approval of the financial statements as of December 31, 2023, since no binding agreement that determined the nature of such investment had been signed, the funds received were classified as a current liability.

	(2)	On March 31, 2024, the Company signed a Loan Agreement (“the Loan”) in the amount of US$500 thousand with a related party. The loan amount shall bear no interest. The amount is made up of two equal payments in the amount of US$250 thousand, the first payment was received in December 2023 (see section 1 above), and the second payment was received in April 2024. The first payment may be used by the Company for its operations. The second payment shall be restricted for use and deposited in an escrow, until the related party directs the Company to use those US$250 thousand, or if the Company enters into a share purchase agreement (“SPA”) with the related party. The entire loan of US$500 thousand shall be repaid on December 30, 2024, unless the SPA is closed by June 30, 2024, when if so, the entire loan shall be forgiven.

EX-101.SCH 7 nstm-20240331.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Statements of Shareholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - NATURE OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - EQUITY METHOD INVESTMENTS link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - EQUITY link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - EQUITY METHOD INVESTMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - NOTES PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - NATURE OF OPERATIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE NUMBER OF SHARES OF DILUTIVE (Details) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - SCHEDULE OF WARRANTS AND STOCK OPTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - SCHEDULE OF INVESTMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - SCHEDULE OF OPERATIONS AND FINANCIAL POSITION INVESTMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - EQUITY METHOD INVESTMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - SCHEDULE OF LONG TERM NOTES PAYABLE (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - SCHEDULE OF FAIR VALUE OF OPTION USING VALUATION ASSUMPTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - SUMMARY OF WARRANTS ACTIVITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - SCHEDULE OF INCOME BEFORE INCOME TAX (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - SCHEDULE OF INCOME BEFORE INCOME TAX (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 nstm-20240331_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 nstm-20240331_def.xml XBRL DEFINITION FILE EX-101.LAB 10 nstm-20240331_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Treasury Stock, Common [Member] Investment, Name [Axis] New Stem Ltd [Member] NetCo Partners [Member] Title and Position [Axis] Shareholders And Directors [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Antidilutive Securities [Axis] Warrant [Member] Equity Option [Member] Statistical Measurement [Axis] Maximum [Member] Affiliation [Axis] Investment, Affiliated Issuer, Controlled, Not Majority-Owned [Member] Statement of Financial Position Location, Balance [Axis] Accounts Payable [Member] Legal Entity [Axis] Related and Nonrelated Parties [Axis] Hewlett Fund [Member] AIGH Investment Partners, LLC [Member] Debt Instrument [Axis] Two Short Term Notes Payable [Member] Two Individuals [Member] Shareholder [Member] Related Party [Member] Omni Bridgeway (Fund 4) Invt. 3 L.P. [Member] Director and Executive Chairman [Member] Directot and Investor [Member] Director [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Convertible Debt Agreements [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current assets: Cash Accounts receivable, administrative fees Prepaid expenses Total current assets Investment in Netco Partners Note receivable, NewStem Ltd Investment in NewStem Ltd Total assets LIABILITIES AND SHAREHOLDERS’ DEFICIT Current liabilities: Accounts payable Notes payable Current portion of long-term notes payable, including accrued interest Accrued expenses Total current liabilities Long-term liabilities: Long-term notes payable, including accrued interest, net Derivative liability, guarantee Total long-term liabilities Total liabilities Commitments and contingencies (see Note 7) Shareholders’ deficit: Common stock, $.01 par value, 100,000,000 shares authorized, 50,316,672 shares issued, and 46,881,475 shares outstanding as of March 31, 2024 and December 31, 2023 Additional paid-in capital Accumulated deficit Treasury stock, at cost, 3,435,197 shares as of March 31, 2024 and December 31, 2023 Total shareholders’ deficit Total liabilities and shareholders’ deficit Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Treasury stock, shares Income Statement [Abstract] Administrative fee income Operating expenses: General and administrative expenses Total operating expenses Loss from operations Other expenses: Gain on derivative instrument Interest expense Total other expenses Loss before income taxes Provision for income tax Loss before equity in net income of equity method investees Equity in net loss of equity method investees Net loss Basic and diluted net loss per share: Net loss per share - basic Net loss per share - diluted Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Diluted Statement [Table] Statement [Line Items] Balance, value Balance, shares Net loss Stock option compensation Balance, value Balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities: Equity in net loss of equity method investees Distribution from NetCo Partners Accretion of discount on note payable Accrued interest added to long-term notes payable Stock-based compensation Change in operating assets and liabilities: Accounts receivable, administrative fees Prepaid expenses Accounts payable Accrued expenses Net cash used in operating activities Cash flows from investing activities: Loans made Net cash used in investing activities Cash flows from financing activities: Proceeds from long term notes payable Net cash provided by financing activities Net change in cash Cash at the beginning of the period Cash at the end of the period Supplemental cash flow information: Cash paid during the period for: Interest Organization, Consolidation and Presentation of Financial Statements [Abstract] NATURE OF OPERATIONS Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Equity Method Investments and Joint Ventures [Abstract] EQUITY METHOD INVESTMENTS Debt Disclosure [Abstract] NOTES PAYABLE Equity [Abstract] EQUITY EX-101.PRE 11 nstm-20240331_pre.xml XBRL PRESENTATION FILE XML 13 R1.htm IDEA: XBRL DOCUMENT

Cover - shares	3 Months Ended
Cover - shares	Mar. 31, 2024	May 15, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-14332
Entity Registrant Name	NOVELSTEM INTERNATIONAL CORP.
Entity Central Index Key	0000912544
Entity Tax Identification Number	65-0385686
Entity Incorporation, State or Country Code	FL
Entity Address, Address Line One	2255 Glades Road
Entity Address, Address Line Two	Suite 221A
Entity Address, City or Town	Boca Raton
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33431
City Area Code	410
Local Phone Number	598-9024
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		46,881,475

XML 14 R2.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash	$ 5,181	$ 53,063
Accounts receivable, administrative fees	3,000
Prepaid expenses	27,855	33,540
Total current assets	36,036	86,603
Investment in Netco Partners	132,358	133,709
Note receivable, NewStem Ltd	500,000	250,000
Investment in NewStem Ltd	1,732,375	1,784,234
Total assets	2,400,769	2,254,546
Current liabilities:
Accounts payable	149,672	54,257
Notes payable	250,000	250,000
Current portion of long-term notes payable, including accrued interest	2,850,916
Accrued expenses	45,974	42,223
Total current liabilities	3,296,562	346,480
Long-term liabilities:
Long-term notes payable, including accrued interest, net	810,527	3,324,599
Derivative liability, guarantee	535,000	535,000
Total long-term liabilities	1,345,527	3,859,599
Total liabilities	4,642,089	4,206,079
Commitments and contingencies (see Note 7)
Shareholders’ deficit:
Common stock, $.01 par value, 100,000,000 shares authorized, 50,316,672 shares issued, and 46,881,475 shares outstanding as of March 31, 2024 and December 31, 2023	468,815	468,815
Additional paid-in capital	290,920,710	290,907,217
Accumulated deficit	(293,431,091)	(293,127,811)
Treasury stock, at cost, 3,435,197 shares as of March 31, 2024 and December 31, 2023	(199,754)	(199,754)
Total shareholders’ deficit	(2,241,320)	(1,951,533)
Total liabilities and shareholders’ deficit	$ 2,400,769	$ 2,254,546

XML 15 R3.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	50,316,672	50,316,672
Common stock, shares outstanding	46,881,475	46,881,475
Treasury stock, shares	3,435,197	3,435,197

XML 16 R4.htm IDEA: XBRL DOCUMENT

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Administrative fee income	$ 3,000
Operating expenses:
General and administrative expenses	183,306	164,792
Total operating expenses	183,306	164,792
Loss from operations	(180,306)	(164,792)
Other expenses:
Gain on derivative instrument	(25,000)
Interest expense	94,764	7,313
Total other expenses	69,764	7,313
Loss before income taxes	(250,070)	(172,105)
Provision for income tax
Loss before equity in net income of equity method investees	(250,070)	(172,105)
Equity in net loss of equity method investees	(53,210)	(96,716)
Net loss	$ (303,280)	$ (268,821)
Basic and diluted net loss per share:
Net loss per share - basic	$ (0.01)	$ (0.01)
Net loss per share - diluted	$ (0.01)	$ (0.01)
Weighted Average Number of Shares Outstanding, Basic	46,881,475	46,881,475
Weighted Average Number of Shares Outstanding, Diluted	46,881,475	46,881,475

XML 17 R5.htm IDEA: XBRL DOCUMENT

Condensed Statements of Shareholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Treasury Stock, Common [Member]	Total
Balance, value at Dec. 31, 2022	$ 468,815	$ 290,604,327	$ (288,940,510)	$ (199,754)	$ 1,932,878
Balance, shares at Dec. 31, 2022	46,881,475			3,435,197
Net loss			(268,821)		(268,821)
Stock option compensation		15,077			15,077
Balance, value at Mar. 31, 2023	$ 468,815	290,619,404	(289,209,331)	$ (199,754)	1,679,134
Balance, shares at Mar. 31, 2023	46,881,475			3,435,197
Balance, value at Dec. 31, 2023	$ 468,815	290,907,217	(293,127,811)	$ (199,754)	(1,951,533)
Balance, shares at Dec. 31, 2023	46,881,475			3,435,197
Net loss			(303,280)		(303,280)
Stock option compensation		13,493			13,493
Balance, value at Mar. 31, 2024	$ 468,815	$ 290,920,710	$ (293,431,091)	$ (199,754)	$ (2,241,320)
Balance, shares at Mar. 31, 2024	46,881,475			3,435,197

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

- Definition

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2

+ Details

XML 18 R6.htm IDEA: XBRL DOCUMENT

Condensed Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net loss	$ (303,280)	$ (268,821)
Equity in net loss of equity method investees	53,210	96,716
Distribution from NetCo Partners		7,875
Accretion of discount on note payable	44,398
Gain on derivative instrument	(25,000)
Accrued interest added to long-term notes payable	42,446	7,079
Stock-based compensation	13,493	15,077
Change in operating assets and liabilities:
Accounts receivable, administrative fees	(3,000)	12,000
Prepaid expenses	5,685	994
Accounts payable	95,415	107,296
Accrued expenses	3,751	(6,000)
Net cash used in operating activities	(72,882)	(27,784)
Cash flows from investing activities:
Loans made	(250,000)
Net cash used in investing activities	(250,000)
Cash flows from financing activities:
Proceeds from long term notes payable	275,000	62,000
Net cash provided by financing activities	275,000	62,000
Net change in cash	(47,882)	34,216
Cash at the beginning of the period	53,063	6,346
Cash at the end of the period	5,181	40,562
Cash paid during the period for:
Interest	$ 441	$ 234

XML 19 R7.htm IDEA: XBRL DOCUMENT

NATURE OF OPERATIONS

3 Months Ended

Mar. 31, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

NATURE OF OPERATIONS

NOTE 1—NATURE OF OPERATIONS

Description of Business

Going Concern, Liquidity and Management’s Plans

XML 20 R8.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2—SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

Equity Investments

The Company reviews equity investments for impairment on an annual basis, or earlier if events or changes in circumstances indicate that the carrying amounts might not be recoverable.

Derivative Financial Instruments

Basic and Diluted Net Loss Per Share

The following data represents the amounts used in computing earnings per share and the effect on loss and the weighted average number of shares of dilutive potential common stock (unaudited):


	Three Months Ended March 31,
	2024			2023
Net loss attributable to common shareholders	$	(303,280	)	$	(268,821	)

Weighted average shares outstanding:
-Basic		46,881,475			46,881,475
Add: Warrants		-			-
Add: Stock options		-			-
-Diluted		46,881,475			46,881,475

Basic and diluted net loss per share	$	(0.01	)	$	(0.01	)

Options and warrants excluded from the computation of earnings per share:

SCHEDULE OF WARRANTS AND STOCK OPTIONS

	2024		2023
	Three Months Ended March 31,
	2024		2023
Warrants		3,000,000		3,000,000
Stock options		5,760,000		5,760,000
Anti-dilutive securities		5,760,000		5,760,000

XML 21 R9.htm IDEA: XBRL DOCUMENT

EQUITY METHOD INVESTMENTS

3 Months Ended

Mar. 31, 2024

Equity Method Investments and Joint Ventures [Abstract]

EQUITY METHOD INVESTMENTS

NOTE 3—EQUITY METHOD INVESTMENTS

Investment in NewStem

The Company assesses its investment in NewStem for impairment on an annual basis or more frequently if indicators of impairment exist.

The following table represents the Company’s investment in NewStem:

SCHEDULE OF INVESTMENTS

	2024			2023
	Three Months Ended March 31, 2024			Year Ended December 31, 2023
	(Unaudited)
Investment in NewStem, beginning	$	1,784,234		$	2,090,286
Allocation of net loss from NewStem, Ltd.		(51,859	)		(342,191	)
Gain on dilution of equity method investment		-			36,139
Distribution from NetCo
Investment in NewStem, ending	$	1,732,375		$	1,784,234

The results of operations of the Company’s investment in NewStem is summarized below (unaudited):

	2024			2023
	Three Months Ended March 31,
	2024			2023
Condensed income statement information:
Net revenues	$	-		$	95,000
Gross margin	$	-		$	84,000
Net loss	$	(170,000	)	$	(342,000	)
Company’s allocation of net loss from NewStem, Ltd.	$	(51,859	)	$	(104,591	)

The financial position of the Company’s investment in NewStem is summarized below:

	2024		2023
	As of
	March 31,		December 31,
	2024		2023
	(Unaudited)
Condensed balance sheet information:
Current assets	$	246,000	$	353,000
Non-current assets	$	6,000	$	9,000
Current liabilities	$	86,000	$	284,000
Non-current liabilities	$	250,000	$	-

Investment in NetCo

The following table represents the Company’s investment in NetCo:

SCHEDULE OF INVESTMENTS

	Three Months Ended March 31, 2024			Year Ended December 31, 2023
		(Unaudited)
Investment in NetCo, beginning	$	133,709		$	137,011
Allocation of net income (loss) from NetCo		(1,351	)		3,573
Distribution from NetCo		-			(6,875	)
Investment in NetCo, ending	$	132,358		$	133,709

The results of operations of the Company’s investment in NetCo is summarized below (unaudited):

	2024			2023
	Three Months Ended March 31,
	2024			2023
Condensed income statement information:
Net sales	$	373		$	15,750
Gross margin	$	373		$	15,750
Net income	$	(2,702	)	$	15,750
Company’s allocation of net income from NetCo	$	(1,351	)	$	7,875

The financial position of the Company’s investment in NetCo is summarized below:

	2024		2023
	As of
	March 31,		December 31,
	2024		2023
	(Unaudited)
Condensed balance sheet information:
Current assets	$	2,042	$	1,820
Non-current assets	$	272,799	$	272,799
Current liabilities	$	3,249	$	325
Non-current liabilities	$	-	$	-

XML 22 R10.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE

3 Months Ended

Mar. 31, 2024

Debt Disclosure [Abstract]

NOTES PAYABLE

NOTE 4—NOTES PAYABLE

Long-term notes payable are summarized as follows:

SCHEDULE OF LONG TERM NOTES PAYABLE

	As of
	March 31,			December 31,
	2024			2023
	(Unaudited)
Notes payable related parties:
Notes payable director and Executive Chairman	$	650,000		$	400,000
Accrued interest added to note balance		54,314			43,588
Total notes payable director and Executive Chairman		704,314			443,588
Note payable shareholder, principal amount		300,000			275,000
Less unamortized discount		(193,787	)		(213,185	)
Total note payable shareholder		106,213			61,815
Note payable, litigation funding agreement:
Note payable Omni Bridgeway (Fund 4) Invt. 3 L.P.		2,819,196			2,819,196
Accrued interest added to agreement balance		31,720			-
Total note payable, litigation funding agreement		2,850,916			2,819,196
Total notes payable		3,661,443			3,324,599
Less current portion		(2,850,916	)		-
Long-term notes payable	$	810,527		$	3,324,599

Note Payable, Litigation Funding Agreement

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/470/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

+ Details

XML 23 R11.htm IDEA: XBRL DOCUMENT

EQUITY

3 Months Ended

Mar. 31, 2024

Equity [Abstract]

EQUITY

NOTE 5—EQUITY

(a) General

(b) Summary Employee Option Information

Risk-free interest rate		3.5	%
Expected term of options, in years		4.00
Expected annual volatility		191.1	%
Expected dividend yield		0	%
Determined weighted average grant date fair value per option	$	0.19

A summary of the Company’s option plans for the three months ended March 31, 2024, is presented below (unaudited):

SCHEDULE OF STOCK OPTION ACTIVITIES

	Number		Weighted
	of		Average
	Options		Exercise
	(in shares)		Price
Outstanding, December 31, 2023		5,760,000	$	0.14
Granted		-		-
Outstanding, March 31, 2024		5,760,000	$	0.14
Exercisable, March 31, 2024		5,760,000	$	0.14

Stock-based compensation expense was approximately $13,000 and $15,000 in the three months ended March 31, 2024 and 2023, respectively.

(d) Warrants

SUMMARY OF WARRANTS ACTIVITY

	Number of		Weighted
	shares		Average
	underlying		Exercise
	warrants		Price
Outstanding, December 31, 2023		3,000,000	$	0.12
Granted		-		-
Exercised		-		-
Forfeited or expired		-		-
Outstanding, March 31, 2024		3,000,000	$	0.12

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

+ Details

XML 24 R12.htm IDEA: XBRL DOCUMENT

INCOME TAXES

3 Months Ended

Mar. 31, 2024

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 6—INCOME TAXES

SCHEDULE OF INCOME BEFORE INCOME TAX

	2024			2023
	Three Months Ended March 31,
	2024			2023
Computed tax at the federal statutory rate of 21%	$	(63,689	)	$	(56,452	)
State income taxes, net of federal income tax benefit		(13,178	)		(11,680	)
Change in federal valuation allowance		85,164			87,972
Foreign rate differential		(8,297	)		(19,840	)
Total provision for income tax	$	-		$	-

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

XML 25 R13.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES

3 Months Ended

Mar. 31, 2024

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 7—COMMITMENTS AND CONTINGENCIES

As a result of this ruling, the costs related to the litigation funding agreement disclosed in Note 4 were recognized and a total liability of $2,819,196 was recorded.

XML 26 R14.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS

3 Months Ended

Mar. 31, 2024

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 8—SUBSEQUENT EVENTS

The Company evaluated subsequent events through the date these financial statements were available to be issued and filed with the SEC.

An additional 600,000 options were issued to directors on April 1, 2024 pursuant to the Company’s Equity Incentive Plan.

XML 27 R15.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

3 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

Equity Investments

Equity Investments

The Company reviews equity investments for impairment on an annual basis, or earlier if events or changes in circumstances indicate that the carrying amounts might not be recoverable.

Derivative Financial Instruments

Derivative Financial Instruments

Basic and Diluted Net Loss Per Share

Basic and Diluted Net Loss Per Share

The following data represents the amounts used in computing earnings per share and the effect on loss and the weighted average number of shares of dilutive potential common stock (unaudited):


	Three Months Ended March 31,
	2024			2023
Net loss attributable to common shareholders	$	(303,280	)	$	(268,821	)

Weighted average shares outstanding:
-Basic		46,881,475			46,881,475
Add: Warrants		-			-
Add: Stock options		-			-
-Diluted		46,881,475			46,881,475

Basic and diluted net loss per share	$	(0.01	)	$	(0.01	)

Options and warrants excluded from the computation of earnings per share:

SCHEDULE OF WARRANTS AND STOCK OPTIONS

	2024		2023
	Three Months Ended March 31,
	2024		2023
Warrants		3,000,000		3,000,000
Stock options		5,760,000		5,760,000
Anti-dilutive securities		5,760,000		5,760,000

XML 28 R16.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

3 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

SCHEDULE OF WEIGHTED AVERAGE NUMBER OF SHARES OF DILUTIVE

The following data represents the amounts used in computing earnings per share and the effect on loss and the weighted average number of shares of dilutive potential common stock (unaudited):


	Three Months Ended March 31,
	2024			2023
Net loss attributable to common shareholders	$	(303,280	)	$	(268,821	)

Weighted average shares outstanding:
-Basic		46,881,475			46,881,475
Add: Warrants		-			-
Add: Stock options		-			-
-Diluted		46,881,475			46,881,475

Basic and diluted net loss per share	$	(0.01	)	$	(0.01	)

SCHEDULE OF WARRANTS AND STOCK OPTIONS

Options and warrants excluded from the computation of earnings per share:

SCHEDULE OF WARRANTS AND STOCK OPTIONS

	2024		2023
	Three Months Ended March 31,
	2024		2023
Warrants		3,000,000		3,000,000
Stock options		5,760,000		5,760,000
Anti-dilutive securities		5,760,000		5,760,000

XML 29 R17.htm IDEA: XBRL DOCUMENT

EQUITY METHOD INVESTMENTS (Tables)

3 Months Ended

Mar. 31, 2024

New Stem Ltd [Member]

SCHEDULE OF INVESTMENTS

The following table represents the Company’s investment in NewStem:

SCHEDULE OF INVESTMENTS

	2024			2023
	Three Months Ended March 31, 2024			Year Ended December 31, 2023
	(Unaudited)
Investment in NewStem, beginning	$	1,784,234		$	2,090,286
Allocation of net loss from NewStem, Ltd.		(51,859	)		(342,191	)
Gain on dilution of equity method investment		-			36,139
Distribution from NetCo
Investment in NewStem, ending	$	1,732,375		$	1,784,234

SCHEDULE OF OPERATIONS AND FINANCIAL POSITION INVESTMENT

The results of operations of the Company’s investment in NewStem is summarized below (unaudited):

	2024			2023
	Three Months Ended March 31,
	2024			2023
Condensed income statement information:
Net revenues	$	-		$	95,000
Gross margin	$	-		$	84,000
Net loss	$	(170,000	)	$	(342,000	)
Company’s allocation of net loss from NewStem, Ltd.	$	(51,859	)	$	(104,591	)

The financial position of the Company’s investment in NewStem is summarized below:

	2024		2023
	As of
	March 31,		December 31,
	2024		2023
	(Unaudited)
Condensed balance sheet information:
Current assets	$	246,000	$	353,000
Non-current assets	$	6,000	$	9,000
Current liabilities	$	86,000	$	284,000
Non-current liabilities	$	250,000	$	-

NetCo Partners [Member]

SCHEDULE OF INVESTMENTS

The following table represents the Company’s investment in NetCo:

SCHEDULE OF INVESTMENTS

	Three Months Ended March 31, 2024			Year Ended December 31, 2023
		(Unaudited)
Investment in NetCo, beginning	$	133,709		$	137,011
Allocation of net income (loss) from NetCo		(1,351	)		3,573
Distribution from NetCo		-			(6,875	)
Investment in NetCo, ending	$	132,358		$	133,709

SCHEDULE OF OPERATIONS AND FINANCIAL POSITION INVESTMENT

The results of operations of the Company’s investment in NetCo is summarized below (unaudited):

	2024			2023
	Three Months Ended March 31,
	2024			2023
Condensed income statement information:
Net sales	$	373		$	15,750
Gross margin	$	373		$	15,750
Net income	$	(2,702	)	$	15,750
Company’s allocation of net income from NetCo	$	(1,351	)	$	7,875

The financial position of the Company’s investment in NetCo is summarized below:

	2024		2023
	As of
	March 31,		December 31,
	2024		2023
	(Unaudited)
Condensed balance sheet information:
Current assets	$	2,042	$	1,820
Non-current assets	$	272,799	$	272,799
Current liabilities	$	3,249	$	325
Non-current liabilities	$	-	$	-

XML 30 R18.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Tables)

3 Months Ended

Mar. 31, 2024

Debt Disclosure [Abstract]

SCHEDULE OF LONG TERM NOTES PAYABLE

Long-term notes payable are summarized as follows:

SCHEDULE OF LONG TERM NOTES PAYABLE

	As of
	March 31,			December 31,
	2024			2023
	(Unaudited)
Notes payable related parties:
Notes payable director and Executive Chairman	$	650,000		$	400,000
Accrued interest added to note balance		54,314			43,588
Total notes payable director and Executive Chairman		704,314			443,588
Note payable shareholder, principal amount		300,000			275,000
Less unamortized discount		(193,787	)		(213,185	)
Total note payable shareholder		106,213			61,815
Note payable, litigation funding agreement:
Note payable Omni Bridgeway (Fund 4) Invt. 3 L.P.		2,819,196			2,819,196
Accrued interest added to agreement balance		31,720			-
Total note payable, litigation funding agreement		2,850,916			2,819,196
Total notes payable		3,661,443			3,324,599
Less current portion		(2,850,916	)		-
Long-term notes payable	$	810,527		$	3,324,599

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

+ Details

XML 31 R19.htm IDEA: XBRL DOCUMENT

EQUITY (Tables)

3 Months Ended

Mar. 31, 2024

Equity [Abstract]

SCHEDULE OF FAIR VALUE OF OPTION USING VALUATION ASSUMPTIONS

Risk-free interest rate		3.5	%
Expected term of options, in years		4.00
Expected annual volatility		191.1	%
Expected dividend yield		0	%
Determined weighted average grant date fair value per option	$	0.19

SCHEDULE OF STOCK OPTION ACTIVITIES

A summary of the Company’s option plans for the three months ended March 31, 2024, is presented below (unaudited):

SCHEDULE OF STOCK OPTION ACTIVITIES

	Number		Weighted
	of		Average
	Options		Exercise
	(in shares)		Price
Outstanding, December 31, 2023		5,760,000	$	0.14
Granted		-		-
Outstanding, March 31, 2024		5,760,000	$	0.14
Exercisable, March 31, 2024		5,760,000	$	0.14

SUMMARY OF WARRANTS ACTIVITY

	Number of		Weighted
	shares		Average
	underlying		Exercise
	warrants		Price
Outstanding, December 31, 2023		3,000,000	$	0.12
Granted		-		-
Exercised		-		-
Forfeited or expired		-		-
Outstanding, March 31, 2024		3,000,000	$	0.12

XML 32 R20.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Tables)

3 Months Ended

Mar. 31, 2024

Income Tax Disclosure [Abstract]

SCHEDULE OF INCOME BEFORE INCOME TAX

	2024			2023
	Three Months Ended March 31,
	2024			2023
Computed tax at the federal statutory rate of 21%	$	(63,689	)	$	(56,452	)
State income taxes, net of federal income tax benefit		(13,178	)		(11,680	)
Change in federal valuation allowance		85,164			87,972
Foreign rate differential		(8,297	)		(19,840	)
Total provision for income tax	$	-		$	-

XML 33 R21.htm IDEA: XBRL DOCUMENT

NATURE OF OPERATIONS (Details Narrative) - USD ($)	3 Months Ended
NATURE OF OPERATIONS (Details Narrative) - USD ($)	Mar. 31, 2024	Apr. 30, 2024	Dec. 31, 2023	Dec. 31, 2018	Sep. 30, 2018
Accumulated deficit	$ 293,431,091		$ 293,127,811		$ 6,750,000
Advance from borrowings			$ 350,000
Subsequent Event [Member]
Advance from borrowings		$ 350,000
Shareholders And Directors [Member]
Borrow for working capital needs	650,000
Additional Borrowings for working capital needs	$ 300,000
New Stem Ltd [Member]
Equity interest percentage	30.51%		30.51%	20.00%
NetCo Partners [Member]
Equity interest percentage	50.00%

- Definition

Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.

+ References + Details

- Definition

Amount of accumulated undistributed earnings (deficit).

+ References + Details

XML 34 R22.htm IDEA: XBRL DOCUMENT

SCHEDULE OF WEIGHTED AVERAGE NUMBER OF SHARES OF DILUTIVE (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Accounting Policies [Abstract]
Net loss attributable to common shareholders	$ (303,280)	$ (268,821)
Weighted average shares outstanding:
-Basic	46,881,475	46,881,475
Add: Warrants
Add: Stock options
-Diluted	46,881,475	46,881,475
Basic net loss per share	$ (0.01)	$ (0.01)
Diluted net loss per share	$ (0.01)	$ (0.01)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

XML 35 R23.htm IDEA: XBRL DOCUMENT

SCHEDULE OF WARRANTS AND STOCK OPTIONS (Details) - shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	3,000,000	3,000,000
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	5,760,000	5,760,000

XML 36 R24.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	3 Months Ended
	Mar. 31, 2024 USD ($)
Equity method investment description	investee company’s board of directors and ownership level, which is generally a 20% to 50% interest in the voting securities of the investee company.
Loss on derivative instrument	$ 25,000
NetCo Partners [Member]
Equity interest percentage	50.00%

XML 37 R25.htm IDEA: XBRL DOCUMENT

SCHEDULE OF INVESTMENTS (Details) - USD ($)	3 Months Ended	12 Months Ended
SCHEDULE OF INVESTMENTS (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
New Stem Ltd [Member]
Investment in NetCo, beginning	$ 1,784,234	$ 2,090,286
Allocation of net income (loss) from NetCo	(51,859)	(342,191)
Gain on dilution of equity method investment		36,139
Investment in NetCo, ending	1,732,375	1,784,234
NetCo Partners [Member]
Investment in NetCo, beginning	133,709	137,011
Allocation of net income (loss) from NetCo	(1,351)	3,573
Distribution from NetCo		(6,875)
Investment in NetCo, ending	$ 132,358	$ 133,709

- Definition

Fair value of investment in security owned.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(11))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478795/946-210-50-6

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 55
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477439/946-210-55-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478795/946-210-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478795/946-210-50-6

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478795/946-210-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478795/946-210-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478795/946-210-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478795/946-210-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478795/946-210-50-2

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478795/946-210-50-6

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(2)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(2)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column A)(Footnote 1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 6))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column A)(Footnote 6))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column A)(Footnote 7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column F))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column F)(Footnote 4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column F)(Footnote 7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

+ Details

XML 38 R26.htm IDEA: XBRL DOCUMENT

SCHEDULE OF OPERATIONS AND FINANCIAL POSITION INVESTMENT (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Net income	$ (303,280)	$ (268,821)
Company’s allocation of net income from NetCo	(53,210)	(96,716)
Current assets	36,036		$ 86,603
Current liabilities	3,296,562		346,480
Non-current liabilities	1,345,527		3,859,599
New Stem Ltd [Member]
Net sales		95,000
Gross margin		84,000
Net income	(170,000)	(342,000)
Company’s allocation of net income from NetCo	(51,859)	(104,591)
Current assets	246,000		353,000
Non-current assets	6,000		9,000
Current liabilities	86,000		284,000
Non-current liabilities	250,000
NetCo Partners [Member]
Net sales	373	15,750
Gross margin	373	15,750
Net income	(2,702)	15,750
Company’s allocation of net income from NetCo	(1,351)	$ 7,875
Current assets	2,042		1,820
Non-current assets	272,799		272,799
Current liabilities	3,249		325
Non-current liabilities

XML 39 R27.htm IDEA: XBRL DOCUMENT

EQUITY METHOD INVESTMENTS (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
EQUITY METHOD INVESTMENTS (Details Narrative) - USD ($)	Apr. 30, 2022	Mar. 31, 2024	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2023
Schedule of Equity Method Investments [Line Items]
Advance payable		$ 250,000				$ 250,000
New Stem Ltd [Member]
Schedule of Equity Method Investments [Line Items]
Sale of stock					50,000
Percentage of outstanding shares					33.00%
Shares acquisitions shares			12,500	12,500	25,000
Shares acquisitions			$ 1,000,000	$ 1,000,000	$ 2,000,000
Equity interest percentage		30.51%			20.00%	30.51%
Audit and audit related costs		$ 37,000
Advance payable		$ 250,000				$ 250,000
Debt instrument maturity date		Dec. 30, 2024
Additional funding	$ 1,450,000
New Stem Ltd [Member] \| Accounts Payable [Member]
Schedule of Equity Method Investments [Line Items]
Reimbursement due		$ 36,000
New Stem Ltd [Member] \| Investment, Affiliated Issuer, Controlled, Not Majority-Owned [Member]
Schedule of Equity Method Investments [Line Items]
Carrying value of investment		$ 1,655,000				$ 1,800,000
NetCo Partners [Member]
Schedule of Equity Method Investments [Line Items]
Equity interest percentage		50.00%
Maximum [Member] \| New Stem Ltd [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investments					$ 4,000,000

XML 40 R28.htm IDEA: XBRL DOCUMENT

SCHEDULE OF LONG TERM NOTES PAYABLE (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Total notes payable	$ 3,661,443	$ 3,324,599
Less current portion	(2,850,916)
Long-term notes payable	810,527	3,324,599
Omni Bridgeway (Fund 4) Invt. 3 L.P. [Member]
Total notes payable	2,819,196	2,819,196
Director and Executive Chairman [Member]
Total notes payable	704,314	443,588
Director and Executive Chairman [Member] \| Omni Bridgeway (Fund 4) Invt. 3 L.P. [Member]
Total notes payable	2,850,916	2,819,196
Related Party [Member] \| Omni Bridgeway (Fund 4) Invt. 3 L.P. [Member]
Accrued interest added to note balance	31,720
Related Party [Member] \| Director and Executive Chairman [Member]
Total notes payable	650,000	400,000
Accrued interest added to note balance	54,314	43,588
Note payable, principal amount	300,000	275,000
Less unamortized discount	(193,787)	(213,185)
Related Party [Member] \| Shareholder [Member]
Total notes payable	$ 106,213	$ 61,815

XML 41 R29.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Details Narrative) - USD ($)				1 Months Ended	3 Months Ended		12 Months Ended
NOTES PAYABLE (Details Narrative) - USD ($)	May 05, 2023	Nov. 11, 2022	Feb. 11, 2022	May 31, 2022	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Oct. 31, 2023
Short-Term Debt [Line Items]
Notes payable					$ 250,000		$ 250,000
Long term note payable					810,527		3,324,599
Accretion of discount on note payable					44,398
Liability					$ 4,642,089		$ 4,206,079
Two Short Term Notes Payable [Member]
Short-Term Debt [Line Items]
Interest rate							12.00%
Maturity date						Dec. 21, 2024
Debt instrument, description					The note agreements include a provision whereby, in the event of a capital raise transaction by the Company, the note holders would be entitled to participate in the transaction in an amount equal to 133% of the amounts owed on the note agreements at the closing of the transaction.
Interest expense debt					$ 7,479
New Stem Ltd [Member]
Short-Term Debt [Line Items]
Notes payable					$ 250,000		$ 250,000
Maturity date					Dec. 30, 2024
Hewlett Fund [Member]
Short-Term Debt [Line Items]
Notes payable							125,000
AIGH Investment Partners, LLC [Member]
Short-Term Debt [Line Items]
Notes payable							125,000
Two Individuals [Member]
Short-Term Debt [Line Items]
Notes payable				$ 600,000	$ 650,000
Interest rate				8.00%
Maturity date				Sep. 01, 2025
Short term debt, interest rate increase		10.00%
Proceeds form related party					650,000		400,000
Shareholder [Member]
Short-Term Debt [Line Items]
Maturity date	May 05, 2025
Long term note payable	$ 300,000
Advance of long term note payable	$ 150,000							$ 150,000
Derivative fair value liability					$ 535,000		535,000
Related Party [Member]
Short-Term Debt [Line Items]
Interest rate	0.00%
Omni Bridgeway (Fund 4) Invt. 3 L.P. [Member]
Short-Term Debt [Line Items]
Notes payable							$ 310,000
Interest rate							5.00%
Maturity date							Jan. 10, 2025
Litigation settlement, expense			$ 1,000,000
Due to related parties							$ 933,065
Investment return due							1,886,131
Liability							$ 2,819,196

XML 42 R30.htm IDEA: XBRL DOCUMENT

SCHEDULE OF FAIR VALUE OF OPTION USING VALUATION ASSUMPTIONS (Details) - $ / shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Equity [Abstract]
Risk-free interest rate		3.50%
Expected term, in years		4 years
Risk-free interest rate		191.10%
Risk-free interest rate	0.00%	0.00%
Risk-free interest rate		$ 0.19

XML 43 R31.htm IDEA: XBRL DOCUMENT

SCHEDULE OF STOCK OPTION ACTIVITIES (Details)	3 Months Ended
SCHEDULE OF STOCK OPTION ACTIVITIES (Details)	Mar. 31, 2024 $ / shares shares
Equity [Abstract]
Number of Options Outstanding beginning \| shares	5,760,000
Weighted Average Exercise Price Outstanding beginning \| $ / shares	$ 0.14
Number of Options, Granted \| shares
Weighted Average Exercise Price, Granted \| $ / shares
Number of Options Outstanding ending \| shares	5,760,000
Weighted Average Exercise Price Outstanding ending \| $ / shares	$ 0.14
Number of Options Exercisable \| shares	5,760,000
Weighted Average Exercise Price, Exercisable \| $ / shares	$ 0.14

XML 44 R32.htm IDEA: XBRL DOCUMENT

SUMMARY OF WARRANTS ACTIVITY (Details) - Warrant [Member]	3 Months Ended
	Mar. 31, 2024 $ / shares shares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares underlying warrants, Beginning balance	3,000,000
Weighted average exercise price, Beginning balance \| $ / shares	$ 0.12
Number of shares underlying warrants, Granted
Weighted average exercise price, Granted \| $ / shares
Number of shares underlying warrants, Exercised
Number of shares underlying warrants, Forfeited or expired
Number of shares underlying warrants, Ending balance	3,000,000
Weighted average exercise price, Ending balance \| $ / shares	$ 0.12

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

XML 45 R33.htm IDEA: XBRL DOCUMENT

EQUITY (Details Narrative) - USD ($)			3 Months Ended
EQUITY (Details Narrative) - USD ($)	Apr. 01, 2024	Nov. 12, 2018	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares issued			46,881,475		46,881,475
Common stock, shares outstanding			46,881,475		46,881,475
Common stock, par value			$ 0.01		$ 0.01
Number of option granted
Granted term			7 years
Expected dividend yield			0.00%	0.00%
Stock-based compensation expense			$ 13,493	$ 15,077
Compensation cost				$ 67,000
Options unvested				360,000
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Maturity date			Jun. 28, 2025
Directot and Investor [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of option granted		5,760,000
Director [Member] \| Subsequent Event [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of option granted	600,000

XML 46 R34.htm IDEA: XBRL DOCUMENT

SCHEDULE OF INCOME BEFORE INCOME TAX (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Computed tax at the federal statutory rate of 21%	$ (63,689)	$ (56,452)
State income taxes, net of federal income tax benefit	(13,178)	(11,680)
Change in federal valuation allowance	85,164	87,972
Foreign rate differential	(8,297)	(19,840)
Total provision for income tax

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-10

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Subparagraph (a)
-SubTopic 20
-Topic 740
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482659/740-20-45-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-SubTopic 10
-Topic 235
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

+ Details

XML 47 R35.htm IDEA: XBRL DOCUMENT

SCHEDULE OF INCOME BEFORE INCOME TAX (Details) (Parenthetical)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Computed tax at the federal statutory rate	21.00%	21.00%

XML 48 R36.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Liability	$ 4,642,089	$ 4,206,079
Omni Bridgeway (Fund 4) Invt. 3 L.P. [Member]
Liability		$ 2,819,196
NetCo Partners [Member]
Equity interest percentage	50.00%

- Definition

Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-SubTopic 10
-Topic 210
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(24))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(26))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(21))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (bb)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(14))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7

Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7

Reference 29: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

XML 49 R37.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS (Details Narrative) - USD ($)		1 Months Ended	3 Months Ended
SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Apr. 01, 2024	Apr. 30, 2024	Mar. 31, 2024	Dec. 31, 2023
Subsequent Event [Line Items]
[custom:NoteReceivableNonCurrent-0]			$ 500,000	$ 250,000
Number of option granted
Subsequent Event [Member] \| Convertible Debt Agreements [Member]
Subsequent Event [Line Items]
Long term debt unrelated parties		$ 100,000
Debt instrumental stated percentage		1000.00%
Debt instrument maturity date		Dec. 30, 2025
Debt conversion price	$ 0.13
Director [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Number of option granted	600,000
New Stem Ltd [Member]
Subsequent Event [Line Items]
[custom:NoteReceivableNonCurrent-0]				$ 500,000
Debt instrument maturity date			Dec. 30, 2024

EXCEL 50 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 52 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 54 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 104 180 1 false 29 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://novelstem.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Balance Sheets Sheet http://novelstem.com/role/BalanceSheets Condensed Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://novelstem.com/role/BalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://novelstem.com/role/StatementsOfOperations Condensed Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Statements of Shareholders' Equity (Unaudited) Sheet http://novelstem.com/role/StatementsOfShareholdersEquity Condensed Statements of Shareholders' Equity (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://novelstem.com/role/StatementsOfCashFlows Condensed Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - NATURE OF OPERATIONS Sheet http://novelstem.com/role/NatureOfOperations NATURE OF OPERATIONS Notes 7 false false R8.htm 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://novelstem.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 00000009 - Disclosure - EQUITY METHOD INVESTMENTS Sheet http://novelstem.com/role/EquityMethodInvestments EQUITY METHOD INVESTMENTS Notes 9 false false R10.htm 00000010 - Disclosure - NOTES PAYABLE Notes http://novelstem.com/role/NotesPayable NOTES PAYABLE Notes 10 false false R11.htm 00000011 - Disclosure - EQUITY Sheet http://novelstem.com/role/Equity EQUITY Notes 11 false false R12.htm 00000012 - Disclosure - INCOME TAXES Sheet http://novelstem.com/role/IncomeTaxes INCOME TAXES Notes 12 false false R13.htm 00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://novelstem.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 13 false false R14.htm 00000014 - Disclosure - SUBSEQUENT EVENTS Sheet http://novelstem.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 14 false false R15.htm 00000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://novelstem.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 15 false false R16.htm 00000016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://novelstem.com/role/SummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://novelstem.com/role/SummaryOfSignificantAccountingPolicies 16 false false R17.htm 00000017 - Disclosure - EQUITY METHOD INVESTMENTS (Tables) Sheet http://novelstem.com/role/EquityMethodInvestmentsTables EQUITY METHOD INVESTMENTS (Tables) Tables http://novelstem.com/role/EquityMethodInvestments 17 false false R18.htm 00000018 - Disclosure - NOTES PAYABLE (Tables) Notes http://novelstem.com/role/NotesPayableTables NOTES PAYABLE (Tables) Tables http://novelstem.com/role/NotesPayable 18 false false R19.htm 00000019 - Disclosure - EQUITY (Tables) Sheet http://novelstem.com/role/EquityTables EQUITY (Tables) Tables http://novelstem.com/role/EquityMethodInvestments 19 false false R20.htm 00000020 - Disclosure - INCOME TAXES (Tables) Sheet http://novelstem.com/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://novelstem.com/role/IncomeTaxes 20 false false R21.htm 00000021 - Disclosure - NATURE OF OPERATIONS (Details Narrative) Sheet http://novelstem.com/role/NatureOfOperationsDetailsNarrative NATURE OF OPERATIONS (Details Narrative) Details http://novelstem.com/role/NatureOfOperations 21 false false R22.htm 00000022 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE NUMBER OF SHARES OF DILUTIVE (Details) Sheet http://novelstem.com/role/ScheduleOfWeightedAverageNumberOfSharesOfDilutiveDetails SCHEDULE OF WEIGHTED AVERAGE NUMBER OF SHARES OF DILUTIVE (Details) Details 22 false false R23.htm 00000023 - Disclosure - SCHEDULE OF WARRANTS AND STOCK OPTIONS (Details) Sheet http://novelstem.com/role/ScheduleOfWarrantsAndStockOptionsDetails SCHEDULE OF WARRANTS AND STOCK OPTIONS (Details) Details 23 false false R24.htm 00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://novelstem.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://novelstem.com/role/SummaryOfSignificantAccountingPoliciesTables 24 false false R25.htm 00000025 - Disclosure - SCHEDULE OF INVESTMENTS (Details) Sheet http://novelstem.com/role/ScheduleOfInvestmentsDetails SCHEDULE OF INVESTMENTS (Details) Details 25 false false R26.htm 00000026 - Disclosure - SCHEDULE OF OPERATIONS AND FINANCIAL POSITION INVESTMENT (Details) Sheet http://novelstem.com/role/ScheduleOfOperationsAndFinancialPositionInvestmentDetails SCHEDULE OF OPERATIONS AND FINANCIAL POSITION INVESTMENT (Details) Details 26 false false R27.htm 00000027 - Disclosure - EQUITY METHOD INVESTMENTS (Details Narrative) Sheet http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative EQUITY METHOD INVESTMENTS (Details Narrative) Details http://novelstem.com/role/EquityMethodInvestmentsTables 27 false false R28.htm 00000028 - Disclosure - SCHEDULE OF LONG TERM NOTES PAYABLE (Details) Notes http://novelstem.com/role/ScheduleOfLongTermNotesPayableDetails SCHEDULE OF LONG TERM NOTES PAYABLE (Details) Details 28 false false R29.htm 00000029 - Disclosure - NOTES PAYABLE (Details Narrative) Notes http://novelstem.com/role/NotesPayableDetailsNarrative NOTES PAYABLE (Details Narrative) Details http://novelstem.com/role/NotesPayableTables 29 false false R30.htm 00000030 - Disclosure - SCHEDULE OF FAIR VALUE OF OPTION USING VALUATION ASSUMPTIONS (Details) Sheet http://novelstem.com/role/ScheduleOfFairValueOfOptionUsingValuationAssumptionsDetails SCHEDULE OF FAIR VALUE OF OPTION USING VALUATION ASSUMPTIONS (Details) Details 30 false false R31.htm 00000031 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITIES (Details) Sheet http://novelstem.com/role/ScheduleOfStockOptionActivitiesDetails SCHEDULE OF STOCK OPTION ACTIVITIES (Details) Details 31 false false R32.htm 00000032 - Disclosure - SUMMARY OF WARRANTS ACTIVITY (Details) Sheet http://novelstem.com/role/SummaryOfWarrantsActivityDetails SUMMARY OF WARRANTS ACTIVITY (Details) Details 32 false false R33.htm 00000033 - Disclosure - EQUITY (Details Narrative) Sheet http://novelstem.com/role/EquityDetailsNarrative EQUITY (Details Narrative) Details http://novelstem.com/role/EquityMethodInvestmentsTables 33 false false R34.htm 00000034 - Disclosure - SCHEDULE OF INCOME BEFORE INCOME TAX (Details) Sheet http://novelstem.com/role/ScheduleOfIncomeBeforeIncomeTaxDetails SCHEDULE OF INCOME BEFORE INCOME TAX (Details) Details 34 false false R35.htm 00000035 - Disclosure - SCHEDULE OF INCOME BEFORE INCOME TAX (Details) (Parenthetical) Sheet http://novelstem.com/role/ScheduleOfIncomeBeforeIncomeTaxDetailsParenthetical SCHEDULE OF INCOME BEFORE INCOME TAX (Details) (Parenthetical) Details 35 false false R36.htm 00000036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://novelstem.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://novelstem.com/role/CommitmentsAndContingencies 36 false false R37.htm 00000037 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://novelstem.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://novelstem.com/role/SubsequentEvents 37 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:EquityMethodInvestmentOwnershipPercentage - form10-q.htm 52 form10-q.htm nstm-20240331.xsd nstm-20240331_cal.xml nstm-20240331_def.xml nstm-20240331_lab.xml nstm-20240331_pre.xml http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 true true JSON 57 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form10-q.htm": { "nsprefix": "NSTM", "nsuri": "http://novelstem.com/20240331", "dts": { "inline": { "local": [ "form10-q.htm" ] }, "schema": { "local": [ "nstm-20240331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "nstm-20240331_cal.xml" ] }, "definitionLink": { "local": [ "nstm-20240331_def.xml" ] }, "labelLink": { "local": [ "nstm-20240331_lab.xml" ] }, "presentationLink": { "local": [ "nstm-20240331_pre.xml" ] } }, "keyStandard": 168, "keyCustom": 12, "axisStandard": 11, "axisCustom": 1, "memberStandard": 12, "memberCustom": 12, "hidden": { "total": 53, "http://fasb.org/us-gaap/2024": 44, "http://xbrl.sec.gov/dei/2024": 4, "http://novelstem.com/20240331": 5 }, "contextCount": 104, "entityCount": 1, "segmentCount": 29, "elementCount": 299, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 405, "http://xbrl.sec.gov/dei/2024": 28 }, "report": { "R1": { "role": "http://novelstem.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R2": { "role": "http://novelstem.com/role/BalanceSheets", "longName": "00000002 - Statement - Condensed Balance Sheets", "shortName": "Condensed Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R3": { "role": "http://novelstem.com/role/BalanceSheetsParenthetical", "longName": "00000003 - Statement - Condensed Balance Sheets (Parenthetical)", "shortName": "Condensed Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R4": { "role": "http://novelstem.com/role/StatementsOfOperations", "longName": "00000004 - Statement - Condensed Statements of Operations (Unaudited)", "shortName": "Condensed Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "NSTM:AdministrativeFeeIncome", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "NSTM:AdministrativeFeeIncome", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R5": { "role": "http://novelstem.com/role/StatementsOfShareholdersEquity", "longName": "00000005 - Statement - Condensed Statements of Shareholders' Equity (Unaudited)", "shortName": "Condensed Statements of Shareholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R6": { "role": "http://novelstem.com/role/StatementsOfCashFlows", "longName": "00000006 - Statement - Condensed Statements of Cash Flows (Unaudited)", "shortName": "Condensed Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-03-31", "name": "us-gaap:EquityMethodInvestmentDividendsOrDistributions", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R7": { "role": "http://novelstem.com/role/NatureOfOperations", "longName": "00000007 - Disclosure - NATURE OF OPERATIONS", "shortName": "NATURE OF OPERATIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R8": { "role": "http://novelstem.com/role/SummaryOfSignificantAccountingPolicies", "longName": "00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R9": { "role": "http://novelstem.com/role/EquityMethodInvestments", "longName": "00000009 - Disclosure - EQUITY METHOD INVESTMENTS", "shortName": "EQUITY METHOD INVESTMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R10": { "role": "http://novelstem.com/role/NotesPayable", "longName": "00000010 - Disclosure - NOTES PAYABLE", "shortName": "NOTES PAYABLE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R11": { "role": "http://novelstem.com/role/Equity", "longName": "00000011 - Disclosure - EQUITY", "shortName": "EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R12": { "role": "http://novelstem.com/role/IncomeTaxes", "longName": "00000012 - Disclosure - INCOME TAXES", "shortName": "INCOME TAXES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R13": { "role": "http://novelstem.com/role/CommitmentsAndContingencies", "longName": "00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R14": { "role": "http://novelstem.com/role/SubsequentEvents", "longName": "00000014 - Disclosure - SUBSEQUENT EVENTS", "shortName": "SUBSEQUENT EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R15": { "role": "http://novelstem.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "longName": "00000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "15", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R16": { "role": "http://novelstem.com/role/SummaryOfSignificantAccountingPoliciesTables", "longName": "00000016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "16", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R17": { "role": "http://novelstem.com/role/EquityMethodInvestmentsTables", "longName": "00000017 - Disclosure - EQUITY METHOD INVESTMENTS (Tables)", "shortName": "EQUITY METHOD INVESTMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "17", "firstAnchor": { "contextRef": "From2024-01-012024-03-31_custom_NewStemLtdMember98631062", "name": "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-03-31_custom_NewStemLtdMember98631062", "name": "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R18": { "role": "http://novelstem.com/role/NotesPayableTables", "longName": "00000018 - Disclosure - NOTES PAYABLE (Tables)", "shortName": "NOTES PAYABLE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "18", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R19": { "role": "http://novelstem.com/role/EquityTables", "longName": "00000019 - Disclosure - EQUITY (Tables)", "shortName": "EQUITY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R20": { "role": "http://novelstem.com/role/IncomeTaxesTables", "longName": "00000020 - Disclosure - INCOME TAXES (Tables)", "shortName": "INCOME TAXES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R21": { "role": "http://novelstem.com/role/NatureOfOperationsDetailsNarrative", "longName": "00000021 - Disclosure - NATURE OF OPERATIONS (Details Narrative)", "shortName": "NATURE OF OPERATIONS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "21", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2018-09-30", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "us-gaap:NatureOfOperations", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R22": { "role": "http://novelstem.com/role/ScheduleOfWeightedAverageNumberOfSharesOfDilutiveDetails", "longName": "00000022 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE NUMBER OF SHARES OF DILUTIVE (Details)", "shortName": "SCHEDULE OF WEIGHTED AVERAGE NUMBER OF SHARES OF DILUTIVE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "22", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": null }, "R23": { "role": "http://novelstem.com/role/ScheduleOfWarrantsAndStockOptionsDetails", "longName": "00000023 - Disclosure - SCHEDULE OF WARRANTS AND STOCK OPTIONS (Details)", "shortName": "SCHEDULE OF WARRANTS AND STOCK OPTIONS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "From2024-01-012024-03-31_us-gaap_WarrantMember", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-03-31_us-gaap_WarrantMember", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R24": { "role": "http://novelstem.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "longName": "00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "NSTM:EquityMethodInvestmentDescriptionOfPrincipal", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "us-gaap:EquityMethodInvestmentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "NSTM:EquityMethodInvestmentDescriptionOfPrincipal", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "us-gaap:EquityMethodInvestmentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R25": { "role": "http://novelstem.com/role/ScheduleOfInvestmentsDetails", "longName": "00000025 - Disclosure - SCHEDULE OF INVESTMENTS (Details)", "shortName": "SCHEDULE OF INVESTMENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "AsOf2023-12-31_custom_NewStemLtdMember98631171", "name": "us-gaap:InvestmentOwnedAtFairValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31_custom_NewStemLtdMember", "name": "us-gaap:InvestmentOwnedAtFairValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R26": { "role": "http://novelstem.com/role/ScheduleOfOperationsAndFinancialPositionInvestmentDetails", "longName": "00000026 - Disclosure - SCHEDULE OF OPERATIONS AND FINANCIAL POSITION INVESTMENT (Details)", "shortName": "SCHEDULE OF OPERATIONS AND FINANCIAL POSITION INVESTMENT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-03-31_custom_NewStemLtdMember", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:EquityMethodInvestmentsTextBlock", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R27": { "role": "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative", "longName": "00000027 - Disclosure - EQUITY METHOD INVESTMENTS (Details Narrative)", "shortName": "EQUITY METHOD INVESTMENTS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:NotesPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2018-01-012018-12-31_custom_NewStemLtdMember", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R28": { "role": "http://novelstem.com/role/ScheduleOfLongTermNotesPayableDetails", "longName": "00000028 - Disclosure - SCHEDULE OF LONG TERM NOTES PAYABLE (Details)", "shortName": "SCHEDULE OF LONG TERM NOTES PAYABLE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:NotesPayable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:NotesPayable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R29": { "role": "http://novelstem.com/role/NotesPayableDetailsNarrative", "longName": "00000029 - Disclosure - NOTES PAYABLE (Details Narrative)", "shortName": "NOTES PAYABLE (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:NotesPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_custom_TwoShortTermNotesPayableMember", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R30": { "role": "http://novelstem.com/role/ScheduleOfFairValueOfOptionUsingValuationAssumptionsDetails", "longName": "00000030 - Disclosure - SCHEDULE OF FAIR VALUE OF OPTION USING VALUATION ASSUMPTIONS (Details)", "shortName": "SCHEDULE OF FAIR VALUE OF OPTION USING VALUATION ASSUMPTIONS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "From2023-01-012023-03-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-03-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R31": { "role": "http://novelstem.com/role/ScheduleOfStockOptionActivitiesDetails", "longName": "00000031 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITIES (Details)", "shortName": "SCHEDULE OF STOCK OPTION ACTIVITIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R32": { "role": "http://novelstem.com/role/SummaryOfWarrantsActivityDetails", "longName": "00000032 - Disclosure - SUMMARY OF WARRANTS ACTIVITY (Details)", "shortName": "SUMMARY OF WARRANTS ACTIVITY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_WarrantMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_WarrantMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R33": { "role": "http://novelstem.com/role/EquityDetailsNarrative", "longName": "00000033 - Disclosure - EQUITY (Details Narrative)", "shortName": "EQUITY (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "NSTM:CommonStockSharesIssuedExclusiveTreasuryShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31", "name": "NSTM:CommonStockSharesIssuedExclusiveTreasuryShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R34": { "role": "http://novelstem.com/role/ScheduleOfIncomeBeforeIncomeTaxDetails", "longName": "00000034 - Disclosure - SCHEDULE OF INCOME BEFORE INCOME TAX (Details)", "shortName": "SCHEDULE OF INCOME BEFORE INCOME TAX (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R35": { "role": "http://novelstem.com/role/ScheduleOfIncomeBeforeIncomeTaxDetailsParenthetical", "longName": "00000035 - Disclosure - SCHEDULE OF INCOME BEFORE INCOME TAX (Details) (Parenthetical)", "shortName": "SCHEDULE OF INCOME BEFORE INCOME TAX (Details) (Parenthetical)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-03-31", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R36": { "role": "http://novelstem.com/role/CommitmentsAndContingenciesDetailsNarrative", "longName": "00000036 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:Liabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": null }, "R37": { "role": "http://novelstem.com/role/SubsequentEventsDetailsNarrative", "longName": "00000037 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "NSTM:NoteReceivableNonCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-04-30_us-gaap_SubsequentEventMember_custom_ConvertibleDebtAgreementsMember", "name": "us-gaap:LongTermDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } } }, "tag": { "NSTM_AIGHInvestmentPartnersLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://novelstem.com/20240331", "localname": "AIGHInvestmentPartnersLLCMember", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "AIGH Investment Partners, LLC [Member]", "documentation": "AIGH Investment Partners, LLC [Member]" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://novelstem.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r33", "r485" ] }, "us-gaap_AccountsPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableMember", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accounts Payable [Member]", "documentation": "Obligations incurred and payable to vendors for goods and services received." } } }, "auth_ref": [ "r34" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://novelstem.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts receivable, administrative fees", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r538" ] }, "NSTM_AccretionOfDiscountOnNotePayable": { "xbrltype": "monetaryItemType", "nsuri": "http://novelstem.com/20240331", "localname": "AccretionOfDiscountOnNotePayable", "crdr": "debit", "calculation": { "http://novelstem.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative", "http://novelstem.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accretion of discount on note payable", "documentation": "Accretion of discount on note payable" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://novelstem.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r35" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://novelstem.com/role/EquityDetailsNarrative", "http://novelstem.com/role/SummaryOfWarrantsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r112", "r113", "r316", "r317", "r318", "r319", "r320", "r321" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://novelstem.com/role/EquityDetailsNarrative", "http://novelstem.com/role/SummaryOfWarrantsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r112", "r113", "r316", "r317", "r318", "r319", "r320", "r321" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://novelstem.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r44" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://novelstem.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r367", "r527", "r528", "r529", "r530", "r558", "r590" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://novelstem.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock option compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r21", "r22", "r256" ] }, "NSTM_AdministrativeFeeIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://novelstem.com/20240331", "localname": "AdministrativeFeeIncome", "crdr": "credit", "calculation": { "http://novelstem.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://novelstem.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Administrative fee income", "documentation": "Administrative fee income." } } }, "auth_ref": [] }, "NSTM_AffiliationAxis": { "xbrltype": "stringItemType", "nsuri": "http://novelstem.com/20240331", "localname": "AffiliationAxis", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Affiliation [Axis]", "verboseLabel": "AffiliationAxis [Axis]", "documentation": "Affiliation Axis" } } }, "auth_ref": [] }, "NSTM_AffiliationDomain": { "xbrltype": "domainItemType", "nsuri": "http://novelstem.com/20240331", "localname": "AffiliationDomain", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative" ], "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r511" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://novelstem.com/role/ScheduleOfWarrantsAndStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Anti-dilutive securities", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r156" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://novelstem.com/role/ScheduleOfWarrantsAndStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r14" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://novelstem.com/role/ScheduleOfWarrantsAndStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://novelstem.com/role/ScheduleOfWarrantsAndStockOptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r14" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://novelstem.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r298" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://novelstem.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r78", "r91", "r104", "r125", "r159", "r161", "r170", "r171", "r182", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r299", "r301", "r315", "r341", "r401", "r469", "r470", "r485", "r496", "r547", "r548", "r568" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://novelstem.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://novelstem.com/role/BalanceSheets", "http://novelstem.com/role/ScheduleOfOperationsAndFinancialPositionInvestmentDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r101", "r108", "r125", "r182", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r299", "r301", "r315", "r485", "r547", "r548", "r568" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrent", "crdr": "debit", "presentation": [ "http://novelstem.com/role/ScheduleOfOperationsAndFinancialPositionInvestmentDetails" ], "lang": { "en-us": { "role": { "label": "Non-current assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r125", "r182", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r299", "r301", "r315", "r547", "r548", "r568" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r511" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r194", "r578", "r579" ] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r26", "r27", "r194", "r578", "r579" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://novelstem.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://novelstem.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r13", "r103", "r464" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash at the beginning of the period", "periodEndLabel": "Cash at the end of the period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r13", "r59", "r121" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://novelstem.com/role/StatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net change in cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r59" ] }, "NSTM_CashPaidDuringPeriodForAbstract": { "xbrltype": "stringItemType", "nsuri": "http://novelstem.com/20240331", "localname": "CashPaidDuringPeriodForAbstract", "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash paid during the period for:", "documentation": "Cash Paid During Period For [Abstract]" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://novelstem.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and contingencies (see Note 7)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r40", "r82", "r344", "r388" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://novelstem.com/role/CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r64", "r195", "r196", "r461", "r541", "r546" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://novelstem.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r487", "r488", "r489", "r491", "r492", "r493", "r494", "r527", "r528", "r530", "r558", "r580", "r590" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://novelstem.com/role/BalanceSheetsParenthetical", "http://novelstem.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r43" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://novelstem.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r43", "r389" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://novelstem.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r43" ] }, "NSTM_CommonStockSharesIssuedExclusiveTreasuryShares": { "xbrltype": "sharesItemType", "nsuri": "http://novelstem.com/20240331", "localname": "CommonStockSharesIssuedExclusiveTreasuryShares", "presentation": [ "http://novelstem.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, shares issued", "documentation": "Common stock, shares issued exclusive treasury shares.", "label": "CommonStockSharesIssuedExclusiveTreasuryShares" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://novelstem.com/role/BalanceSheetsParenthetical", "http://novelstem.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r4", "r43", "r389", "r407", "r590", "r591" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://novelstem.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common stock, $.01 par value, 100,000,000 shares authorized, 50,316,672 shares issued, and 46,881,475 shares outstanding as of March 31, 2024 and December 31, 2023", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r43", "r345", "r485" ] }, "NSTM_ConvertibleDebtAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://novelstem.com/20240331", "localname": "ConvertibleDebtAgreementsMember", "presentation": [ "http://novelstem.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible Debt Agreements [Member]", "documentation": "Convertible Debt Agreements [Member]" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "NSTM_CurrentPortionOfLongtermNotesPayableIncludingAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://novelstem.com/20240331", "localname": "CurrentPortionOfLongtermNotesPayableIncludingAccruedInterest", "crdr": "credit", "calculation": { "http://novelstem.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current portion of long-term notes payable, including accrued interest", "documentation": "Current portion of long-term notes payable, including accrued interest." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://novelstem.com/role/NotesPayable" ], "lang": { "en-us": { "role": { "label": "NOTES PAYABLE", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r65", "r123", "r189", "r190", "r191", "r192", "r193", "r201", "r202", "r212", "r218", "r219", "r220", "r221", "r222", "r223", "r228", "r235", "r236", "r237", "r324" ] }, "us-gaap_DebtInstrumentAnnualPrincipalPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAnnualPrincipalPayment", "crdr": "debit", "presentation": [ "http://novelstem.com/role/ScheduleOfLongTermNotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Note payable, principal amount", "documentation": "Amount of annual principal payment for debt instrument." } } }, "auth_ref": [ "r10" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r10", "r34", "r35", "r79", "r81", "r130", "r213", "r214", "r215", "r216", "r217", "r219", "r224", "r225", "r226", "r227", "r229", "r230", "r231", "r232", "r233", "r234", "r472", "r473", "r474", "r475", "r476", "r484", "r524", "r542", "r543", "r544", "r564", "r565" ] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://novelstem.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt conversion price", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r66", "r215" ] }, "us-gaap_DebtInstrumentDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentDescription", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt instrument, description", "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total." } } }, "auth_ref": [ "r10", "r16", "r31", "r34", "r79", "r81", "r324" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative", "http://novelstem.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest rate", "verboseLabel": "Debt instrumental stated percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r37", "r214" ] }, "us-gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentMaturityDate", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative", "http://novelstem.com/role/NotesPayableDetailsNarrative", "http://novelstem.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt instrument maturity date", "verboseLabel": "Maturity date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": [ "r106", "r472", "r560", "r561" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r10", "r130", "r213", "r214", "r215", "r216", "r217", "r219", "r224", "r225", "r226", "r227", "r229", "r230", "r231", "r232", "r233", "r234", "r472", "r473", "r474", "r475", "r476", "r484", "r524", "r542", "r543", "r544", "r564", "r565" ] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "presentation": [ "http://novelstem.com/role/ScheduleOfLongTermNotesPayableDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less unamortized discount", "label": "Debt Instrument, Unamortized Discount", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": [ "r550", "r563", "r564", "r565" ] }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeGainLossOnDerivativeNet", "crdr": "credit", "presentation": [ "http://novelstem.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loss on derivative instrument", "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement." } } }, "auth_ref": [ "r557" ] }, "us-gaap_DerivativeGainOnDerivative": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeGainOnDerivative", "crdr": "credit", "calculation": { "http://novelstem.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 }, "http://novelstem.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows", "http://novelstem.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Gain on derivative instrument", "label": "Derivative, Gain on Derivative", "documentation": "Amount of increase in the fair value of derivatives recognized in the income statement." } } }, "auth_ref": [ "r303" ] }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://novelstem.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Derivative liability, guarantee", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r109" ] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesPolicyTextBlock", "presentation": [ "http://novelstem.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Derivative Financial Instruments", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": [ "r5", "r23", "r24", "r25", "r28", "r129", "r144" ] }, "NSTM_DirectorAndExecutiveChairmanMember": { "xbrltype": "domainItemType", "nsuri": "http://novelstem.com/20240331", "localname": "DirectorAndExecutiveChairmanMember", "presentation": [ "http://novelstem.com/role/ScheduleOfLongTermNotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Director and Executive Chairman [Member]", "documentation": "Director and Executive Chairman [Member]" } } }, "auth_ref": [] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "DirectorMember", "presentation": [ "http://novelstem.com/role/EquityDetailsNarrative", "http://novelstem.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Director [Member]" } } }, "auth_ref": [ "r537", "r587" ] }, "NSTM_DirectotAndInvestorMember": { "xbrltype": "domainItemType", "nsuri": "http://novelstem.com/20240331", "localname": "DirectotAndInvestorMember", "presentation": [ "http://novelstem.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Directot and Investor [Member]", "documentation": "Directot And Investor [Member]" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r510" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r508", "r510", "r511" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r509" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r497" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r510" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r510" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r512" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r500" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://novelstem.com/role/ScheduleOfWeightedAverageNumberOfSharesOfDilutiveDetails", "http://novelstem.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net loss per share - basic", "verboseLabel": "Basic net loss per share", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r116", "r136", "r137", "r138", "r139", "r140", "r141", "r145", "r147", "r153", "r154", "r155", "r158", "r294", "r297", "r312", "r313", "r339", "r353", "r466" ] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicAbstract", "presentation": [ "http://novelstem.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Basic and diluted net loss per share:" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://novelstem.com/role/ScheduleOfWeightedAverageNumberOfSharesOfDilutiveDetails", "http://novelstem.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net loss per share - diluted", "verboseLabel": "Diluted net loss per share", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r116", "r136", "r137", "r138", "r139", "r140", "r141", "r147", "r153", "r154", "r155", "r158", "r294", "r297", "r312", "r313", "r339", "r353", "r466" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://novelstem.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basic and Diluted Net Loss Per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r14", "r15", "r157" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": [ "http://novelstem.com/role/ScheduleOfIncomeBeforeIncomeTaxDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Computed tax at the federal statutory rate", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r126", "r271", "r284", "r479" ] }, "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability", "crdr": "credit", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Derivative fair value liability", "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability." } } }, "auth_ref": [ "r77", "r559", "r560", "r561" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://novelstem.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Compensation cost", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r551" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r503" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r499" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsTables", "http://novelstem.com/role/ScheduleOfInvestmentsDetails", "http://novelstem.com/role/ScheduleOfLongTermNotesPayableDetails", "http://novelstem.com/role/ScheduleOfOperationsAndFinancialPositionInvestmentDetails" ], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r499" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r516" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r499" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r513" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r511" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r499" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r499" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r499" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r499" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r514" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://novelstem.com/role/EquityDetailsNarrative", "http://novelstem.com/role/StatementsOfShareholdersEquity", "http://novelstem.com/role/SummaryOfWarrantsActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r4", "r99", "r112", "r113", "r114", "r131", "r132", "r133", "r135", "r140", "r142", "r144", "r160", "r184", "r185", "r188", "r252", "r282", "r283", "r291", "r292", "r293", "r295", "r296", "r297", "r304", "r305", "r306", "r307", "r308", "r309", "r311", "r316", "r317", "r318", "r319", "r320", "r321", "r325", "r326", "r327", "r352", "r357", "r358", "r359", "r367", "r426" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://novelstem.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative", "http://novelstem.com/role/NatureOfOperationsDetailsNarrative", "http://novelstem.com/role/NotesPayableDetailsNarrative", "http://novelstem.com/role/SubsequentEventsDetailsNarrative", "http://novelstem.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "auth_ref": [ "r178", "r179", "r181", "r290", "r517", "r518", "r519", "r553", "r554", "r555", "r556" ] }, "NSTM_EquityMethodInvestmentDescriptionOfPrincipal": { "xbrltype": "stringItemType", "nsuri": "http://novelstem.com/20240331", "localname": "EquityMethodInvestmentDescriptionOfPrincipal", "presentation": [ "http://novelstem.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity method investment description", "documentation": "Equity method investment description of principal." } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestmentDividendsOrDistributions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentDividendsOrDistributions", "crdr": "debit", "calculation": { "http://novelstem.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Distribution from NetCo Partners", "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities." } } }, "auth_ref": [ "r1", "r3", "r51", "r349" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://novelstem.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative", "http://novelstem.com/role/NatureOfOperationsDetailsNarrative", "http://novelstem.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity interest percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r178" ] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestments", "crdr": "debit", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity method investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r159", "r168", "r171", "r176", "r521", "r539" ] }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "lang": { "en-us": { "role": { "label": "Equity Method Investments and Joint Ventures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentsDisclosureTextBlock", "presentation": [ "http://novelstem.com/role/EquityMethodInvestments" ], "lang": { "en-us": { "role": { "label": "EQUITY METHOD INVESTMENTS", "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group." } } }, "auth_ref": [ "r96", "r180", "r183", "r519" ] }, "us-gaap_EquityMethodInvestmentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentsPolicy", "presentation": [ "http://novelstem.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Equity Investments", "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received." } } }, "auth_ref": [ "r1", "r29", "r179" ] }, "us-gaap_EquityMethodInvestmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentsTextBlock", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF OPERATIONS AND FINANCIAL POSITION INVESTMENT", "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information." } } }, "auth_ref": [ "r177" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "NSTM_GainOnDilutionOfEquityMethodInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://novelstem.com/20240331", "localname": "GainOnDilutionOfEquityMethodInvestment", "crdr": "credit", "presentation": [ "http://novelstem.com/role/ScheduleOfInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Gain on dilution of equity method investment", "documentation": "Gain on dilution of equity method investment." } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://novelstem.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://novelstem.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "General and administrative expenses", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r54", "r411" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "presentation": [ "http://novelstem.com/role/ScheduleOfOperationsAndFinancialPositionInvestmentDetails" ], "lang": { "en-us": { "role": { "label": "Gross margin", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r49", "r52", "r90", "r125", "r182", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r315", "r468", "r469", "r532", "r533", "r534", "r535", "r536", "r547" ] }, "NSTM_HewlettFundMember": { "xbrltype": "domainItemType", "nsuri": "http://novelstem.com/20240331", "localname": "HewlettFundMember", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Hewlett Fund [Member]", "documentation": "Hewlett Fund [Member]" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://novelstem.com/role/StatementsOfOperations": { "parentTag": "NSTM_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://novelstem.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r50", "r85", "r90", "r340", "r350", "r468", "r469", "r532", "r533", "r534", "r535", "r536" ] }, "NSTM_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://novelstem.com/20240331", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment", "crdr": "credit", "calculation": { "http://novelstem.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://novelstem.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before equity in net income of equity method investees", "documentation": "Income loss from continuing operations before income taxes minority interest and income loss from equity method investment.", "label": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://novelstem.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 }, "http://novelstem.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://novelstem.com/role/ScheduleOfOperationsAndFinancialPositionInvestmentDetails", "http://novelstem.com/role/StatementsOfCashFlows", "http://novelstem.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Equity in net loss of equity method investees", "negatedLabel": "Equity in net loss of equity method investees", "verboseLabel": "Company\u2019s allocation of net income from NetCo", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": [ "r3", "r51", "r84", "r159", "r165", "r171", "r176", "r349" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://novelstem.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "label": "INCOME TAXES", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r126", "r269", "r271", "r277", "r278", "r279", "r280", "r281", "r285", "r287", "r288", "r289", "r366", "r479" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://novelstem.com/role/StatementsOfOperations": { "parentTag": "NSTM_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestment", "weight": -1.0, "order": 2.0 }, "http://novelstem.com/role/ScheduleOfIncomeBeforeIncomeTaxDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://novelstem.com/role/ScheduleOfIncomeBeforeIncomeTaxDetails", "http://novelstem.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Provision for income tax", "totalLabel": "Total provision for income tax", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r92", "r94", "r143", "r144", "r159", "r166", "r171", "r270", "r271", "r286", "r354", "r479" ] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "calculation": { "http://novelstem.com/role/ScheduleOfIncomeBeforeIncomeTaxDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://novelstem.com/role/ScheduleOfIncomeBeforeIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Change in federal valuation allowance", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r276", "r479", "r552" ] }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "crdr": "debit", "calculation": { "http://novelstem.com/role/ScheduleOfIncomeBeforeIncomeTaxDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://novelstem.com/role/ScheduleOfIncomeBeforeIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Foreign rate differential", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)." } } }, "auth_ref": [ "r272", "r275", "r479", "r552" ] }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "calculation": { "http://novelstem.com/role/ScheduleOfIncomeBeforeIncomeTaxDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://novelstem.com/role/ScheduleOfIncomeBeforeIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Computed tax at the federal statutory rate of 21%", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r271", "r479" ] }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "crdr": "debit", "calculation": { "http://novelstem.com/role/ScheduleOfIncomeBeforeIncomeTaxDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://novelstem.com/role/ScheduleOfIncomeBeforeIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "State income taxes, net of federal income tax benefit", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)." } } }, "auth_ref": [ "r274", "r479", "r552" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://novelstem.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://novelstem.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable, administrative fees", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://novelstem.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued expenses", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Change in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://novelstem.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses", "label": "Increase (Decrease) in Prepaid Expense", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "presentation": [ "http://novelstem.com/role/ScheduleOfWeightedAverageNumberOfSharesOfDilutiveDetails" ], "lang": { "en-us": { "role": { "label": "Add: Warrants", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method." } } }, "auth_ref": [ "r148", "r149", "r150", "r155" ] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "presentation": [ "http://novelstem.com/role/ScheduleOfWeightedAverageNumberOfSharesOfDilutiveDetails" ], "lang": { "en-us": { "role": { "label": "Add: Stock options", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r148", "r149", "r151", "r155", "r257" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://novelstem.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://novelstem.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Interest expense", "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." } } }, "auth_ref": [ "r159", "r161", "r164", "r167", "r171", "r323", "r469", "r470" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest expense debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r58", "r232", "r239", "r475", "r476" ] }, "us-gaap_InterestExpenseLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseLongTermDebt", "crdr": "debit", "calculation": { "http://novelstem.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accrued interest added to long-term notes payable", "documentation": "Aggregate amount of interest paid or due on all long-term debt." } } }, "auth_ref": [ "r87", "r97", "r98" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r117", "r119", "r120" ] }, "us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentHoldingsScheduleOfInvestmentsTableTextBlock", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF INVESTMENTS", "documentation": "Tabular disclosure of data and information required in the supplementary schedule applicable to management investment companies listing holdings of unaffiliated investments." } } }, "auth_ref": [ "r581", "r582", "r583", "r584", "r585", "r586" ] }, "us-gaap_InvestmentIncomeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeNet", "crdr": "credit", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Investment return due", "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities." } } }, "auth_ref": [ "r55", "r56", "r58" ] }, "us-gaap_InvestmentOwnedAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentOwnedAtFairValue", "crdr": "debit", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative", "http://novelstem.com/role/ScheduleOfInvestmentsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Investment in NetCo, beginning", "periodEndLabel": "Investment in NetCo, ending", "label": "Carrying value of investment", "documentation": "Fair value of investment in security owned." } } }, "auth_ref": [ "r363", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r379", "r380", "r392", "r393", "r432", "r434", "r435", "r436", "r440", "r441", "r442", "r443", "r444", "r446", "r448", "r456", "r458", "r459", "r489", "r496", "r584" ] }, "NSTM_InvestmentsInAffiliatesSubsidiaries": { "xbrltype": "monetaryItemType", "nsuri": "http://novelstem.com/20240331", "localname": "InvestmentsInAffiliatesSubsidiaries", "crdr": "debit", "calculation": { "http://novelstem.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Investment in Netco Partners", "documentation": "Investments in affiliates subsidiaries." } } }, "auth_ref": [] }, "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "crdr": "debit", "calculation": { "http://novelstem.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Investment in NewStem Ltd", "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate." } } }, "auth_ref": [ "r522" ] }, "us-gaap_InvestmentsInAndAdvancesToAffiliatesAtFairValueGrossReductions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInAndAdvancesToAffiliatesAtFairValueGrossReductions", "crdr": "credit", "presentation": [ "http://novelstem.com/role/ScheduleOfInvestmentsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Distribution from NetCo", "label": "Investments in and Advances to Affiliates, at Fair Value, Gross Reductions", "documentation": "Gross reductions to the investment in and advance to the affiliate." } } }, "auth_ref": [ "r447" ] }, "us-gaap_InvestmentsInAndAdvancesToAffiliatesAtFairValuePeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInAndAdvancesToAffiliatesAtFairValuePeriodIncreaseDecrease", "presentation": [ "http://novelstem.com/role/ScheduleOfInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Allocation of net income (loss) from NetCo", "documentation": "Amount of increase (decrease) in the investments in and advances to affiliates." } } }, "auth_ref": [ "r592" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsTables", "http://novelstem.com/role/ScheduleOfInvestmentsDetails", "http://novelstem.com/role/ScheduleOfLongTermNotesPayableDetails", "http://novelstem.com/role/ScheduleOfOperationsAndFinancialPositionInvestmentDetails" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://novelstem.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://novelstem.com/role/BalanceSheets", "http://novelstem.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://novelstem.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liability", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r10", "r34", "r35", "r36", "r38", "r39", "r40", "r41", "r125", "r182", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r300", "r301", "r302", "r315", "r387", "r467", "r496", "r547", "r568", "r569" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://novelstem.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and shareholders\u2019 deficit", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r48", "r83", "r347", "r485", "r525", "r540", "r562" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "LIABILITIES AND SHAREHOLDERS\u2019 DEFICIT" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://novelstem.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://novelstem.com/role/BalanceSheets", "http://novelstem.com/role/ScheduleOfOperationsAndFinancialPositionInvestmentDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r36", "r102", "r125", "r182", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r300", "r301", "r302", "r315", "r485", "r547", "r568", "r569" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://novelstem.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://novelstem.com/role/BalanceSheets", "http://novelstem.com/role/ScheduleOfOperationsAndFinancialPositionInvestmentDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total long-term liabilities", "label": "Non-current liabilities", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r10", "r38", "r39", "r40", "r41", "r125", "r182", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r300", "r301", "r302", "r315", "r547", "r568", "r569" ] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long-term liabilities:" } } }, "auth_ref": [] }, "us-gaap_LitigationSettlementExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationSettlementExpense", "crdr": "debit", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Litigation settlement, expense", "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees." } } }, "auth_ref": [ "r520" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "presentation": [ "http://novelstem.com/role/NatureOfOperationsDetailsNarrative", "http://novelstem.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Borrow for working capital needs", "verboseLabel": "Long term debt unrelated parties", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r10", "r81", "r225", "r238", "r473", "r474", "r484", "r576" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "presentation": [ "http://novelstem.com/role/ScheduleOfLongTermNotesPayableDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less current portion", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r105" ] }, "us-gaap_LongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermNotesPayable", "crdr": "credit", "calculation": { "http://novelstem.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://novelstem.com/role/BalanceSheets", "http://novelstem.com/role/NotesPayableDetailsNarrative", "http://novelstem.com/role/ScheduleOfLongTermNotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Long-term notes payable, including accrued interest, net", "verboseLabel": "Long-term notes payable", "terseLabel": "Long term note payable", "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion." } } }, "auth_ref": [ "r10" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r197", "r198", "r199", "r200", "r255", "r268", "r314", "r337", "r355", "r356", "r362", "r377", "r378", "r433", "r437", "r438", "r439", "r449", "r462", "r463", "r471", "r477", "r478", "r480", "r481", "r482", "r483", "r486", "r549", "r570", "r571", "r572", "r573", "r574", "r575" ] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": [ "http://novelstem.com/role/NatureOfOperations" ], "lang": { "en-us": { "role": { "label": "NATURE OF OPERATIONS", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [ "r93", "r95" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://novelstem.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r118" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://novelstem.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r118" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://novelstem.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r59", "r60", "r61" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "NSTM_NetCoPartnersMember": { "xbrltype": "domainItemType", "nsuri": "http://novelstem.com/20240331", "localname": "NetCoPartnersMember", "presentation": [ "http://novelstem.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative", "http://novelstem.com/role/EquityMethodInvestmentsTables", "http://novelstem.com/role/NatureOfOperationsDetailsNarrative", "http://novelstem.com/role/ScheduleOfInvestmentsDetails", "http://novelstem.com/role/ScheduleOfOperationsAndFinancialPositionInvestmentDetails", "http://novelstem.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "NetCo Partners [Member]", "documentation": "NetCo Partners [Member]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://novelstem.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://novelstem.com/role/StatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://novelstem.com/role/ScheduleOfOperationsAndFinancialPositionInvestmentDetails", "http://novelstem.com/role/ScheduleOfWeightedAverageNumberOfSharesOfDilutiveDetails", "http://novelstem.com/role/StatementsOfCashFlows", "http://novelstem.com/role/StatementsOfOperations", "http://novelstem.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "label": "Net loss", "verboseLabel": "Net loss attributable to common shareholders", "terseLabel": "Net income", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r53", "r61", "r86", "r100", "r110", "r111", "r114", "r125", "r134", "r136", "r137", "r138", "r139", "r140", "r143", "r144", "r152", "r182", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r294", "r297", "r313", "r315", "r351", "r409", "r424", "r425", "r495", "r547" ] }, "NSTM_NewStemLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://novelstem.com/20240331", "localname": "NewStemLtdMember", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative", "http://novelstem.com/role/EquityMethodInvestmentsTables", "http://novelstem.com/role/NatureOfOperationsDetailsNarrative", "http://novelstem.com/role/NotesPayableDetailsNarrative", "http://novelstem.com/role/ScheduleOfInvestmentsDetails", "http://novelstem.com/role/ScheduleOfOperationsAndFinancialPositionInvestmentDetails", "http://novelstem.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "New Stem Ltd [Member]", "documentation": "New Stem Ltd [Member]" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://novelstem.com/role/StatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://novelstem.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total other expenses", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r57" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://novelstem.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other expenses:" } } }, "auth_ref": [] }, "NSTM_NoteReceivableNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://novelstem.com/20240331", "localname": "NoteReceivableNonCurrent", "crdr": "debit", "calculation": { "http://novelstem.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://novelstem.com/role/BalanceSheets", "http://novelstem.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Note receivable, NewStem Ltd", "verboseLabel": "[custom:NoteReceivableNonCurrent-0]", "documentation": "Note receivable, non-current." } } }, "auth_ref": [] }, "us-gaap_NotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayable", "crdr": "credit", "presentation": [ "http://novelstem.com/role/ScheduleOfLongTermNotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Total notes payable", "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r10", "r81", "r576", "r577" ] }, "us-gaap_NotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayableCurrent", "crdr": "credit", "calculation": { "http://novelstem.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://novelstem.com/role/BalanceSheets", "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative", "http://novelstem.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Notes payable", "verboseLabel": "Advance payable", "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r34", "r35" ] }, "NSTM_OmniBridgewayFund4Invt3LPMember": { "xbrltype": "domainItemType", "nsuri": "http://novelstem.com/20240331", "localname": "OmniBridgewayFund4Invt3LPMember", "presentation": [ "http://novelstem.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://novelstem.com/role/NotesPayableDetailsNarrative", "http://novelstem.com/role/ScheduleOfLongTermNotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Omni Bridgeway (Fund 4) Invt. 3 L.P. [Member]", "documentation": "Omni Bridgeway (Fund 4) Invt. 3 L.P. [Member]" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://novelstem.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://novelstem.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://novelstem.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://novelstem.com/role/StatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://novelstem.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r90", "r468", "r532", "r533", "r534", "r535", "r536" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://novelstem.com/role/ScheduleOfLongTermNotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Accrued interest added to note balance", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r35" ] }, "us-gaap_OtherControlledCompaniesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherControlledCompaniesMember", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Investment, Affiliated Issuer, Controlled, Not Majority-Owned [Member]", "documentation": "Controlled affiliated issuer of investment that is not majority-owned." } } }, "auth_ref": [ "r445", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458" ] }, "us-gaap_OtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilities", "crdr": "credit", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Due to related parties", "documentation": "Amount of liabilities classified as other." } } }, "auth_ref": [ "r80", "r342", "r382", "r383", "r496", "r577", "r587" ] }, "us-gaap_OtherLongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLongTermNotesPayable", "crdr": "credit", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Advance of long term note payable", "documentation": "Amount of long-term notes classified as other, payable after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r10" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r510" ] }, "us-gaap_OtherShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherShortTermBorrowings", "crdr": "credit", "presentation": [ "http://novelstem.com/role/NatureOfOperationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Advance from borrowings", "documentation": "Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r32", "r386" ] }, "us-gaap_PaymentsForProceedsFromInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromInvestments", "crdr": "credit", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Additional funding", "documentation": "The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets." } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireLoansReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireLoansReceivable", "crdr": "credit", "calculation": { "http://novelstem.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Loans made", "label": "Payments to Acquire Loans Receivable", "documentation": "The cash outflow for the purchase of loan receivable arising from the financing of goods and services." } } }, "auth_ref": [ "r11" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r504" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r506" ] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://novelstem.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r107", "r186", "r187", "r465" ] }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "presentation": [ "http://novelstem.com/role/NatureOfOperationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Additional Borrowings for working capital needs", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": [ "r523" ] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "calculation": { "http://novelstem.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from long term notes payable", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r12", "r364" ] }, "us-gaap_ProceedsFromRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromRelatedPartyDebt", "crdr": "debit", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds form related party", "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates." } } }, "auth_ref": [ "r12" ] }, "us-gaap_ProfessionalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfessionalFees", "crdr": "debit", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Audit and audit related costs", "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer." } } }, "auth_ref": [ "r469", "r495", "r588", "r589" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r197", "r198", "r199", "r200", "r253", "r255", "r265", "r266", "r267", "r268", "r314", "r335", "r336", "r337", "r355", "r356", "r362", "r377", "r378", "r433", "r437", "r438", "r439", "r449", "r462", "r463", "r471", "r477", "r478", "r480", "r481", "r482", "r483", "r486", "r489", "r545", "r549", "r560", "r571", "r572", "r573", "r574", "r575" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative" ], "auth_ref": [ "r197", "r198", "r199", "r200", "r253", "r255", "r265", "r266", "r267", "r268", "r314", "r335", "r336", "r337", "r355", "r356", "r362", "r377", "r378", "r433", "r437", "r438", "r439", "r449", "r462", "r463", "r471", "r477", "r478", "r480", "r481", "r482", "r483", "r486", "r489", "r545", "r549", "r560", "r571", "r572", "r573", "r574", "r575" ] }, "us-gaap_ReimbursementFromLimitedPartnershipInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReimbursementFromLimitedPartnershipInvestment", "crdr": "debit", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Reimbursement due", "documentation": "A payment from an investee, in which the investment basis has previously been reduced to zero. This amount reduces net cash used in operating activities." } } }, "auth_ref": [ "r3" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [ "http://novelstem.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://novelstem.com/role/NotesPayableDetailsNarrative", "http://novelstem.com/role/ScheduleOfLongTermNotesPayableDetails" ], "lang": { "en-us": { "role": { "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r175", "r254", "r328", "r329", "r343", "r348", "r381", "r382", "r383", "r384", "r385", "r406", "r408", "r431" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative", "http://novelstem.com/role/ScheduleOfLongTermNotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r127", "r128", "r328", "r329", "r330", "r331", "r343", "r348", "r381", "r382", "r383", "r384", "r385", "r406", "r408", "r431" ] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://novelstem.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://novelstem.com/role/NotesPayableDetailsNarrative", "http://novelstem.com/role/ScheduleOfLongTermNotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r175", "r254", "r328", "r329", "r343", "r348", "r381", "r382", "r383", "r384", "r385", "r406", "r408", "r431", "r567" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://novelstem.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://novelstem.com/role/BalanceSheets", "http://novelstem.com/role/NatureOfOperationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "negatedLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r45", "r70", "r346", "r360", "r361", "r365", "r390", "r485" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://novelstem.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r99", "r131", "r132", "r133", "r135", "r140", "r142", "r144", "r184", "r185", "r188", "r282", "r283", "r291", "r292", "r293", "r295", "r296", "r297", "r304", "r306", "r307", "r309", "r311", "r325", "r326", "r357", "r359", "r367", "r590" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "presentation": [ "http://novelstem.com/role/ScheduleOfOperationsAndFinancialPositionInvestmentDetails" ], "lang": { "en-us": { "role": { "label": "Net sales", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r88", "r89", "r115", "r125", "r159", "r162", "r163", "r169", "r171", "r172", "r173", "r174", "r182", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r315", "r340", "r469", "r547" ] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of stock", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://novelstem.com/role/ScheduleOfWarrantsAndStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r14" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://novelstem.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF WARRANTS AND STOCK OPTIONS", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r14" ] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://novelstem.com/role/NotesPayableTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF LONG TERM NOTES PAYABLE", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r10", "r16", "r17", "r30", "r68", "r69", "r473", "r475", "r526", "r564" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://novelstem.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF WEIGHTED AVERAGE NUMBER OF SHARES OF DILUTIVE", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r531" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://novelstem.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF INCOME BEFORE INCOME TAX", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r273", "r479", "r552" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://novelstem.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative", "http://novelstem.com/role/NatureOfOperationsDetailsNarrative", "http://novelstem.com/role/NotesPayableDetailsNarrative", "http://novelstem.com/role/SubsequentEventsDetailsNarrative", "http://novelstem.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r178", "r179", "r181", "r290", "r517", "r518", "r519", "r553", "r554", "r555", "r556" ] }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Equity Method Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r125", "r178", "r179", "r181", "r182", "r315" ] }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEquityMethodInvestmentsTable", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity Method Investment [Table]", "documentation": "Disclosure of information about equity method investment. Includes, but is not limited to, name of investee or group of investees, percentage ownership, difference between investment and value of underlying equity in net assets." } } }, "auth_ref": [ "r100", "r125", "r178", "r179", "r181", "r182", "r315" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://novelstem.com/role/EquityTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF STOCK OPTION ACTIVITIES", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r8", "r9", "r71" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://novelstem.com/role/EquityTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF FAIR VALUE OF OPTION USING VALUATION ASSUMPTIONS", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r76" ] }, "us-gaap_ScheduleOfShortTermDebtTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShortTermDebtTable", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt [Table]", "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability." } } }, "auth_ref": [ "r34" ] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://novelstem.com/role/EquityTables" ], "lang": { "en-us": { "role": { "label": "SUMMARY OF WARRANTS ACTIVITY", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r20" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r498" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r502" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r501" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r507" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://novelstem.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://novelstem.com/role/EquityDetailsNarrative", "http://novelstem.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation", "verboseLabel": "Stock-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://novelstem.com/role/EquityDetailsNarrative", "http://novelstem.com/role/ScheduleOfFairValueOfOptionUsingValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Risk-free interest rate", "label": "Expected dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r266" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://novelstem.com/role/ScheduleOfFairValueOfOptionUsingValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r265" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://novelstem.com/role/ScheduleOfFairValueOfOptionUsingValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Risk-free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r267" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "presentation": [ "http://novelstem.com/role/SummaryOfWarrantsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Number of shares underlying warrants, Exercised", "documentation": "Number of non-option equity instruments exercised by participants." } } }, "auth_ref": [ "r7" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations", "presentation": [ "http://novelstem.com/role/SummaryOfWarrantsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Number of shares underlying warrants, Forfeited or expired", "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired." } } }, "auth_ref": [ "r74", "r75" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "presentation": [ "http://novelstem.com/role/SummaryOfWarrantsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Number of shares underlying warrants, Granted", "documentation": "Net number of non-option equity instruments granted to participants." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "presentation": [ "http://novelstem.com/role/SummaryOfWarrantsActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of shares underlying warrants, Beginning balance", "periodEndLabel": "Number of shares underlying warrants, Ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments." } } }, "auth_ref": [ "r72", "r73" ] }, "NSTM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://novelstem.com/20240331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice", "presentation": [ "http://novelstem.com/role/SummaryOfWarrantsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, Granted", "documentation": "Share based compensation arrangement by share based payment award non options granted weighted average exercise price." } } }, "auth_ref": [] }, "NSTM_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://novelstem.com/20240331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://novelstem.com/role/SummaryOfWarrantsActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average exercise price, Beginning balance", "periodEndLabel": "Weighted average exercise price, Ending balance", "documentation": "Share based compensation arrangement by share based payment award non options outstanding weighted average exercise price.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://novelstem.com/role/ScheduleOfStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Number of Options Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r260" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://novelstem.com/role/EquityDetailsNarrative", "http://novelstem.com/role/ScheduleOfStockOptionActivitiesDetails", "http://novelstem.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of Options, Granted", "verboseLabel": "Number of option granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r261" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://novelstem.com/role/ScheduleOfFairValueOfOptionUsingValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r262" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://novelstem.com/role/ScheduleOfStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of Options Outstanding beginning", "periodEndLabel": "Number of Options Outstanding ending", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r258", "r259" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://novelstem.com/role/ScheduleOfStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted Average Exercise Price Outstanding beginning", "periodEndLabel": "Weighted Average Exercise Price Outstanding ending", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r258", "r259" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": [ "http://novelstem.com/role/ScheduleOfStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Weighted Average Exercise Price, Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r263" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Percentage of outstanding shares", "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://novelstem.com/role/ScheduleOfStockOptionActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price, Granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r261" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://novelstem.com/role/ScheduleOfFairValueOfOptionUsingValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Expected term, in years", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r264" ] }, "NSTM_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://novelstem.com/20240331", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2", "presentation": [ "http://novelstem.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Granted term", "documentation": "Granted term." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "presentation": [ "http://novelstem.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Options unvested", "documentation": "Number of non-vested options outstanding." } } }, "auth_ref": [] }, "NSTM_ShareholderMember": { "xbrltype": "domainItemType", "nsuri": "http://novelstem.com/20240331", "localname": "ShareholderMember", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative", "http://novelstem.com/role/ScheduleOfLongTermNotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Shareholder [Member]", "documentation": "Shareholder [Member]" } } }, "auth_ref": [] }, "NSTM_ShareholdersAndDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://novelstem.com/20240331", "localname": "ShareholdersAndDirectorsMember", "presentation": [ "http://novelstem.com/role/NatureOfOperationsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shareholders And Directors [Member]", "documentation": "Shareholders And Directors [Member]" } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [ "http://novelstem.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, shares", "periodEndLabel": "Balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtInterestRateIncrease": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtInterestRateIncrease", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Short term debt, interest rate increase", "documentation": "Percentage increase in the stated interest rate on a short-term debt instrument." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtLineItems", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://novelstem.com/role/SummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r62", "r122" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r505" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://novelstem.com/role/EquityDetailsNarrative", "http://novelstem.com/role/StatementsOfShareholdersEquity", "http://novelstem.com/role/SummaryOfWarrantsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r4", "r43", "r46", "r47", "r99", "r112", "r113", "r114", "r131", "r132", "r133", "r135", "r140", "r142", "r144", "r160", "r184", "r185", "r188", "r252", "r282", "r283", "r291", "r292", "r293", "r295", "r296", "r297", "r304", "r305", "r306", "r307", "r308", "r309", "r311", "r316", "r317", "r318", "r319", "r320", "r321", "r325", "r326", "r327", "r352", "r357", "r358", "r359", "r367", "r426" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://novelstem.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://novelstem.com/role/EquityMethodInvestmentsTables", "http://novelstem.com/role/NatureOfOperationsDetailsNarrative", "http://novelstem.com/role/ScheduleOfInvestmentsDetails", "http://novelstem.com/role/ScheduleOfLongTermNotesPayableDetails", "http://novelstem.com/role/ScheduleOfOperationsAndFinancialPositionInvestmentDetails", "http://novelstem.com/role/StatementsOfShareholdersEquity", "http://novelstem.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r131", "r132", "r133", "r160", "r326", "r338", "r363", "r368", "r379", "r381", "r382", "r383", "r384", "r385", "r389", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r402", "r403", "r404", "r405", "r406", "r408", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r426", "r490" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://novelstem.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://novelstem.com/role/EquityMethodInvestmentsTables", "http://novelstem.com/role/NatureOfOperationsDetailsNarrative", "http://novelstem.com/role/ScheduleOfInvestmentsDetails", "http://novelstem.com/role/ScheduleOfLongTermNotesPayableDetails", "http://novelstem.com/role/ScheduleOfOperationsAndFinancialPositionInvestmentDetails", "http://novelstem.com/role/StatementsOfShareholdersEquity", "http://novelstem.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r131", "r132", "r133", "r160", "r175", "r326", "r338", "r363", "r368", "r379", "r381", "r382", "r383", "r384", "r385", "r389", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r402", "r403", "r404", "r405", "r406", "r408", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r426", "r490" ] }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesAcquisitions", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares acquisitions shares", "documentation": "Number of shares of stock issued during the period pursuant to acquisitions." } } }, "auth_ref": [ "r42", "r43", "r70" ] }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueAcquisitions", "crdr": "credit", "presentation": [ "http://novelstem.com/role/EquityMethodInvestmentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares acquisitions", "documentation": "Value of stock issued pursuant to acquisitions during the period." } } }, "auth_ref": [ "r4", "r43", "r46", "r47", "r70" ] }, "us-gaap_StockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockOptionMember", "presentation": [ "http://novelstem.com/role/ScheduleOfWarrantsAndStockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Equity Option [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": [ "r489" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://novelstem.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://novelstem.com/role/BalanceSheets", "http://novelstem.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total shareholders\u2019 deficit", "periodStartLabel": "Balance, value", "periodEndLabel": "Balance, value", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r43", "r46", "r47", "r63", "r391", "r407", "r427", "r428", "r485", "r496", "r525", "r540", "r562", "r590" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Shareholders\u2019 deficit:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://novelstem.com/role/Equity" ], "lang": { "en-us": { "role": { "label": "EQUITY", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r67", "r124", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r310", "r429", "r430", "r460" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": [ "http://novelstem.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r322", "r333" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [ "http://novelstem.com/role/EquityDetailsNarrative", "http://novelstem.com/role/NatureOfOperationsDetailsNarrative", "http://novelstem.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r322", "r333" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": [ "http://novelstem.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": [ "r322", "r333" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://novelstem.com/role/EquityDetailsNarrative", "http://novelstem.com/role/NatureOfOperationsDetailsNarrative", "http://novelstem.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r322", "r333" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://novelstem.com/role/EquityDetailsNarrative", "http://novelstem.com/role/NatureOfOperationsDetailsNarrative", "http://novelstem.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r322", "r333" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://novelstem.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r332", "r334" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://novelstem.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental cash flow information:" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": [ "http://novelstem.com/role/EquityDetailsNarrative", "http://novelstem.com/role/NatureOfOperationsDetailsNarrative", "http://novelstem.com/role/ScheduleOfLongTermNotesPayableDetails", "http://novelstem.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]" } } }, "auth_ref": [ "r537", "r566" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://novelstem.com/role/EquityDetailsNarrative", "http://novelstem.com/role/NatureOfOperationsDetailsNarrative", "http://novelstem.com/role/ScheduleOfLongTermNotesPayableDetails", "http://novelstem.com/role/SubsequentEventsDetailsNarrative" ], "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": [ "http://novelstem.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r18" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": [ "http://novelstem.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Treasury stock, shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r18" ] }, "us-gaap_TreasuryStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValue", "crdr": "debit", "calculation": { "http://novelstem.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://novelstem.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "negatedLabel": "Treasury stock, at cost, 3,435,197 shares as of March 31, 2024 and December 31, 2023", "label": "Treasury Stock, Value", "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury." } } }, "auth_ref": [ "r18", "r19", "r43", "r46" ] }, "NSTM_TwoIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://novelstem.com/20240331", "localname": "TwoIndividualsMember", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Two Individuals [Member]", "documentation": "Two Individuals [Member]" } } }, "auth_ref": [] }, "NSTM_TwoShortTermNotesPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://novelstem.com/20240331", "localname": "TwoShortTermNotesPayableMember", "presentation": [ "http://novelstem.com/role/NotesPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Two Short Term Notes Payable [Member]", "documentation": "Two Short Term Notes Payable [Member]" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [ "http://novelstem.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r298" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [ "http://novelstem.com/role/EquityDetailsNarrative", "http://novelstem.com/role/ScheduleOfWarrantsAndStockOptionsDetails", "http://novelstem.com/role/SummaryOfWarrantsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r487", "r488", "r491", "r492", "r493", "r494" ] }, "us-gaap_WarrantsAndRightsOutstandingMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingMaturityDate", "presentation": [ "http://novelstem.com/role/EquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maturity date", "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format." } } }, "auth_ref": [ "r559", "r560", "r561" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://novelstem.com/role/ScheduleOfWeightedAverageNumberOfSharesOfDilutiveDetails", "http://novelstem.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "verboseLabel": "-Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r146", "r155" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://novelstem.com/role/ScheduleOfWeightedAverageNumberOfSharesOfDilutiveDetails", "http://novelstem.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "verboseLabel": "-Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r145", "r155" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "presentation": [ "http://novelstem.com/role/ScheduleOfWeightedAverageNumberOfSharesOfDilutiveDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average shares outstanding:" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://novelstem.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r515" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21D", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21D" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "323", "Publisher": "FASB", "URI": "https://asc.fasb.org/323/tableOfContent" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-26" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column C)(Footnote 6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column D)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column D)(Footnote 6)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r467": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r468": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r469": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r470": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r471": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r472": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r473": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r474": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r475": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r476": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r477": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r478": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r479": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r480": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r481": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r482": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r483": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r484": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r485": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r486": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r487": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r489": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r494": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r495": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r496": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r497": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r498": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r499": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r501": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r503": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r504": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r505": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r506": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r507": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r508": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r509": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r510": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r511": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r512": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r514": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r515": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r516": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r517": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r520": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(6))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r521": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r522": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r523": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r524": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r525": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r526": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r527": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r528": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r529": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r530": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r531": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r532": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r533": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r534": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r535": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r536": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r537": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r538": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r539": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r540": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r541": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r542": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r543": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r544": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r545": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r546": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r547": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r548": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r549": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r550": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r551": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r552": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r553": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r554": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r555": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r556": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r557": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r558": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r559": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r560": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r561": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r562": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r563": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r564": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r565": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r566": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r567": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r568": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r569": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r570": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r571": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r572": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r573": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r574": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r575": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r576": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r577": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r578": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r579": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r580": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r581": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r582": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r583": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r584": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r585": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r586": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r587": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r588": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r589": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r590": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r591": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r592": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" } } } ZIP 58 0001493152-24-019729-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-019729-xbrl.zip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end XML 60 form10-q_htm.xml IDEA: XBRL DOCUMENT 0000912544 2024-01-01 2024-03-31 0000912544 2024-05-15 0000912544 2024-03-31 0000912544 2023-12-31 0000912544 2023-01-01 2023-03-31 0000912544 us-gaap:CommonStockMember 2023-12-31 0000912544 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000912544 us-gaap:RetainedEarningsMember 2023-12-31 0000912544 us-gaap:TreasuryStockCommonMember 2023-12-31 0000912544 us-gaap:CommonStockMember 2022-12-31 0000912544 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000912544 us-gaap:RetainedEarningsMember 2022-12-31 0000912544 us-gaap:TreasuryStockCommonMember 2022-12-31 0000912544 2022-12-31 0000912544 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000912544 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000912544 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000912544 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0000912544 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000912544 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000912544 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000912544 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0000912544 us-gaap:CommonStockMember 2024-03-31 0000912544 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000912544 us-gaap:RetainedEarningsMember 2024-03-31 0000912544 us-gaap:TreasuryStockCommonMember 2024-03-31 0000912544 us-gaap:CommonStockMember 2023-03-31 0000912544 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000912544 us-gaap:RetainedEarningsMember 2023-03-31 0000912544 us-gaap:TreasuryStockCommonMember 2023-03-31 0000912544 2023-03-31 0000912544 NSTM:NewStemLtdMember 2024-03-31 0000912544 NSTM:NetCoPartnersMember 2024-03-31 0000912544 2018-09-30 0000912544 NSTM:ShareholdersAndDirectorsMember 2024-03-31 0000912544 NSTM:ShareholdersAndDirectorsMember 2024-01-01 2024-03-31 0000912544 us-gaap:SubsequentEventMember 2024-04-30 0000912544 us-gaap:WarrantMember 2024-01-01 2024-03-31 0000912544 us-gaap:WarrantMember 2023-01-01 2023-03-31 0000912544 us-gaap:StockOptionMember 2024-01-01 2024-03-31 0000912544 us-gaap:StockOptionMember 2023-01-01 2023-03-31 0000912544 srt:MaximumMember NSTM:NewStemLtdMember 2018-12-31 0000912544 NSTM:NewStemLtdMember 2018-01-01 2018-12-31 0000912544 NSTM:NewStemLtdMember 2018-12-31 0000912544 NSTM:NewStemLtdMember 2019-01-01 2019-12-31 0000912544 NSTM:NewStemLtdMember 2020-01-01 2020-12-31 0000912544 NSTM:NewStemLtdMember 2023-12-31 0000912544 NSTM:NewStemLtdMember us-gaap:OtherControlledCompaniesMember 2024-03-31 0000912544 NSTM:NewStemLtdMember us-gaap:OtherControlledCompaniesMember 2023-12-31 0000912544 NSTM:NewStemLtdMember us-gaap:AccountsPayableMember 2024-01-01 2024-03-31 0000912544 NSTM:NewStemLtdMember 2024-01-01 2024-03-31 0000912544 NSTM:NewStemLtdMember 2022-04-01 2022-04-30 0000912544 NSTM:NewStemLtdMember 2024-01-01 2024-03-31 0000912544 NSTM:NetCoPartnersMember 2024-01-01 2024-03-31 0000912544 NSTM:NewStemLtdMember 2023-12-31 0000912544 NSTM:NewStemLtdMember 2022-12-31 0000912544 NSTM:NewStemLtdMember 2023-01-01 2023-12-31 0000912544 NSTM:NewStemLtdMember 2024-03-31 0000912544 NSTM:NetCoPartnersMember 2023-12-31 0000912544 NSTM:NetCoPartnersMember 2022-12-31 0000912544 NSTM:NetCoPartnersMember 2023-01-01 2023-12-31 0000912544 NSTM:NetCoPartnersMember 2024-03-31 0000912544 NSTM:NewStemLtdMember 2023-01-01 2023-03-31 0000912544 NSTM:NetCoPartnersMember 2023-01-01 2023-03-31 0000912544 NSTM:HewlettFundMember 2023-12-31 0000912544 NSTM:AIGHInvestmentPartnersLLCMember 2023-12-31 0000912544 NSTM:TwoShortTermNotesPayableMember 2023-12-31 0000912544 NSTM:TwoShortTermNotesPayableMember 2023-01-01 2023-03-31 0000912544 NSTM:TwoShortTermNotesPayableMember 2024-01-01 2024-03-31 0000912544 NSTM:TwoIndividualsMember 2022-05-31 0000912544 NSTM:TwoIndividualsMember 2024-03-31 0000912544 NSTM:TwoIndividualsMember 2022-11-11 2022-11-11 0000912544 NSTM:TwoIndividualsMember 2022-05-01 2022-05-31 0000912544 NSTM:TwoIndividualsMember 2024-01-01 2024-03-31 0000912544 NSTM:TwoIndividualsMember 2023-01-01 2023-12-31 0000912544 NSTM:ShareholderMember 2023-05-05 0000912544 NSTM:ShareholderMember 2023-10-31 0000912544 us-gaap:RelatedPartyMember 2023-05-05 0000912544 NSTM:ShareholderMember 2023-05-05 2023-05-05 0000912544 NSTM:ShareholderMember 2024-03-31 0000912544 NSTM:ShareholderMember 2023-12-31 0000912544 NSTM:OmniBridgewayFund4Invt3LPMember 2022-02-11 2022-02-11 0000912544 NSTM:OmniBridgewayFund4Invt3LPMember 2023-12-31 0000912544 NSTM:OmniBridgewayFund4Invt3LPMember 2023-01-01 2023-12-31 0000912544 NSTM:DirectorAndExecutiveChairmanMember us-gaap:RelatedPartyMember 2024-03-31 0000912544 NSTM:DirectorAndExecutiveChairmanMember us-gaap:RelatedPartyMember 2023-12-31 0000912544 NSTM:DirectorAndExecutiveChairmanMember 2024-03-31 0000912544 NSTM:DirectorAndExecutiveChairmanMember 2023-12-31 0000912544 NSTM:ShareholderMember us-gaap:RelatedPartyMember 2024-03-31 0000912544 NSTM:ShareholderMember us-gaap:RelatedPartyMember 2023-12-31 0000912544 NSTM:OmniBridgewayFund4Invt3LPMember 2024-03-31 0000912544 NSTM:OmniBridgewayFund4Invt3LPMember 2023-12-31 0000912544 us-gaap:RelatedPartyMember NSTM:OmniBridgewayFund4Invt3LPMember 2024-03-31 0000912544 us-gaap:RelatedPartyMember NSTM:OmniBridgewayFund4Invt3LPMember 2023-12-31 0000912544 NSTM:DirectorAndExecutiveChairmanMember NSTM:OmniBridgewayFund4Invt3LPMember 2024-03-31 0000912544 NSTM:DirectorAndExecutiveChairmanMember NSTM:OmniBridgewayFund4Invt3LPMember 2023-12-31 0000912544 NSTM:DirectotAndInvestorMember 2018-11-12 2018-11-12 0000912544 srt:DirectorMember us-gaap:SubsequentEventMember 2024-04-01 2024-04-01 0000912544 us-gaap:WarrantMember 2024-03-31 0000912544 us-gaap:WarrantMember 2023-12-31 0000912544 us-gaap:WarrantMember 2024-01-01 2024-03-31 0000912544 us-gaap:SubsequentEventMember NSTM:ConvertibleDebtAgreementsMember 2024-04-30 0000912544 us-gaap:SubsequentEventMember NSTM:ConvertibleDebtAgreementsMember 2024-04-01 2024-04-30 0000912544 us-gaap:SubsequentEventMember NSTM:ConvertibleDebtAgreementsMember 2024-04-01 iso4217:USD shares iso4217:USD shares pure false Q1 --12-31 0000912544 0.3051 10-Q true 2024-03-31 2024 false 001-14332 NOVELSTEM INTERNATIONAL CORP. FL 65-0385686 2255 Glades Road Suite 221A Boca Raton FL 33431 410 598-9024 Yes Yes Non-accelerated Filer true true false false 46881475 5181 53063 3000 27855 33540 36036 86603 132358 133709 500000 250000 1732375 1784234 2400769 2254546 149672 54257 250000 250000 2850916 45974 42223 3296562 346480 810527 3324599 535000 535000 1345527 3859599 4642089 4206079 0.01 0.01 100000000 100000000 50316672 50316672 46881475 46881475 468815 468815 290920710 290907217 -293431091 -293127811 3435197 3435197 199754 199754 -2241320 -1951533 2400769 2254546 3000 183306 164792 183306 164792 -180306 -164792 25000 94764 7313 -69764 -7313 -250070 -172105 -250070 -172105 -53210 -96716 -303280 -268821 -0.01 -0.01 -0.01 -0.01 46881475 46881475 46881475 46881475 46881475 468815 290907217 -293127811 3435197 -199754 -1951533 -303280 -303280 13493 13493 46881475 468815 290920710 -293431091 3435197 -199754 -2241320 46881475 468815 290604327 -288940510 3435197 -199754 1932878 46881475 468815 290604327 -288940510 3435197 -199754 1932878 -268821 -268821 15077 15077 46881475 468815 290619404 -289209331 3435197 -199754 1679134 46881475 468815 290619404 -289209331 3435197 -199754 1679134 -303280 -268821 -53210 -96716 7875 44398 25000 42446 7079 13493 15077 3000 -12000 -5685 -994 95415 107296 3751 -6000 -72882 -27784 250000 -250000 275000 62000 275000 62000 -47882 34216 53063 6346 5181 40562 441 234 NOTE 1—NATURE OF OPERATIONS Description of Business NovelStem International Corp. (“NovelStem” or the “Company”) is a holding company whose principal assets are an approximate <span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dpxL_uPure_c20240331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NewStemLtdMember_zbbJCtR23Jy2" title="Equity interest percentage::XDX::30.51">31% equity interest in NewStem Ltd, an Israeli biotech company (“NewStem”), and a <span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20240331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NetCoPartnersMember_zOXHYO4phhF1" title="Equity interest percentage">50% equity interest in NetCo Partners (“NetCo”). NovelStem was formerly known as Hollywood Media Corp. The Company was incorporated in the State of Florida on January 22, 1993 and changed its name to NovelStem International Corp. in September 2018 as a result of its business focus shift from a media business to biotech. NewStem focuses on the development and commercialization of diagnostic technology that can predict patients’ anti-cancer drug resistance, allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. NewStem is collaborating with life sciences companies for the development of drugs and reagents. NetCo is a legacy media business interest which owns “Net Force”, a book publishing franchise. Going Concern, Liquidity and Management’s Plans Since inception, the Company has accumulated a deficit of approximately $293,000,000. The accumulated deficit of the Company subsequent to its business focus shift and name change in September 2018 is approximately $6,750,000 which is comprised primarily of allocated losses from equity method investments and general and administrative costs incurred by the Company. The Company will need to obtain additional funds to continue its operations. Management’s plans with regard to these matters include additional financing and fundraising until its equity investment in NewStem is profitable. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient cash from financing on terms acceptable to the Company, or that NewStem will be able to continue as a going concern and become profitable (see Note 3). The Company has in place a finance agreement with two individuals who are shareholders and directors to borrow $650,000 and an additional finance agreement with a shareholder to borrow $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfDebt_pp0p0_c20240101__20240331__srt--TitleOfIndividualAxis__custom--ShareholdersAndDirectorsMember_zgZfPbEkf9Bl" title="Additional Borrowings for working capital needs">300,000 for working capital needs (see Note 4). Additionally, the Company entered into additional finance agreements with unrelated parties in December 2023 and April 2024 to borrow an additional $350,000 for working capital needs and to fund NewStem (see Note 4). As of the date of these financial statements, these borrowings have been fully utilized and the Company will need to obtain additional funds to continue operations for the next 12 months. In view of the matters described above, the Company’s ability to meet financing requirements is dependent upon the ability to complete additional fundraising or obtain additional financing, and/or monetize its investment in NetCo, along with NewStem continuing as a going concern. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence. 0.50 -293000000 -6750000 650000 300000 350000 350000 NOTE 2—SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period. The accompanying unaudited condensed financial statements and related disclosures have been prepared with the presumption that users of the unaudited condensed financial statements have read or have access to the audited financial statements for the preceding fiscal year. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Form 10-K, which was filed with the United States Securities and Exchange Commission (“SEC”) on April 1, 2024, from which the Company derived the balance sheet data at December 31, 2023. Certain information and footnote disclosures normally included in condensed financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations for interim reporting. The Company believes that the disclosures contained herein are adequate to make the information presented not misleading. These condensed financial statements should be read in conjunction with the Company’s Form 10K filed with the Securities and Exchange Commission on April 1, 2024 for the years ended December 31, 2023 and 2022. Equity Investments Investee companies that are not consolidated, but over which the Company exercises significant influence, are accounted for under the equity method of accounting. Whether or not the Company exercises significant influence with respect to an investee depends on an evaluation of several factors, including, among others, representation on the investee company’s board of directors and ownership level, which is generally a 20% to 50% interest in the voting securities of the investee company. Under the equity method of accounting, an investee company’s accounts are not reflected within the Company’s balance sheets or statements of operations; however, the Company’s share of the earnings or losses of the investee company is reflected in the caption “Equity in net income (loss) of investee company” in the statements of operations. The Company’s carrying value in an equity method investee company is reflected in the caption “Investment in investee company’ in the Company’s balance sheets. The Company reviews equity investments for impairment on an annual basis, or earlier if events or changes in circumstances indicate that the carrying amounts might not be recoverable. The Company holds a minority investment in an entity, NewStem, which is accounted for pursuant to the equity method of accounting. Additionally, the Company is a <span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20240331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NetCoPartnersMember_zOBPyOTCfh3d" title="Equity interest percentage">50% partner in NetCo (which is accounted for pursuant to the equity method of accounting). See Note 3. Derivative Financial Instruments The Company has in place a financial instrument, in the form of a note payable, with an identified embedded derivative in the form of a guarantee. The identified embedded derivative has been bifurcated and accounted for separately. Such derivative financial instruments are measured at fair value at each financial statement reporting date. If the fair value of a financial liability (the derivative) exceeds the proceeds received for the issuance of a hybrid instrument in an arms length transaction with no rights or privileges that require separate accounting recognition as an asset identified, then the embedded derivative is recorded at fair value with the excess of fair value over proceeds recognized as a loss in earnings. During the three months ended March 31, 2024, the Company recognized a gain on derivative financial instruments of $25,000. Proceeds from the note payable are shown as cash from financing instruments and the gain on derivative instrument is included as an adjustment to reconcile loss to net cash used in operating activities in the statements of cash flows for the three months ended March 31, 2024. Basic and Diluted Net Loss Per Share Basic net loss per share is computed by dividing the net loss by the weighted average number of shares outstanding during the period, excluding treasury stock. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares outstanding plus the dilutive potential of common shares which would result from the exercise of stock options and warrants. The dilutive effects of stock options and warrants are excluded from the computation of diluted net income (loss) per share if the effect of doing so would be antidilutive. <p id="xdx_894_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zSC05E9OZ6Pl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The following data represents the amounts used in computing earnings per share and the effect on loss and the weighted average number of shares of dilutive potential common stock (unaudited): SCHEDULE OF WEIGHTED AVERAGE NUMBER OF SHARES OF DILUTIVE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_496_20240101__20240331_z25mSKvm9Xz1"> </td><td> </td><td> </td> <td colspan="2" id="xdx_497_20230101__20230331_zSNv1EK6ymCf"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--NetIncomeLoss_zcLiAuShK816" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Net loss attributable to common shareholders</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(303,280</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(268,821</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_zAComgTkiQ91" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average shares outstanding:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_zGQqc21nPiP2" style="vertical-align: bottom; background-color: White"> <td>-Basic</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,881,475</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,881,475</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_i01_zCfwheQShqb6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Add: Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_i01_zAI4CPWDMRQh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Add: Stock options</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01_z6Wj7aR6V8Y8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">-Diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">46,881,475</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">46,881,475</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Basic and diluted net loss per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.01</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.01</td><td style="text-align: left">)</td></tr> </table> Options and warrants excluded from the computation of earnings per share: SCHEDULE OF WARRANTS AND STOCK OPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20240101__20240331_zcW43VS7P4Gh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20230101__20230331_zZ3Oy6K5PQRl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zThuQXrXjMk3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">3,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">3,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zXYGhYHMAW7c" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,760,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,760,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zCcH9WBOPJI7" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Anti-dilutive securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,760,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,760,000</td><td style="text-align: left"> </td></tr> </table> Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period. The accompanying unaudited condensed financial statements and related disclosures have been prepared with the presumption that users of the unaudited condensed financial statements have read or have access to the audited financial statements for the preceding fiscal year. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Form 10-K, which was filed with the United States Securities and Exchange Commission (“SEC”) on April 1, 2024, from which the Company derived the balance sheet data at December 31, 2023. Certain information and footnote disclosures normally included in condensed financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations for interim reporting. The Company believes that the disclosures contained herein are adequate to make the information presented not misleading. These condensed financial statements should be read in conjunction with the Company’s Form 10K filed with the Securities and Exchange Commission on April 1, 2024 for the years ended December 31, 2023 and 2022. Equity Investments Investee companies that are not consolidated, but over which the Company exercises significant influence, are accounted for under the equity method of accounting. Whether or not the Company exercises significant influence with respect to an investee depends on an evaluation of several factors, including, among others, representation on the investee company’s board of directors and ownership level, which is generally a 20% to 50% interest in the voting securities of the investee company. Under the equity method of accounting, an investee company’s accounts are not reflected within the Company’s balance sheets or statements of operations; however, the Company’s share of the earnings or losses of the investee company is reflected in the caption “Equity in net income (loss) of investee company” in the statements of operations. The Company’s carrying value in an equity method investee company is reflected in the caption “Investment in investee company’ in the Company’s balance sheets. The Company reviews equity investments for impairment on an annual basis, or earlier if events or changes in circumstances indicate that the carrying amounts might not be recoverable. The Company holds a minority investment in an entity, NewStem, which is accounted for pursuant to the equity method of accounting. Additionally, the Company is a <span id="xdx_90D_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20240331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NetCoPartnersMember_zOBPyOTCfh3d" title="Equity interest percentage">50% partner in NetCo (which is accounted for pursuant to the equity method of accounting). See Note 3. investee company’s board of directors and ownership level, which is generally a 20% to 50% interest in the voting securities of the investee company. 0.50 Derivative Financial Instruments The Company has in place a financial instrument, in the form of a note payable, with an identified embedded derivative in the form of a guarantee. The identified embedded derivative has been bifurcated and accounted for separately. Such derivative financial instruments are measured at fair value at each financial statement reporting date. If the fair value of a financial liability (the derivative) exceeds the proceeds received for the issuance of a hybrid instrument in an arms length transaction with no rights or privileges that require separate accounting recognition as an asset identified, then the embedded derivative is recorded at fair value with the excess of fair value over proceeds recognized as a loss in earnings. During the three months ended March 31, 2024, the Company recognized a gain on derivative financial instruments of $25,000. Proceeds from the note payable are shown as cash from financing instruments and the gain on derivative instrument is included as an adjustment to reconcile loss to net cash used in operating activities in the statements of cash flows for the three months ended March 31, 2024. 25000 Basic and Diluted Net Loss Per Share Basic net loss per share is computed by dividing the net loss by the weighted average number of shares outstanding during the period, excluding treasury stock. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares outstanding plus the dilutive potential of common shares which would result from the exercise of stock options and warrants. The dilutive effects of stock options and warrants are excluded from the computation of diluted net income (loss) per share if the effect of doing so would be antidilutive. <p id="xdx_894_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zSC05E9OZ6Pl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The following data represents the amounts used in computing earnings per share and the effect on loss and the weighted average number of shares of dilutive potential common stock (unaudited): SCHEDULE OF WEIGHTED AVERAGE NUMBER OF SHARES OF DILUTIVE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_496_20240101__20240331_z25mSKvm9Xz1"> </td><td> </td><td> </td> <td colspan="2" id="xdx_497_20230101__20230331_zSNv1EK6ymCf"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--NetIncomeLoss_zcLiAuShK816" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Net loss attributable to common shareholders</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(303,280</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(268,821</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_zAComgTkiQ91" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average shares outstanding:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_zGQqc21nPiP2" style="vertical-align: bottom; background-color: White"> <td>-Basic</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,881,475</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,881,475</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_i01_zCfwheQShqb6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Add: Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_i01_zAI4CPWDMRQh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Add: Stock options</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01_z6Wj7aR6V8Y8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">-Diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">46,881,475</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">46,881,475</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Basic and diluted net loss per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.01</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.01</td><td style="text-align: left">)</td></tr> </table> Options and warrants excluded from the computation of earnings per share: SCHEDULE OF WARRANTS AND STOCK OPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20240101__20240331_zcW43VS7P4Gh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20230101__20230331_zZ3Oy6K5PQRl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zThuQXrXjMk3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">3,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">3,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zXYGhYHMAW7c" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,760,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,760,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zCcH9WBOPJI7" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Anti-dilutive securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,760,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,760,000</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_894_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zSC05E9OZ6Pl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The following data represents the amounts used in computing earnings per share and the effect on loss and the weighted average number of shares of dilutive potential common stock (unaudited): SCHEDULE OF WEIGHTED AVERAGE NUMBER OF SHARES OF DILUTIVE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_496_20240101__20240331_z25mSKvm9Xz1"> </td><td> </td><td> </td> <td colspan="2" id="xdx_497_20230101__20230331_zSNv1EK6ymCf"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--NetIncomeLoss_zcLiAuShK816" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Net loss attributable to common shareholders</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(303,280</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(268,821</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_zAComgTkiQ91" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average shares outstanding:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_zGQqc21nPiP2" style="vertical-align: bottom; background-color: White"> <td>-Basic</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,881,475</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,881,475</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_i01_zCfwheQShqb6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Add: Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_i01_zAI4CPWDMRQh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Add: Stock options</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01_z6Wj7aR6V8Y8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">-Diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">46,881,475</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">46,881,475</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Basic and diluted net loss per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.01</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.01</td><td style="text-align: left">)</td></tr> </table> -303280 -268821 46881475 46881475 46881475 46881475 -0.01 -0.01 -0.01 -0.01 Options and warrants excluded from the computation of earnings per share: SCHEDULE OF WARRANTS AND STOCK OPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20240101__20240331_zcW43VS7P4Gh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20230101__20230331_zZ3Oy6K5PQRl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zThuQXrXjMk3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">3,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">3,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zXYGhYHMAW7c" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,760,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,760,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zCcH9WBOPJI7" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Anti-dilutive securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,760,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,760,000</td><td style="text-align: left"> </td></tr> </table> 3000000 3000000 5760000 5760000 5760000 5760000 NOTE 3—EQUITY METHOD INVESTMENTS Investment in NewStem In 2018, the Company entered into a Share Purchase Agreement with NewStem and other related parties to provide aggregate funding of up to $<span id="xdx_900_eus-gaap--EquityMethodInvestments_iI_c20181231__srt--RangeAxis__srt--MaximumMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NewStemLtdMember_zubu4YvpEQWj" title="Equity method investments">4,000,000 to NewStem. This funding was to be provided through the sale of up to <span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20180101__20181231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NewStemLtdMember_zuk6ZO79nUMd" title="Sale of stock">50,000 common shares of NewStem to the Company representing <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_uPure_c20180101__20181231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NewStemLtdMember_zAMOCehixwfi" title="Percentage of outstanding shares">33% of New Stem’s outstanding shares. In 2018, the Company purchased <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20180101__20181231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NewStemLtdMember_z5bBN2iRNtq9" title="Shares acquisitions shares">25,000 shares of NewStem for $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_c20180101__20181231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NewStemLtdMember_zCgPo369Jgp8" title="Shares acquisitions">2,000,000 acquiring an ownership interest of <span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20181231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NewStemLtdMember_zv8ImeLWHj9e" title="Equity interest percentage">20%. The Company made additional investments in 2019 and 2020 purchasing <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20190101__20191231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NewStemLtdMember_zpQXfdc8dLM1" title="Shares acquisitions shares"><span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20200101__20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NewStemLtdMember_zlHJjaRDiQ68" title="Shares acquisitions shares">12,500 shares each year for a $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_c20190101__20191231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NewStemLtdMember_zVIt5eIkJ9D5" title="Shares acquisitions"><span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_c20200101__20201231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NewStemLtdMember_zBRNFlbP6tp" title="Shares acquisitions">1,000,000 investment each year. NewStem sold and issued shares to third party investors in 2021, 2022 and 2023 resulting in the Company recognizing a gain on dilution of equity method investment. These transactions resulted in the Company having an ownership interest of <span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20240331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NewStemLtdMember_zj5R7MmMOTre" title="Ownership investment percentage"><span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NewStemLtdMember_zfRDdZ5gQ6Aj" title="Ownership investment percentage">30.51% as of March 31, 2024 and December 31, 2023. The Company accounts for its investment in NewStem under the equity method. As of March 31, 2024 and December 31, 2023, the carrying value of the investment in NewStem exceeded its portion of the underlying net assets of NewStem by approximately $<span id="xdx_906_eus-gaap--InvestmentOwnedAtFairValue_iI_c20240331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NewStemLtdMember__custom--AffiliationAxis__us-gaap--OtherControlledCompaniesMember_zjW0utBCoABg" title="Carrying value of investment">1,655,000 and $<span id="xdx_90A_eus-gaap--InvestmentOwnedAtFairValue_iI_c20231231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NewStemLtdMember__custom--AffiliationAxis__us-gaap--OtherControlledCompaniesMember_z5L88GCBn8C7" title="Carrying value of investment">1,800,000, respectively. The excess relates to identified intangible assets including license agreements, specialized work force (goodwill) and two separate projects of in process research and development (“IPR&D”) related to stem cell-based diagnostics and therapeutics for cancer chemotherapies. The Company assesses its investment in NewStem for impairment on an annual basis or more frequently if indicators of impairment exist. During the three months ended March 31, 2024, the Company recorded a reimbursement due to NewStem of approximately $<span id="xdx_909_eus-gaap--ReimbursementFromLimitedPartnershipInvestment_c20240101__20240331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NewStemLtdMember__us-gaap--BalanceSheetLocationAxis__us-gaap--AccountsPayableMember_zVFNQTzu4oT8" title="Reimbursement due">36,000 (included in accounts payable in the accompanying balance sheet) for audit related costs. During the three months ended March 31, 2023, the Company reimbursed NewStem for audit related costs of approximately $<span id="xdx_909_eus-gaap--ProfessionalFees_c20240101__20240331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NewStemLtdMember_zRXWJjbHXQFl" title="Audit and audit related costs">37,000. As disclosed in Note 8, the Company is in negotiations to acquire the remainder of NewStem in exchange for shares of Company stock. In anticipation of this transaction, the Company advanced $250,000 to NewStem in December 2023 and an additional $250,000 in March 2024. The related note agreement bears no interest and is payable on <span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_c20240101__20240331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NewStemLtdMember_zYSdmXYeUwzb" title="Debt instrument maturity date">December 30, 2024. The agreement provides for discharge of the note upon the closing of the anticipated acquisition transaction. This note receivable has been presented as a noncurrent asset along with the investment in NewStem in the accompanying balance sheets. The second advance on the note was not received and recorded by NewStem until April 2024 and therefore is not reflected in the schedule of financial position of NewStem presented below. NewStem is in the development stage and has incurred losses since its inception and has generated only minimal revenues under a licensing agreement. NewStem will need to obtain additional funds to continue its operations. NewStem management’s plans with regard to these matters include continued development, marketing and licensing of its products, as well as seeking additional financing arrangements. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient cash from sales, licensing or financing on terms acceptable to the Company. NewStem obtained additional funding of approximately $<span id="xdx_909_eus-gaap--PaymentsForProceedsFromInvestments_c20220401__20220430__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NewStemLtdMember_zwQMAULK9FCl" title="Additional funding">1,450,000 in April 2022 through the sale of shares of ordinary stock. NewStem’s management has adopted a cost reduction plan in order to adjust future operation expenses to its cash balance. In October 2023, the NewStem board of directors unanimously resolved to dismiss most employees which occurred in December 2023. The aforementioned events indicate significant difficulties to continue as a concern. Additionally, Israel declared a state of war in October 2023 which resulted in a decrease in Israel’s economic and business activity. The security situation in Israel led to a disruption in the chain of supply and production, a decrease in the volume of national transportation, and a shortage in manpower as well as a decrease in the value of financial assets. As a result of the movement and work restrictions, NewStem began operating on a limited scale. Additionally, the situation has brought further difficulties in management’s efforts to seek additional financing. <p id="xdx_89B_eus-gaap--InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_hdei--LegalEntityAxis__custom--NewStemLtdMember_zIBW940VevSb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The following table represents the Company’s investment in NewStem: SCHEDULE OF INVESTMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20240101__20240331__dei--LegalEntityAxis__custom--NewStemLtdMember_zACt3CZQYBXb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20230101__20231231__dei--LegalEntityAxis__custom--NewStemLtdMember_zN3aE9SuH0g3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-size: 11pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Three Months Ended March 31, 2024</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Year Ended December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 11pt"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">(Unaudited)</td><td style="font-weight: bold"> </td><td style="font-size: 11pt"> </td> <td colspan="2" style="font-size: 11pt"> </td><td style="font-size: 11pt"> </td></tr> <tr id="xdx_403_eus-gaap--InvestmentOwnedAtFairValue_iS_zIFRrJYud305" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Investment in NewStem, beginning </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,784,234</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,090,286</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--InvestmentsInAndAdvancesToAffiliatesAtFairValuePeriodIncreaseDecrease_z27w3uFBid25" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Allocation of net loss from NewStem, Ltd. </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(51,859</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(342,191</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_ecustom--GainOnDilutionOfEquityMethodInvestment_zM25FOslSxV6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">Gain on dilution of equity method investment </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">36,139</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--InvestmentsInAndAdvancesToAffiliatesAtFairValueGrossReductions_iN_di_z3t9RfkGeoyb" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">Distribution from NetCo</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--InvestmentOwnedAtFairValue_iE_z2VnjePRwyqa" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left">Investment in NewStem, ending </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,732,375</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,784,234</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_89A_eus-gaap--EquityMethodInvestmentsTextBlock_hdei--LegalEntityAxis__custom--NewStemLtdMember_zok85v01w5O6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The results of operations of the Company’s investment in NewStem is summarized below (unaudited): SCHEDULE OF OPERATIONS AND FINANCIAL POSITION INVESTMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20240101__20240331__dei--LegalEntityAxis__custom--NewStemLtdMember_zl3yBargM5L6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20230101__20230331__dei--LegalEntityAxis__custom--NewStemLtdMember_zmSHC78Kmqfl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Condensed income statement information:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--Revenues_zZ8lLWURWtKa" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left; padding-bottom: 2.5pt">Net revenues</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">-</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">95,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--GrossProfit_z7MrJG9PFCR6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Gross margin</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">84,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--NetIncomeLoss_zouuIPboMM4b" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(170,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(342,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--IncomeLossFromEquityMethodInvestments_zrtbxProz2fj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Company’s allocation of net loss from NewStem, Ltd.</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(51,859</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(104,591</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> The financial position of the Company’s investment in NewStem is summarized below: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20240331__dei--LegalEntityAxis__custom--NewStemLtdMember_z8TuYkNoSh7e" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20231231__dei--LegalEntityAxis__custom--NewStemLtdMember_zyinZbuCZD48" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Condensed balance sheet information:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AssetsCurrent_iI_zskQ9IxdwGcl" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left; padding-bottom: 2.5pt">Current assets</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">246,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">353,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AssetsNoncurrent_iI_zWQwMvxzyMGj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Non-current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LiabilitiesCurrent_iI_zQam2vcIOO5l" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Current liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">86,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">284,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LiabilitiesNoncurrent_iI_zEhNsHfXigYc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Non-current liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">250,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Investment in NetCo NovelStem owns a <span id="xdx_901_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20240331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NetCoPartnersMember_zEHcsUSm64v7" title="Equity interest percentage">50% interest in NetCo, a joint venture that owns the Net Force publishing franchise. The Company accounts for its investment in NetCo under the equity method and recognizes nominal royalties and administrative fees from this arrangement. The Company assesses its investment in NetCo for impairment on an annual basis or more frequently if indicators of impairment exist. <p id="xdx_89F_eus-gaap--InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_hdei--LegalEntityAxis__custom--NetCoPartnersMember_zsJ1Foctsfce" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The following table represents the Company’s investment in NetCo: SCHEDULE OF INVESTMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-size: 11pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_491_20240101__20240331__dei--LegalEntityAxis__custom--NetCoPartnersMember_zDHf831TnW9g" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Three Months Ended March 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_491_20230101__20231231__dei--LegalEntityAxis__custom--NetCoPartnersMember_zcjS74NKbLP8" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Year Ended December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 11pt"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold; text-align: left"> </td><td style="font-size: 11pt"> </td> <td style="font-size: 11pt; text-align: left"> </td><td style="font-size: 11pt; text-align: right"> </td><td style="font-size: 11pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--InvestmentOwnedAtFairValue_iS_zsNNixslS3c6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Investment in NetCo, beginning</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">133,709</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">137,011</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--InvestmentsInAndAdvancesToAffiliatesAtFairValuePeriodIncreaseDecrease_z4y1LwDaqohf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Allocation of net income (loss) from NetCo</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,351</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,573</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--InvestmentsInAndAdvancesToAffiliatesAtFairValueGrossReductions_iN_di_zAoJt1BPMQQ2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">Distribution from NetCo</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,875</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--InvestmentOwnedAtFairValue_iE_zxZ8CZvw1wz2" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left">Investment in NetCo, ending</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">132,358</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">133,709</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_89F_eus-gaap--EquityMethodInvestmentsTextBlock_hdei--LegalEntityAxis__custom--NetCoPartnersMember_zbxi3N2xong1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The results of operations of the Company’s investment in NetCo is summarized below (unaudited): SCHEDULE OF OPERATIONS AND FINANCIAL POSITION INVESTMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20240101__20240331__dei--LegalEntityAxis__custom--NetCoPartnersMember_zkXetGuhBRq7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20230101__20230331__dei--LegalEntityAxis__custom--NetCoPartnersMember_zVjeRzg8Dgp8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Condensed income statement information:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--Revenues_zaK8rRKJ4SFa" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left; padding-bottom: 2.5pt">Net sales</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">373</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">15,750</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--GrossProfit_zkNgv18BMeD1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Gross margin</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">373</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,750</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--NetIncomeLoss_ztcHwGvbIEJ2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net income</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,702</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,750</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--IncomeLossFromEquityMethodInvestments_zih3ISJoPESl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Company’s allocation of net income from NetCo</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,351</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,875</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The financial position of the Company’s investment in NetCo is summarized below: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20240331__dei--LegalEntityAxis__custom--NetCoPartnersMember_zzVwK0V1MgAi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20231231__dei--LegalEntityAxis__custom--NetCoPartnersMember_z1OWKNwJq7S7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Condensed balance sheet information:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AssetsCurrent_iI_zT1Gu1ULMWu8" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left; padding-bottom: 2.5pt">Current assets</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">2,042</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">1,820</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AssetsNoncurrent_iI_zqzDoa9FVdTk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Non-current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">272,799</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">272,799</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LiabilitiesCurrent_iI_zIVg2oI5oiG5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Current liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,249</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">325</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LiabilitiesNoncurrent_iI_zhB8gwPVJgGj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Non-current liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 4000000 50000 0.33 25000 2000000 0.20 12500 12500 1000000 1000000 0.3051 0.3051 1655000 1800000 36000 37000 250000 250000 2024-12-30 1450000 <p id="xdx_89B_eus-gaap--InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_hdei--LegalEntityAxis__custom--NewStemLtdMember_zIBW940VevSb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The following table represents the Company’s investment in NewStem: SCHEDULE OF INVESTMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20240101__20240331__dei--LegalEntityAxis__custom--NewStemLtdMember_zACt3CZQYBXb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20230101__20231231__dei--LegalEntityAxis__custom--NewStemLtdMember_zN3aE9SuH0g3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-size: 11pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Three Months Ended March 31, 2024</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Year Ended December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 11pt"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">(Unaudited)</td><td style="font-weight: bold"> </td><td style="font-size: 11pt"> </td> <td colspan="2" style="font-size: 11pt"> </td><td style="font-size: 11pt"> </td></tr> <tr id="xdx_403_eus-gaap--InvestmentOwnedAtFairValue_iS_zIFRrJYud305" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Investment in NewStem, beginning </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,784,234</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,090,286</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--InvestmentsInAndAdvancesToAffiliatesAtFairValuePeriodIncreaseDecrease_z27w3uFBid25" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Allocation of net loss from NewStem, Ltd. </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(51,859</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(342,191</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_ecustom--GainOnDilutionOfEquityMethodInvestment_zM25FOslSxV6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">Gain on dilution of equity method investment </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">36,139</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--InvestmentsInAndAdvancesToAffiliatesAtFairValueGrossReductions_iN_di_z3t9RfkGeoyb" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">Distribution from NetCo</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--InvestmentOwnedAtFairValue_iE_z2VnjePRwyqa" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left">Investment in NewStem, ending </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,732,375</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,784,234</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1784234 2090286 -51859 -342191 36139 1732375 1784234 <p id="xdx_89A_eus-gaap--EquityMethodInvestmentsTextBlock_hdei--LegalEntityAxis__custom--NewStemLtdMember_zok85v01w5O6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The results of operations of the Company’s investment in NewStem is summarized below (unaudited): SCHEDULE OF OPERATIONS AND FINANCIAL POSITION INVESTMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20240101__20240331__dei--LegalEntityAxis__custom--NewStemLtdMember_zl3yBargM5L6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20230101__20230331__dei--LegalEntityAxis__custom--NewStemLtdMember_zmSHC78Kmqfl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Condensed income statement information:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--Revenues_zZ8lLWURWtKa" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left; padding-bottom: 2.5pt">Net revenues</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">-</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">95,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--GrossProfit_z7MrJG9PFCR6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Gross margin</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">84,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--NetIncomeLoss_zouuIPboMM4b" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(170,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(342,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--IncomeLossFromEquityMethodInvestments_zrtbxProz2fj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Company’s allocation of net loss from NewStem, Ltd.</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(51,859</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(104,591</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> The financial position of the Company’s investment in NewStem is summarized below: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20240331__dei--LegalEntityAxis__custom--NewStemLtdMember_z8TuYkNoSh7e" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20231231__dei--LegalEntityAxis__custom--NewStemLtdMember_zyinZbuCZD48" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Condensed balance sheet information:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AssetsCurrent_iI_zskQ9IxdwGcl" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left; padding-bottom: 2.5pt">Current assets</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">246,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">353,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AssetsNoncurrent_iI_zWQwMvxzyMGj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Non-current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LiabilitiesCurrent_iI_zQam2vcIOO5l" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Current liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">86,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">284,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LiabilitiesNoncurrent_iI_zEhNsHfXigYc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Non-current liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">250,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 95000 84000 -170000 -342000 -51859 -104591 246000 353000 6000 9000 86000 284000 250000 0.50 <p id="xdx_89F_eus-gaap--InvestmentHoldingsScheduleOfInvestmentsTableTextBlock_hdei--LegalEntityAxis__custom--NetCoPartnersMember_zsJ1Foctsfce" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The following table represents the Company’s investment in NetCo: SCHEDULE OF INVESTMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-size: 11pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_491_20240101__20240331__dei--LegalEntityAxis__custom--NetCoPartnersMember_zDHf831TnW9g" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Three Months Ended March 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_491_20230101__20231231__dei--LegalEntityAxis__custom--NetCoPartnersMember_zcjS74NKbLP8" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Year Ended December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 11pt"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold; text-align: left"> </td><td style="font-size: 11pt"> </td> <td style="font-size: 11pt; text-align: left"> </td><td style="font-size: 11pt; text-align: right"> </td><td style="font-size: 11pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--InvestmentOwnedAtFairValue_iS_zsNNixslS3c6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Investment in NetCo, beginning</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">133,709</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">137,011</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--InvestmentsInAndAdvancesToAffiliatesAtFairValuePeriodIncreaseDecrease_z4y1LwDaqohf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Allocation of net income (loss) from NetCo</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,351</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,573</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--InvestmentsInAndAdvancesToAffiliatesAtFairValueGrossReductions_iN_di_zAoJt1BPMQQ2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">Distribution from NetCo</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,875</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--InvestmentOwnedAtFairValue_iE_zxZ8CZvw1wz2" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left">Investment in NetCo, ending</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">132,358</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">133,709</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 133709 137011 -1351 3573 6875 132358 133709 <p id="xdx_89F_eus-gaap--EquityMethodInvestmentsTextBlock_hdei--LegalEntityAxis__custom--NetCoPartnersMember_zbxi3N2xong1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The results of operations of the Company’s investment in NetCo is summarized below (unaudited): SCHEDULE OF OPERATIONS AND FINANCIAL POSITION INVESTMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20240101__20240331__dei--LegalEntityAxis__custom--NetCoPartnersMember_zkXetGuhBRq7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20230101__20230331__dei--LegalEntityAxis__custom--NetCoPartnersMember_zVjeRzg8Dgp8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Condensed income statement information:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--Revenues_zaK8rRKJ4SFa" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left; padding-bottom: 2.5pt">Net sales</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">373</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">15,750</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--GrossProfit_zkNgv18BMeD1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Gross margin</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">373</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,750</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--NetIncomeLoss_ztcHwGvbIEJ2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net income</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,702</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,750</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--IncomeLossFromEquityMethodInvestments_zih3ISJoPESl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Company’s allocation of net income from NetCo</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,351</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,875</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The financial position of the Company’s investment in NetCo is summarized below: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20240331__dei--LegalEntityAxis__custom--NetCoPartnersMember_zzVwK0V1MgAi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20231231__dei--LegalEntityAxis__custom--NetCoPartnersMember_z1OWKNwJq7S7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Condensed balance sheet information:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AssetsCurrent_iI_zT1Gu1ULMWu8" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left; padding-bottom: 2.5pt">Current assets</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">2,042</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">1,820</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AssetsNoncurrent_iI_zqzDoa9FVdTk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Non-current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">272,799</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">272,799</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LiabilitiesCurrent_iI_zIVg2oI5oiG5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Current liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,249</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">325</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LiabilitiesNoncurrent_iI_zhB8gwPVJgGj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Non-current liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 373 15750 373 15750 -2702 15750 -1351 7875 2042 1820 272799 272799 3249 325 NOTE 4—NOTES PAYABLE In December 2023, the Company entered into two short term notes payable with unrelated parties, Hewlett Fund and AIGH Investment Partners, LLC. The notes are for $125,000 each, for a total of $250,000 in borrowings utilized for the funding of NewStem. The notes bear interest at <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--TwoShortTermNotesPayableMember_z0NjoDIbQ01c" title="Debt instrument, interest bear percentage">12% per annum and mature December 21, 2024, at which time all principal and accrued interest are due and payable. The note agreements include a provision whereby, in the event of a capital raise transaction by the Company, the note holders would be entitled to participate in the transaction in an amount equal to 133% of the amounts owed on the note agreements at the closing of the transaction. Interest expense related to these notes was $7,479 for the three months ended March 31, 2024. Long-term notes payable are summarized as follows: SCHEDULE OF LONG TERM NOTES PAYABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Notes payable related parties:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Notes payable director and Executive Chairman</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--NotesPayable_iI_c20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--DirectorAndExecutiveChairmanMember_zYFyH5yUQSN9" style="width: 16%; text-align: right" title="Total notes payable">650,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--NotesPayable_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--DirectorAndExecutiveChairmanMember_zInwqlmm5R17" style="width: 16%; text-align: right" title="Total notes payable">400,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Accrued interest added to note balance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_c20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--DirectorAndExecutiveChairmanMember_z4qkus7fjmqb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accrued interest added to note balance">54,314</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--DirectorAndExecutiveChairmanMember_zTHpwChnZj0l" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accrued interest added to note balance">43,588</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total notes payable director and Executive Chairman</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--NotesPayable_iI_c20240331__srt--TitleOfIndividualAxis__custom--DirectorAndExecutiveChairmanMember_zhwXW2NrBJ37" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total notes payable">704,314</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--NotesPayable_iI_c20231231__srt--TitleOfIndividualAxis__custom--DirectorAndExecutiveChairmanMember_zJmPFBSAr2pl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total notes payable">443,588</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Note payable shareholder, principal amount</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_c20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--DirectorAndExecutiveChairmanMember_zx7WvNTU1WFc" style="text-align: right" title="Note payable, principal amount">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--DirectorAndExecutiveChairmanMember_z3V5mJk9skBc" style="text-align: right" title="Note payable, principal amount">275,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less unamortized discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_c20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--DirectorAndExecutiveChairmanMember_zdCXZV9rBog3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less unamortized discount">(193,787</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--DirectorAndExecutiveChairmanMember_zdZw4tXiXsV" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less unamortized discount">(213,185</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total note payable shareholder</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--NotesPayable_iI_c20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--ShareholderMember_zAlgNKOSsgKb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total notes payable">106,213</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--NotesPayable_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--ShareholderMember_zDNXm1B84vA" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total notes payable">61,815</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Note payable, litigation funding agreement:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Note payable Omni Bridgeway (Fund 4) Invt. 3 L.P.</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--NotesPayable_iI_c20240331__dei--LegalEntityAxis__custom--OmniBridgewayFund4Invt3LPMember_zAPtvXJklnOi" style="text-align: right" title="Total notes payable">2,819,196</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--NotesPayable_iI_c20231231__dei--LegalEntityAxis__custom--OmniBridgewayFund4Invt3LPMember_zmM6fKPR0l0l" style="text-align: right" title="Total notes payable">2,819,196</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Accrued interest added to agreement balance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_c20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__dei--LegalEntityAxis__custom--OmniBridgewayFund4Invt3LPMember_z93HNLSDQbD7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accrued interest added to note balance">31,720</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__dei--LegalEntityAxis__custom--OmniBridgewayFund4Invt3LPMember_zesZoQOxRrL2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accrued interest added to note balance">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total note payable, litigation funding agreement</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--NotesPayable_iI_c20240331__srt--TitleOfIndividualAxis__custom--DirectorAndExecutiveChairmanMember__dei--LegalEntityAxis__custom--OmniBridgewayFund4Invt3LPMember_zlskqVM3TGS1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total notes payable">2,850,916</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--NotesPayable_iI_c20231231__srt--TitleOfIndividualAxis__custom--DirectorAndExecutiveChairmanMember__dei--LegalEntityAxis__custom--OmniBridgewayFund4Invt3LPMember_z0bPRen7GUuj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total notes payable">2,819,196</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Total notes payable</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--NotesPayable_iI_c20240331_zmIhO5pyZ9K1" style="text-align: right" title="Total notes payable">3,661,443</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--NotesPayable_iI_c20231231_zL6mt2pYMYc4" style="text-align: right" title="Total notes payable">3,324,599</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--LongTermDebtCurrent_iNI_di_c20240331_zDpkCTNVIVe3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less current portion">(2,850,916</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--LongTermDebtCurrent_iNI_di_c20231231_z65mYq4WUIGf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less current portion">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Long-term notes payable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--LongTermNotesPayable_iI_c20240331_zO2fX8kSJALe" style="border-bottom: Black 2.5pt double; text-align: right" title="Long-term notes payable">810,527</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--LongTermNotesPayable_iI_c20231231_zePeoSOeKHMg" style="border-bottom: Black 2.5pt double; text-align: right" title="Long-term notes payable">3,324,599</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> In May 2022, the Company entered into note agreements with two individuals who are related parties to borrow up to $600,000 for working capital needs. The agreements were amended in March 2024 to increase the total borrowing to $650,000 and extend the maturity date. The agreements provide for interest at a rate of 8% per annum through November 11, 2022, at which time the interest rate increased to <span id="xdx_904_eus-gaap--ShortTermDebtInterestRateIncrease_pid_dp_uPure_c20221111__20221111__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TwoIndividualsMember_zcPh5e5TEnq5" title="Short term debt, interest rate increase">10% per annum for subsequent advances. The agreements mature September 1, 2025. The Company received advances of $<span id="xdx_909_eus-gaap--ProceedsFromRelatedPartyDebt_c20240101__20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TwoIndividualsMember_zmsQxUN5XwJ5" title="Proceeds form related party">650,000 and $<span id="xdx_90F_eus-gaap--ProceedsFromRelatedPartyDebt_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TwoIndividualsMember_zRnbQDsRu4ge" title="Proceeds form related party">400,000, respectively, pursuant to these agreements through March 31, 2024 and December 31, 2023. On May 5, 2023, the Company entered into a long term note payable with a shareholder for $300,000 in financing to be funded $150,000 at inception and $150,000 in October 2023. This note bears interest at zero percent (<span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230505__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z62TwTyylnXk" title="Interest rate">0%) and matures on May 5, 2025. The note includes a guarantee which has been identified as an embedded derivative with a fair value of a liability of $<span id="xdx_902_eus-gaap--EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_iI_c20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderMember_zE8AU1pdELza" title="Derivative fair value liability"><span id="xdx_904_eus-gaap--EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderMember_zQ2xjnSJGFFj" title="Derivative fair value liability">535,000 at March 31, 2024 and December 31, 2023 which is reported separately on the balance sheet. The fair value of the note exceeds the proceeds, and the note has been discounted at inception so that the net liability is the fair value of the derivative. Accretion of the note discount of $44,398 has been reflected as part of interest expense in the statement of operations for three months ended March 31, 2024. Note Payable, Litigation Funding Agreement On February 11, 2022, the Company entered into a nonrecourse litigation funding agreement (the “Agreement”) with Omni Bridgeway (Fund 4) Invt. 3 L.P. (“Omni”) related to an arbitration proceeding disclosed in Note 7. The Agreement provides for Omni to fund all costs related to the arbitration up to $<span id="xdx_907_eus-gaap--LitigationSettlementExpense_c20220211__20220211__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OmniBridgewayFund4Invt3LPMember_z26z89euHCn" title="Litigation settlement, expense">1,000,000 in exchange for an assignment of a certain portion of rights to and interest in claims related to this arbitration. The agreement provides for specific calculations of the portion of any claims collected to be received by Omni with the remainder collectible by the Company. Additionally, the agreement provides for repayment of funded costs pursuant to the same multiple calculations in the event of a favorable outcome that does not include the collection of claims. During July 2023, the arbitration was settled with a partially favorable outcome for the Company. As a result of the ruling disclosed in Note 7, the liability became probable and reasonably estimable, and the Company has recorded the full liability due to Omni as of December 31, 2023. This liability consists of expenses funded by Omni of $933,065, including $310,000 advanced for working capital, and related fees or investment return to Omni calculated as contractual multiples of funding totaling $1,886,131 as of December 31, 2023 for a total liability of $2,819,196. This agreement bears interest at <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OmniBridgewayFund4Invt3LPMember_z8UMwTR49hU5" title="Interest rate">5% per annum beginning January 2024 and is payable on <span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDate_dd_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OmniBridgewayFund4Invt3LPMember_zLPzg6oZ8eI4" title="Maturity date">January 10, 2025. 125000 125000 250000 0.12 2024-12-21 The note agreements include a provision whereby, in the event of a capital raise transaction by the Company, the note holders would be entitled to participate in the transaction in an amount equal to 133% of the amounts owed on the note agreements at the closing of the transaction. 7479 Long-term notes payable are summarized as follows: SCHEDULE OF LONG TERM NOTES PAYABLE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Notes payable related parties:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Notes payable director and Executive Chairman</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--NotesPayable_iI_c20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--DirectorAndExecutiveChairmanMember_zYFyH5yUQSN9" style="width: 16%; text-align: right" title="Total notes payable">650,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--NotesPayable_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--DirectorAndExecutiveChairmanMember_zInwqlmm5R17" style="width: 16%; text-align: right" title="Total notes payable">400,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Accrued interest added to note balance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_c20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--DirectorAndExecutiveChairmanMember_z4qkus7fjmqb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accrued interest added to note balance">54,314</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--DirectorAndExecutiveChairmanMember_zTHpwChnZj0l" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accrued interest added to note balance">43,588</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total notes payable director and Executive Chairman</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--NotesPayable_iI_c20240331__srt--TitleOfIndividualAxis__custom--DirectorAndExecutiveChairmanMember_zhwXW2NrBJ37" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total notes payable">704,314</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--NotesPayable_iI_c20231231__srt--TitleOfIndividualAxis__custom--DirectorAndExecutiveChairmanMember_zJmPFBSAr2pl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total notes payable">443,588</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Note payable shareholder, principal amount</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_c20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--DirectorAndExecutiveChairmanMember_zx7WvNTU1WFc" style="text-align: right" title="Note payable, principal amount">300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--DirectorAndExecutiveChairmanMember_z3V5mJk9skBc" style="text-align: right" title="Note payable, principal amount">275,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less unamortized discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_c20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--DirectorAndExecutiveChairmanMember_zdCXZV9rBog3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less unamortized discount">(193,787</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--DirectorAndExecutiveChairmanMember_zdZw4tXiXsV" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less unamortized discount">(213,185</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total note payable shareholder</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--NotesPayable_iI_c20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--ShareholderMember_zAlgNKOSsgKb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total notes payable">106,213</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--NotesPayable_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--TitleOfIndividualAxis__custom--ShareholderMember_zDNXm1B84vA" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total notes payable">61,815</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Note payable, litigation funding agreement:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Note payable Omni Bridgeway (Fund 4) Invt. 3 L.P.</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--NotesPayable_iI_c20240331__dei--LegalEntityAxis__custom--OmniBridgewayFund4Invt3LPMember_zAPtvXJklnOi" style="text-align: right" title="Total notes payable">2,819,196</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--NotesPayable_iI_c20231231__dei--LegalEntityAxis__custom--OmniBridgewayFund4Invt3LPMember_zmM6fKPR0l0l" style="text-align: right" title="Total notes payable">2,819,196</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Accrued interest added to agreement balance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_c20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__dei--LegalEntityAxis__custom--OmniBridgewayFund4Invt3LPMember_z93HNLSDQbD7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accrued interest added to note balance">31,720</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__dei--LegalEntityAxis__custom--OmniBridgewayFund4Invt3LPMember_zesZoQOxRrL2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Accrued interest added to note balance">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total note payable, litigation funding agreement</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--NotesPayable_iI_c20240331__srt--TitleOfIndividualAxis__custom--DirectorAndExecutiveChairmanMember__dei--LegalEntityAxis__custom--OmniBridgewayFund4Invt3LPMember_zlskqVM3TGS1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total notes payable">2,850,916</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--NotesPayable_iI_c20231231__srt--TitleOfIndividualAxis__custom--DirectorAndExecutiveChairmanMember__dei--LegalEntityAxis__custom--OmniBridgewayFund4Invt3LPMember_z0bPRen7GUuj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total notes payable">2,819,196</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Total notes payable</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--NotesPayable_iI_c20240331_zmIhO5pyZ9K1" style="text-align: right" title="Total notes payable">3,661,443</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--NotesPayable_iI_c20231231_zL6mt2pYMYc4" style="text-align: right" title="Total notes payable">3,324,599</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--LongTermDebtCurrent_iNI_di_c20240331_zDpkCTNVIVe3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less current portion">(2,850,916</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--LongTermDebtCurrent_iNI_di_c20231231_z65mYq4WUIGf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less current portion">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Long-term notes payable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--LongTermNotesPayable_iI_c20240331_zO2fX8kSJALe" style="border-bottom: Black 2.5pt double; text-align: right" title="Long-term notes payable">810,527</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--LongTermNotesPayable_iI_c20231231_zePeoSOeKHMg" style="border-bottom: Black 2.5pt double; text-align: right" title="Long-term notes payable">3,324,599</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 650000 400000 54314 43588 704314 443588 300000 275000 193787 213185 106213 61815 2819196 2819196 31720 2850916 2819196 3661443 3324599 2850916 810527 3324599 600000 650000 0.08 0.10 2025-09-01 650000 400000 300000 150000 150000 0 2025-05-05 535000 535000 44398 1000000 933065 310000 1886131 2819196 0.05 2025-01-10 NOTE 5—EQUITY (a) General At March 31, 2024 and December 31, 2023, the Company had issued and outstanding 46,881,475 shares of its common stock, par value $0.01 per share. Holders of outstanding common stock are entitled to receive dividends when, as and if declared by the Board and to share ratably in the assets of the Company legally available for distribution in the event of a liquidation, dissolution or winding up of the Company. (b) Summary Employee Option Information The Company’s stock option plan provides for the grant to officers, directors, third party contractors and other future key employees of options to purchase shares of common stock. The purchase price may be paid in cash or, if the option is “in-the-money”, it is automatically exercised “net”. In a net exercise of an option, the Company does not require a payment of the exercise price of the option from the optionee but reduces the number of shares of common stock issued upon the exercise of the option by the smallest number of whole shares that has an aggregate fair market value equal to or in excess of the aggregate exercise price for the option shares covered by the option exercised. Each option is exercisable to one share of the Company’s common stock. Most options expire within six years from the date of the grant and generally vest on the first anniversary date of their issuance. Pursuant to the Equity Incentive Plan the Company’s board of directors approved on November 12, 2018, an aggregate of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20181112__20181112__srt--TitleOfIndividualAxis__custom--DirectotAndInvestorMember_zrXUmPOUuFcf" title="Number of options, shares">5,760,000 options have been issued to directors and investor relations professionals as of March 31, 2024. An additional <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240401__20240401__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zCS7bOoJpF2b" title="Number of option granted">600,000 options were issued to directors on April 1, 2024. <p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zp3J5O5a0ZEh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The Company utilized the Black-Scholes option-pricing model to estimate fair value, utilizing the following assumptions for the options issued during the three months ended March 31, 2023 (all in weighted averages): SCHEDULE OF FAIR VALUE OF OPTION USING VALUATION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230331_zQk4Y5ebG33h" style="width: 18%; text-align: right" title="Risk-free interest rate">3.5</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term of options, in years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Risk-free interest rate">4.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected annual volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230331_zVJKbbviaBgh" style="text-align: right" title="Risk-free interest rate">191.1</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20230331_z6RakZAHs572" style="text-align: right" title="Risk-free interest rate">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Determined weighted average grant date fair value per option</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20230331_zsBKKl80Ld13" style="text-align: right" title="Risk-free interest rate">0.19</td><td style="text-align: left"> </td></tr> </table> The expected term of the options represents an estimate of the length of time until the expected date of exercising the options. Options granted have a maximum life of 7 years. With respect to determining expected exercise behavior, the Company has grouped its option grants into certain groups to track exercise behavior and establish historical rates. The Company estimated volatility by considering historical stock volatility over the expected term of the option. The risk-free interest rates are based on the U.S. Treasury yields for a period consistent with the expected term. The dividend yield of 0% is based on the Company’s history and expectation of dividend payout. The Company has not paid and does not anticipate paying dividends in the near future. (c) Summary Option Information <p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zNRhkXJ9i2zl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">A summary of the Company’s option plans for the three months ended March 31, 2024, is presented below (unaudited): SCHEDULE OF STOCK OPTION ACTIVITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Number</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">of</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Average</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Options</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Exercise</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">(in shares)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Price</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding, December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20240331_zYL9g5z8cOa8" style="width: 16%; text-align: right" title="Number of Options Outstanding beginning">5,760,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240331_zTfT0nSPaPd4" style="width: 16%; text-align: right" title="Weighted Average Exercise Price Outstanding beginning">0.14</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Granted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240331_zkXUFyaSeNxk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Granted">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240331_zVHq5BCEw5bb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Granted">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding, March 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20240331_zF03aQXimlCf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding ending">5,760,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240331_zS0nWam1AfE1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding ending">0.14</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Exercisable, March 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20240331_zTfrQt7A4oT" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable">5,760,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20240331_zi7xkPM2TrJ8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable">0.14</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Stock-based compensation expense was approximately $13,000 and $15,000 in the three months ended March 31, 2024 and 2023, respectively. The total compensation cost related to non-vested awards not yet recognized was approximately $67,000 as of March 31, 2023. As of March 31, 2023, 360,000 options were unvested. These options vested during March 2024. (d) Warrants <p id="xdx_89A_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zQlT3BFcHUIg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The Company has issued warrants at exercise prices equal to or greater than the market value of the Company’s common stock at the date of issuance. A summary of warrant activity follows (unaudited): SUMMARY OF WARRANTS ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Number of</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">shares</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Average</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">underlying</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Exercise</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">warrants</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Price</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding, December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSSKA4XO87Z2" style="width: 16%; text-align: right" title="Number of shares underlying warrants, Beginning balance">3,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhGdGXdcFY22" style="width: 16%; text-align: right" title="Weighted average exercise price, Beginning balance">0.12</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zINHTjEm9Ke1" style="text-align: right" title="Number of shares underlying warrants, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmkTomTbYEfg" style="text-align: right" title="Weighted average exercise price, Granted">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8pEvJvAQ9L8" style="text-align: right" title="Number of shares underlying warrants, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zw0PBPkmZE85" style="text-align: right" title="Number of shares underlying warrants, Exercised">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Forfeited or expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztwBSv4J1y02" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares underlying warrants, Forfeited or expired">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDaa9X0pj7fj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares underlying warrants, Forfeited or expired">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding, March 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8XTYilQxqAb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares underlying warrants, Ending balance">3,000,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdgXLZLFtnY6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Ending balance">0.12</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The warrant agreements were amended on May 12, 2023 to extend the expiration date to June 28, 2025. The warrants outstanding at March 31, 2024 have a weighted average remaining contractual life of approximately one year and three months. 46881475 46881475 46881475 46881475 0.01 0.01 0.01 0.01 5760000 600000 <p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zp3J5O5a0ZEh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The Company utilized the Black-Scholes option-pricing model to estimate fair value, utilizing the following assumptions for the options issued during the three months ended March 31, 2023 (all in weighted averages): SCHEDULE OF FAIR VALUE OF OPTION USING VALUATION ASSUMPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230331_zQk4Y5ebG33h" style="width: 18%; text-align: right" title="Risk-free interest rate">3.5</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term of options, in years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right" title="Risk-free interest rate">4.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected annual volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230331_zVJKbbviaBgh" style="text-align: right" title="Risk-free interest rate">191.1</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20230331_z6RakZAHs572" style="text-align: right" title="Risk-free interest rate">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Determined weighted average grant date fair value per option</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20230331_zsBKKl80Ld13" style="text-align: right" title="Risk-free interest rate">0.19</td><td style="text-align: left"> </td></tr> </table> 0.035 P4Y 1.911 0 0.19 P7Y 0 <p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zNRhkXJ9i2zl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">A summary of the Company’s option plans for the three months ended March 31, 2024, is presented below (unaudited): SCHEDULE OF STOCK OPTION ACTIVITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Number</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">of</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Average</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Options</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Exercise</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">(in shares)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Price</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding, December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20240331_zYL9g5z8cOa8" style="width: 16%; text-align: right" title="Number of Options Outstanding beginning">5,760,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240331_zTfT0nSPaPd4" style="width: 16%; text-align: right" title="Weighted Average Exercise Price Outstanding beginning">0.14</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Granted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240331_zkXUFyaSeNxk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Granted">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20240331_zVHq5BCEw5bb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Granted">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding, March 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20240331_zF03aQXimlCf" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding ending">5,760,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20240331_zS0nWam1AfE1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding ending">0.14</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Exercisable, March 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20240101__20240331_zTfrQt7A4oT" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable">5,760,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20240331_zi7xkPM2TrJ8" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable">0.14</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 5760000 0.14 5760000 0.14 5760000 0.14 13000 15000 67000 360000 <p id="xdx_89A_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zQlT3BFcHUIg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The Company has issued warrants at exercise prices equal to or greater than the market value of the Company’s common stock at the date of issuance. A summary of warrant activity follows (unaudited): SUMMARY OF WARRANTS ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Number of</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">shares</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Average</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">underlying</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Exercise</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">warrants</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Price</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding, December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSSKA4XO87Z2" style="width: 16%; text-align: right" title="Number of shares underlying warrants, Beginning balance">3,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhGdGXdcFY22" style="width: 16%; text-align: right" title="Weighted average exercise price, Beginning balance">0.12</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zINHTjEm9Ke1" style="text-align: right" title="Number of shares underlying warrants, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmkTomTbYEfg" style="text-align: right" title="Weighted average exercise price, Granted">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8pEvJvAQ9L8" style="text-align: right" title="Number of shares underlying warrants, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zw0PBPkmZE85" style="text-align: right" title="Number of shares underlying warrants, Exercised">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Forfeited or expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztwBSv4J1y02" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares underlying warrants, Forfeited or expired">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDaa9X0pj7fj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares underlying warrants, Forfeited or expired">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding, March 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8XTYilQxqAb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares underlying warrants, Ending balance">3,000,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdgXLZLFtnY6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Ending balance">0.12</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 3000000 0.12 3000000 0.12 2025-06-28 NOTE 6—INCOME TAXES <p id="xdx_891_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zLTZCCDwtSpb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The Company’s income tax provision differs from the expense that would result from applying statutory rates to income (loss) before taxes. A reconciliation of the provision (benefit) for income taxes with amounts determined by applying the statutory U.S. federal income tax rate to income before income taxes is as follows (unaudited): SCHEDULE OF INCOME BEFORE INCOME TAX <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20240101__20240331_z65BCW3GuBI" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20230101__20230331_zkacqLiRkOAf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzO6C_zJ9LxOwfJav9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Computed tax at the federal statutory rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIElOQ09NRSBCRUZPUkUgSU5DT01FIFRBWCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20240101__20240331_z0v0iRuT4ZDd" title="Computed tax at the federal statutory rate"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIElOQ09NRSBCRUZPUkUgSU5DT01FIFRBWCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20230101__20230331_zQ3mFu74erS8" title="Computed tax at the federal statutory rate">21%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(63,689</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(56,452</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzO6C_zjQbxDVQ296h" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State income taxes, net of federal income tax benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(13,178</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(11,680</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzO6C_znI8tnAsZ9q5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in federal valuation allowance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">85,164</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">87,972</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_maITEBzO6C_zsQeTdOuk03j" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Foreign rate differential</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,297</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(19,840</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzO6C_zjamitnhjXH7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total provision for income tax</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_891_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zLTZCCDwtSpb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The Company’s income tax provision differs from the expense that would result from applying statutory rates to income (loss) before taxes. A reconciliation of the provision (benefit) for income taxes with amounts determined by applying the statutory U.S. federal income tax rate to income before income taxes is as follows (unaudited): SCHEDULE OF INCOME BEFORE INCOME TAX <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20240101__20240331_z65BCW3GuBI" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20230101__20230331_zkacqLiRkOAf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzO6C_zJ9LxOwfJav9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Computed tax at the federal statutory rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIElOQ09NRSBCRUZPUkUgSU5DT01FIFRBWCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20240101__20240331_z0v0iRuT4ZDd" title="Computed tax at the federal statutory rate"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIElOQ09NRSBCRUZPUkUgSU5DT01FIFRBWCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20230101__20230331_zQ3mFu74erS8" title="Computed tax at the federal statutory rate">21%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(63,689</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(56,452</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzO6C_zjQbxDVQ296h" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State income taxes, net of federal income tax benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(13,178</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(11,680</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzO6C_znI8tnAsZ9q5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in federal valuation allowance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">85,164</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">87,972</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_maITEBzO6C_zsQeTdOuk03j" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Foreign rate differential</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,297</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(19,840</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzO6C_zjamitnhjXH7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total provision for income tax</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 0.21 0.21 -63689 -56452 -13178 -11680 85164 87972 -8297 -19840 NOTE 7—COMMITMENTS AND CONTINGENCIES The Company was the claimant in an arbitration proceeding against their <span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20240331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--NetCoPartnersMember_zzhJG1CZdgja" title="Equity interest percentage">50% partner in NetCo. The Company initiated the arbitration proceeding in an effort to maximize the total potential value to be derived from fully utilizing the NetCo intellectual property across publishing, entertainment, digital media, merchandising and other ancillary markets. Arbitration hearings were held at the end of July 2022. Arbitration proceedings for the joint owners of NetCo concluded during 2022 and the arbitrator rendered a decision in July 2023. The arbitrator ruled against the Company on certain key issues of the arbitration and in the Company’s favor on two key issues of the arbitration. The Arbitrator ruled in NovelStem’s favor on the issue of contract interpretation of the Netco Partners JV Agreement. The Arbitrator also found that the Company’s joint venture partner failed to use “reasonable, good faith efforts” to license and exploit the Net Force concept, in breach of its contractual obligations under the Netco Partners’ Joint Venture Agreement. The Arbitrator confirmed NovelStem’s contractual right to use Tom Clancy’s name as a possessory credit in the Net Force title (Tom Clancy’s Net Force). As a result of this ruling, the costs related to the litigation funding agreement disclosed in Note 4 were recognized and a total liability of $2,819,196 was recorded. 0.50 2819196 NOTE 8—SUBSEQUENT EVENTS The Company evaluated subsequent events through the date these financial statements were available to be issued and filed with the SEC. During the fourth quarter of 2023, the Company entered into negotiations with NewStem stockholders for the acquisition of the shares not held by the Company. The negotiations are ongoing for the transaction in which the Company would acquire all outstanding shares in exchange for shares of NovelStem stock. Company management anticipates the transaction to conclude in the second quarter of 2024. In anticipation of the Company acquiring the remaining ownership of NewStem, the Company has loaned $500,000 to NewStem to ensure continuing operations. See Note 3. An additional <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240401__20240401__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z6mfm6Z2TMLc" title="Number of option granted">600,000 options were issued to directors on April 1, 2024 pursuant to the Company’s Equity Incentive Plan. In April 2024, the Company borrowed $<span id="xdx_90D_eus-gaap--LongTermDebt_iI_c20240430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleDebtAgreementsMember_z8CDqDQctrVl" title="Long term debt unrelated parties">100,000 from unrelated parties pursuant to convertible debt agreements. These agreements bear interest at <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_c20240430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleDebtAgreementsMember_zJ5i9ZNC7v87" title="Debt instrumental stated percentage">10% per annum and mature <span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_c20240401__20240430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleDebtAgreementsMember_zfSfPzWidpT2" title="Debt instrument maturity date">December 30, 2025. The unpaid principal balance of these notes and any accrued interest may be converted into shares of the Company’s common stock at a conversion price of $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20240401__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleDebtAgreementsMember_zK1eSaKGNKpd" title="Debt conversion price">0.13 per share. 500000 600000 100000 10 2025-12-30 0.13